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Abstract 
The ubiquitin-proteasome system (UPS), composed of classes of proteins central to the 
process of cellular protein turnover in eukaryotes, is essential to the life cycle of the 
malaria parasite, Plasmodium falciparum. Although the UPS has been well characterized 
in other organisms, the extent of its involvement in different stages of P. falciparum 
growth and development has not been investigated in depth. MG132, a small-molecule 
proteasome inhibitor known to target the 20S proteasome core (part of the catalytic center 
for selective protein degradation), has been used successfully in many research studies 
that require proteasome inhibition. We present data supportive of the conclusion that 
MG132 is highly effective as a tool for P. falciparum research. In this thesis, I describe 
the effects of partial and complete proteasome inhibition on parasite growth and 
development by the use of variable concentrations of MG132. I also assess the effects of 
MG132 on 20S P. falciparum proteasome enzymatic activities. I have generated parasite 
lines that exhibit tolerance, or low-level resistance, to MG132, through intermittent 
compound exposure. Sequencing of the catalytic β-5 subunit of the MG132-tolerant 
parasites reveals non-synonymous point mutations in three tolerant parasite lines. The use 
of MG132 as a tool compound for study of the UPS in P. falciparum facilitates research 
into detailed roles of the proteasome using reversible partial and complete inhibition. 
MG132-tolerant lines are also valuable tools for studying the genesis of different levels 
of drug resistance and cross-resistance in parasite evolution. 
 
 
 
 iv 
Acknowledgements 
 
I would like to thank the Biology Department of Boston College (Chestnut Hill, MA) and 
the DeLuca Professorship awarded to Dr. Marc A.T. Muskavitch for financial support of 
this work, and for all other support provided during the course of my graduate work. I 
would also like to thank my advisor, Dr. Marc Muskavitch for support and guidance 
throughout this project, as well as my fellow lab members, Adam Jenkins and Kim Regna. 
I would like to thank Dr. Dyann Wirth and the Wirth laboratory in the Department of 
Immunology and Infectious Diseases of the Harvard T. H. Chan School of Public Health 
for training, resources and use of laboratory facilities for culturing of P. falciparum. I 
would also thank my thesis guidance committee, Dr. Charles Hoffman, Dr. Marc-Jan 
Gubbels, and Dr. Sarah Volkman for support and guidance. I would also like to thank Dr. 
Sarah Volkman and Dr. Matthias Marti from the Harvard School of Public Health for 
consultation on experimental design.  
 
  
 v 
Table of Contents 
 
 Page 
 
Abstract         iii 
 Acknowledgements iv 
 Tables of Contents        v 
 List of Figures         ix 
 List of Tables         xi 
 
Chapter I: Introduction to malaria research and the ubiquitin-proteasome  
system 1 
 Malaria 
 P. falciparum Research 
 The Ubiquitin-Proteasome System 
 References 16 
 
Chapter II:  MG132 functions as an effective small-molecule proteasome inhibitor for 
partial and complete inhibition of the P. falciparum proteasome 
 Abstract 21 
 Introduction 22 
 Materials and Methods 26 
  Bioinformatic Analysis 
  Strains and Cells 
  Proteasome Inhibitors and Control Compounds 
  Culture Conditions and Stage Synchronization 
 vi 
  Culture Growth Assay with SYBR Green® 
  Delayed-Death Assay 
  20S Proteasome Enzymatic Activity Assays 
  Stage Delay Assessment 
  SDS PAGE and Western Blot Analysis 
 Results 32 
  Bioinformatic Analysis 
  P. falciparum Growth Inhibition by Proteasome Inhibitors 
  Delayed Death Assay 
  Inhibition of Proteasome Inhibition Assays 
  Proteasome Inhibition Effects of Various Concentrations of  
           MG132 and Parasite Recovery 
  Stage Delay Assessment   
 Discussion 38 
 References 59 
 
Chapter III: MG132 resistance in P. falciparum: generation and characterization of 
parasite strains with increased tolerance to the proteasome inhibitor MG132 
Abstract 65 
Introduction 66 
Materials and Methods 72 
 Parasite Strains and Cells 
 Compounds and Reagents 
 vii 
 Parasite Culture Conditions 
 Parasite Stage Synchronization 
 Resistance Selection 
 SYBR Green® Assay for Growth Inhibition 
 Dilution Cloning 
 Screening for Increased Drug Tolerance 
 Sequencing and Sequence Analysis 
Results 78 
 Selection of MG132-resistant parasites 
 Growth Inhibition Curves and IC50 Values for Bulk  
      Resistant Cultures 
 Establishment of Reduced-Diversity Subcultures and Clonal  
      Lines From MG132-Resistant Cultures 
 IC50 Calculation for Reduced-Diversity Subcultures and  
      Clonal Lines 
 Sequencing of the β5 subunit of MGR and WT lines 
Discussion 84 
References 104 
 
 
Chapter IV:  Summary and Conclusions       
 Narrative         110 
References         116 
 viii 
 
 
Chapter V: Appendices  
 Appendix I: Protocols 120 
  20S Proteasome Enzymatic Activity Assay  
  Parasite Delayed Death Growth Assay  
  Parasite Minimal Medium / Protein Export Medium  
 
 Appendix II: Additional Figures:  130 
  Proteasome Inhibition and HRP II (Context)  
  HRP II secretion with MG132 exposure   
  HRP II accumulation in parasites due to MG132 exposure  
  References 136 
  
 Appendix III: Multiple Sequence Alignments  137  
  
 Appendix IV: Materials and Methods for Appendices 165 
 
  
 ix 
List of Figures 
 Chapter I: Introduction 
 Figure 1:  Map showing global distribution of malaria infection 10 
 Figure 2:  Life cycle of P. falciparum 11 
 Figure 3:  Transcriptome of P. falciparum 12 
 Figure 4:  Overview of the ubiquitin-proteasome system 13 
 Figure 5:  Chemical structures of proteasome inhibitors 14 
  
 Chapter II:  
 Figure 1:  Schematic diagram of the 26S proteasome 49 
 Figure 2:  Multiple sequence alignment of the   
      β-5 subunit of the proteasome 50 
 Figure 3:  Growth inhibition of P. falciparum by proteasome  
      Inhibitors 52 
 Figure 4:  Delayed death effects of MG132 53 
 Figure 5:  MG132 stage delay assessment 54 
 Figure 6:  Proteasome enzymatic assays  56 
 Figure 7:  MG132 and accumulation of ubiquitylated proteins  
  and culture recovery 58 
 
 Chapter III: 
Figure 1:  Timeline of resistance to anti-malarials 94 
 Figure 2:  MG132 selection in P. falciparum 95 
 x 
 Figure 3:  MG132 tolerance of selection cultures 96 
 Figure 4:  Growth/inhibition curves and IC50 values for  
resistance selection cultures 97 
 Figure 5:  Screening of reduced diversity lines for MG132   
 tolerance  98 
Figure 6:  MG132 vs. mefloquine tolerance chart 100 
Figure 7:  Sequencing chromatograms of the β-5 subunit 101 
Figure 8:  Model of the β-5 subunit sequence 102 
 
 Chapter V: Appendices: 
 Appendix I: Protocols 
  Figure S1: Fluorescence linear range of enzymatic activity assay 123 
  Figure S2: Assessment of minimal medium culture growth 129 
 Appendix II: Gene expression and HRPII 
  Figure S3: HRPII secretion into culture media 134 
  Figure S4: HRPII accumulation in parasites 135 
 Appendix III: Alignments 
  Multiple Sequence Alignments for 20S Proteasome  
      Subunits 138 
  
 xi 
List of Tables 
 
 Chapter I: Introduction 
Table I:  Malaria transmission and treatment information by region 15 
 
 Chapter II:  
Table I:  Orthologous elements common between P. falciparum  
    and other organisms 45 
 Table II:  Proteasome subunits sequence comparison   46 
 Table III:  IC50 values for parasite growth inhibition by  
 proteasome inhibitors 47 
 Table IV:  IC50 Values for Delayed Death Experiment 47 
 Table V:   IC50 Values for Enzymatic Activity Assay 48 
 
 Chapter III:   
Table I:  Selection of MG132 resistance in P. falciparum 91 
Table II:  IC50 values of MG132-tolerant lines 92 
Table III:  Point mutations in the β-5 of MG132-tolerant lines  93 
 
 
 
  
Chapter I:  
 
Introduction to malaria research and the ubiquitin-proteasome system 
 
 
  
 2 
Malaria 
 
 
Malaria is a vector-borne, parasitic illness that affects hundreds of millions of people 
each year, worldwide. It is caused by single-celled apicomplexan parasites from the 
genus Plasmodium, which are spread among human populations by mosquito vectors [1-
2]. Although the global malaria prevalence has been reduced and even eliminated in some 
areas through control efforts, around 200 million people still suffer from malaria 
infection every year, and around 500,000 die as a result, including many young children 
[1-3]. Tropical areas in Africa, Asia, and the Americas, ideal environments for Anopheles 
mosquitos (the primary vector), are the most affected [2-4]. Plasmodium falciparum is 
the species responsible for the most severe forms of malaria and nearly all human deaths 
from the disease [1-4]. The high morbidity and mortality observed in some parts of 
Africa is largely due to the fact that many cases of infection there are caused by P. 
falciparum [1-4]. Other species that can cause human disease are Plasmodium vivax, 
Plasmodium malariae, Plasmodium knowlesi, and Plasmodium ovale [1-2].  
 
Malaria control and eradication efforts have been a priority in endemic areas because of 
the heavy public health burden and crippling morbidity and mortality associated with the 
disease [1-5]. Malaria was problematic in the United States until the early 1950s, when 
comprehensive elimination efforts were successful [1-3]. A current map of areas affected 
by malaria is shown in Figure 1 [6]. 
 
The malaria parasite is spread through female Anopheles mosquito vectors, which 
transmit the infection during blood meals [1-3]. The parasite undergoes many cycles of 
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replication in the human blood stream, destroying red blood cells in the process, which 
results in the pathologies characteristic of malaria, such as anemia and periodic fever [1-
3]. Cerebral vascular complications, coma and death can also result from cerebral malaria, 
which can be the result of a severe case of infection by P. falciparum [1-2]. A schematic 
representation of the full P. falciparum life cycle, including the sexual stages in the 
mosquito and the asexual stages in the human host, is shown in Figure 2  [7].  
 
Prevention and treatment of patients for malaria is central to public health in endemic 
areas and has implications for patient care. Anti-malarial prophylaxis and chemotherapy 
are highly effective, but can be compromised by the spread of resistant parasites [1-3, 8-
10]. Depending on geographic area, the CDC recommends atovaquone/proguanil 
(Malarone), primaquine, mefloquine, doxycycline, or chloroquine in endemic areas, for 
malaria prophylaxis [2]. Atovaquone/proguanil is economically burdensome, but well-
tolerated with very few side effects; primaquine is relatively fast-acting and highly 
effective against P. vivax, but its use is compromised by the presence of glucose-6-
phosphatase dehydrogenase mutations, particularly in African populations [2,3]; 
chloroquine and mefloquine are inexpensive and can be taken by children and pregnant 
women; and doxycycline is very inexpensive and can prevent other infections in addition 
to malaria [2,3].  
 
Resistance selection is always a concern with the use of antimalarial drugs used for 
chemotherapy, so the World Health Organization (WHO) recommends combination 
therapy [1,3,8-10]. The standard in malaria treatment in most highly endemic areas is 
artemisinin-based combination therapy (ACT) [1,3, 8-10]. Chloroquine and mefloquine 
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can be used in areas without high incidence of resistance [2-3]. Information about malaria 
transmission and chemotherapeutic drug regimens by region is presented in Figure 1 and 
Table I [3,6].  
 
 
P. falciparum Research 
 
 
The P. falciparum knowledge base has increased significantly over the past 40 years, 
mainly due to the crossing of significant milestones in laboratory research capabilities 
[11-16]. Culturing of P. falciparum parasites has been possible in the laboratory since 
1976, when the first successful attempt at long-term continuous culture was reported [11]. 
Although there are differences between the parasite life cycle in vivo and in vitro, 
cultivation of P. falciparum has led to considerable advances in research [12-13]. 
Plasmodium culture has allowed for increased insight into the biology of the parasite and 
the development of tools for combatting malaria disease [12]. Research areas that have 
been benefitted significantly from this milestone include drug development and 
characterization, evolutionary bioinformatics, malaria immunology, drug resistance, host-
pathogen interactions, vaccines, gene expression, parasite-mosquito dynamics, parasite 
sexual stages, transmission, and many other areas [8,12-13]. The publication of other 
methods then followed, such as the stage-synchronization of cultured parasites a few 
years later [13]. Another major milestone in P. falciparum research was the complete 
sequencing of the parasite genome in 2002 [14]. Access to complete genomic information 
paved the way for examination of parasite genome on a global scale, including the 
sequences of open reading frames and putative genes not previously identified [7,14]. 
The fact that the parasite genome is very A/T rich (the genome is over 80% A/T, and over 
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90% A/T when introns and non-coding regions are excluded) was confirmed with 
examination of the full genome [7,14]. The subsequent publication of the parasite 
transcriptome and proteome expanded the core knowledge of P. falciparum even more, 
most notably by drawing attention to the fact that gene expression and protein content are 
tightly regulated and highly periodic, with very little overlap between stages [15-16]. A 
heat map of P. falciparum microarray data that shows transcript levels with respect to 
developmental stage is shown in Figure 3 [15].  
 
Other high-impact topics in recent P. falciparum research include the identification of 
single-nucleotide polymorphisms (SNPs) through genomic analysis of laboratory and 
field strains, use of SNP databases in molecular barcoding for the tracking of parasite 
evolution and the spread of a variety of traits, the use of Genome-Wide Association 
Studies (GWAS), which can be used to identify the genetic roots of a variety of 
phenotypic traits, and detailed tracking and molecular study of drug resistance (including 
emerging ACT resistance) [8,17-22].   
 
 
The Ubiquitin-Proteasome System (UPS) 
 
 
The proteasome is a large (~ 2.5 MDa), multi-subunit protein complex that is present in 
nearly all eukaryotic cells [23-27]. It is a central component of the broader ubiquitin 
proteasome system (UPS), which includes a large set of enzymes and structural proteins 
that facilitate the designation and degradation of many intracellular proteins [23-27]. The 
pathway leading to degradation of a protein by the catalytic 20S proteasome core is 
shown in Figure 4 [27]. This multi-step cascade begins with the attachment of a ubiquitin 
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(Ub) peptide to an E1 ubiquitin-activating enzyme, in a process that requires ATP. Next, 
the Ub is transferred to an E2 ubiquitin conjugating enzyme, and the Ub is finally moved 
from the E2 enzyme to the substrate protein by an E3 ubiquitin ligase [23-27]. This 
process happens to the same substrate multiple times, building a polyubiquitin (pUb) 
chain, the signal that is recognized by regulatory complexes as of the 19S proteasome 
[23-27].  
 
The 26S proteasome particle is made up of the 19S regulatory complex, which controls 
substrate entry, and the 20S proteasome core, which includes proteases for the 
dismantling of substrate proteins [23-27]. The basic structure of the 26S proteasome is 
shown in Figure 4 [27]. The 19S proteasome consists of the regulatory particle non-
ATPase (RPN) and regulatory particle triple-A ATPase (RPT) subunits (the “lid and 
base”), which recognize, bind to, and draw polyubiquitinated proteins into the catalytic 
20S proteasome core (shown in dark red in the proteasome complex in Figure 4) [23-27]. 
The 20S proteasome is composed of seven alpha subunits (designated α-1 through α-7), 
which are primarily structural and make up the “outer” ring of the complex, and seven 
beta subunits (designated β-1 through β-7), which make up the “inner” ring of the 
complex and include both structural and catalytic subunits. The β-1, β-2, β-5 subunits are 
active threonine proteases, and constitute the enzymes that actually degrade substrate 
proteins [23-27].  
 
Substrate proteins degraded by the UPS can include those that originate from 
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transcription or translation errors such as misfolded or truncated proteins, cellular signals 
that are no longer needed at a given time, such as cyclins or cytokines, transcription 
factors, or any protein with a cellular presence that is limited to one or more discrete 
temporal intervals during the parasite life cycle [23-27]. Disruption of proteasome 
function can hinder the cell’s ability to rid itself of protein waste, causing the lingering 
presence of poly-ubiquitinated proteins [23,28-29]. If the cell is unable to recycle these 
proteins, the accumulation of this cellular “garbage,” or cellular proteins that are 
unnecessary and possibly toxic, can interfere with many cellular functions [23, 28-29]. 
Progression of the cell cycle, gene expression, actin remodeling, protein transport, and 
apoptosis pathways are all known to be affected by proteasome inhibition  [23,28-29].  
 
A number of compounds interfere with UPS function, including those that target the 20S 
proteasome core directly, inhibiting the catalytic activities of its proteolytic subunits [28, 
30]. Chemical structures of some of these compounds are shown in Figure 5 [29]. Many 
of these small-molecule proteasome inhibitors have been found to have potent anti-
malarial activity against cultured P. falciparum parasites, motivating exploration of the 
UPS as a target for chemotherapeutic intervention in malaria treatment [29, 31-32].  
 
Evidence for the importance of the UPS in P. falciparum 
The UPS has been well studied and characterized in human cells, and has been shown be 
involved in the cell cycle, the immune response, apoptosis, and regulation of transcription 
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factors [23, 28-32]. Many questions remain about the specific roles of the proteasome and 
the consequences of its inhibition in P. falciparum [31-32]. Over 100 components of the 
UPS have been identified in P. falciparum by genomic studies, including nine ubiquitin 
or ubiquitin-like proteins and over thirty components of the 26S proteasome: eight E1 or 
E1-like activating enzymes, fourteen E2 or E2-like conjugating enzymes, over fifty E3 or 
E3-like ubiquitin ligases and twenty-nine de-ubiquitinating (DUB) or DUB-like proteins 
[33-35]. In addition to the demonstrated antimalarial activity of proteasome inhibitors in 
culture, another obvious reason for parasite biologists’ interest in the UPS is the fact that 
P. falciparum depends heavily on protein turnover throughout its life cycle [16].  The P. 
falciparum transcriptome and proteome reveal proteasome expression throughout the 
parasite life cycle, consistent with its importance [15,16].  Many protein components of 
the UPS are encoded by genes that contain SNPs that are under selection in parasite 
populations isolated from patients in disease-endemic areas, suggesting a possible role in 
drug resistance for sequence variation in UPS proteins [15, 18].  
Overall, the occurrence of malaria creates significant individual and societal burdens in 
many regions of the world and continued efforts are necessary for eradication of the 
disease [1-6, 9]. Concerted public health efforts, including vector-targeted strategies and 
malaria chemotherapy, have been highly successful at lessening the impact of malaria 
and reducing morbidity and mortality [4, 6, 9]. Malaria research has provided many 
additional tools for treatment and prevention, and there is a need for these efforts to be 
continued [12-16]. In the area of chemotherapy, these efforts must include the 
development of new malaria drugs with diverse cellular targets in order to limit the 
spread of drug resistance. The UPS contains many possible targets for new drug 
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compounds, and more research is necessary to reveal the roles and functions of UPS 
subunits in parasite growth and development (7-10, 29, 31).  The UPS is known to have a 
role in many mammalian cellular pathways, but the specific roles of the UPS in P. 
falciparum that have yet to be fully defined (23-33). More research is required to clarify 
the roles of the proteasome in P. falciparum, as well as the effects of its inhibition (31-
32). Proteasome inhibition with small-molecule inhibitors like MG132 has proven 
effective in studying the mammalian UPS, and such compounds could be similarly useful 
in the study of the parasite UPS (28-30). In addition to its examination as a possible drug 
target, the UPS is also currently of significant interest in the field of parasite biology 
because it could be a central regulator of many cellular processes, and advancing our 
understanding of UPS functions can advance research in other areas of parasite cell 
biology, as well [29,31-33].  
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Figures and Tables 
 
 
 
 
Figure 1: Global distribution of malaria transmission as reported by the World Health 
Organization in 2014 [3,6], reflecting the aggregated incidence of infection by the five 
species of Plasmodium known to infect humans (Plasmodium falciparum, Plasmodium 
vivax, Plasmodium knowlesi, Plasmodium ovale and Plasmodium malariae). 
 
  
2 | WORLD MALARIA REPORT 2014
The World malaria report 2014 summarizes the status of global efforts 
to control and eliminate malaria. The report is produced every year by the 
WHO Global Malaria Programme, with the help of WHO regional and country 
oﬃces, ministries of health in endemic countries, and a broad range of other 
partners. Data for this year’s report were assembled from 97 countries and 
territories with ongoing malaria transmission, and an additional six countries 
that are working to prevent reintroduction. 
This section outlines the public health burden posed by malaria, the 
strategies that can be used to reduce that burden, and the goals, targets 
and indicators that have been set for 2015. The report then reviews global 
progress towards the goals and targets in relation to funding (Section 2), 
intervention coverage (Sections 3–7), and malaria cases and deaths 
(Section 8). The review is followed by Regional profiles that summarize 
trends in each WHO region. Country profiles are provided both for countries 
with ongoing malaria transmission and for those recently achieving zero local 
cases. Finally, annexes provide sources of data, details of the methodology 
used in the analysis, and tables containing country and regional data.
1.1 The public health challenge posed by 
malaria
Malaria transmission occurs in all six WHO regions. Globally, an 
estimated 3.3 billion people in 97 countries and territories are at risk of being 
infected with malaria and developing disease (Figure 1.1), and 1.2 billion are 
at high risk (>1 in 1000 chance of getting malaria in a year). According to 
the latest estimates, 198 million cases of malaria occurred globally in 2013 
(uncertainty range 124–283 million) and the disease led to 584 000 deaths 
(uncertainty range 367 000–755 000), representing a decrease in malaria 
case incidence and mortality rates of 30% and 47% since 2000, respectively. 
The burden is heaviest in the WHO African Region, where an estimated 90% 
of all malaria deaths occur, and in children aged under 5 years, who account 
for 78% of all deaths.
DATA WERE ASSEMBLED FROM 
97 COUNTRIES AND TERRITORIES 
WITH ONGOING MALARIA 
TRANSMISSION, AND AN 
ADDITIONAL SIX COUNTRIES 
WORKING TO PREVENT 
REINTRODUCTION.
1. INTRODUCTION
Figure 1.1 Countries with ongoing transmission of malaria, 2013
Source: National malaria control programme reports
Confirmed malaria cases per 1000 population
No ongoing malaria transmission
Not applicable
0.1–1
0–0.1
10–50
1–10
>100
50–100
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Figure 2: Life cycle of P. falciparum [7]. Sexual reproduction occurs in the mosquito 
midgut, resulting in the presence of sporozoites in mosquito saliva. Sporozoites enter the 
bloodstream of a human host during blood feeding. The sporozoites infect the liver, 
replicate, and are released into the bloodstream in a form allowing for the infection of red 
blood cells. The parasites then enter the asexual reproduction cycle in the host 
bloodstream. After significant disease progression, gametocytes can form in the blood 
stream of an infected person, and they can be taken up by another mosquito during a 
blood meal. The life cycle can then continue for another round via the initiation of sexual 
reproduction in the mosquito host.  
 
 
 
  
Malaria has confounded some of thebest minds of the past century. Ahundred years after the discovery
that mosquitoes transmit Plasmodium falci-
parum, the major parasite that causes human
malaria, we still do not know enough about
the disease to defeat it permanently. But the
papers on pages 498–542 of this issue1–7,
describing the complete genome sequence of
P. falciparum, may eventually lead to new
drugs and vaccines, and will certainly be an
invaluable guide to future research. These
papers are a testament to the success of a six-
year project undertaken by an international
consortium of labs and funding agencies.
Why genome sequencing?
First, a bit of background. The malaria para-
site leads a complicated life (Fig. 1), existing
mainly inside liver cells and red blood cells in
its human host and, when residing in mos-
quitoes (notably Anopheles gambiae), being
associated with the insect’s gut and salivary
glands. It undergoes several transformations
along the way. The stages of its life cycle were
originally described more than 100 years ago
and were given names based on morphology,
such as merozoite, trophozoite and gameto-
cyte (in humans), and zygote, ookinete and
sporozoite (in mosquitoes). One of the most
curious features of the human stages is the
human immune response — there is much
immune activity, but this does not control
the infection effectively, nor afford protec-
tion against future infections.
Despite massive efforts to eradicate the
disease in the 1950s and early 1960s, more
people are infected with malaria in Africa
today than at any other time in history. Over
500 million people are infected with the 
disease worldwide, and one-quarter of the
population is at risk of infection. More than a
million children die of malaria each year,
mostly in Africa. And those individuals who
survive suffer a combination of anaemia and
immune suppression that leaves them vulner-
able to other fatal illnesses. Alarmingly, drug
resistance in the parasite is now widespread.
These stark facts emphasize the need to
find new treatments for the disease and new
ways of preventing it. The genome project
described in this issue1–7 was conceived with
these goals in mind. With the wealth of infor-
mation now available at the click of a mouse,
malaria researchers have an unprecedented
opportunity to find genes that are potentially
unique to, or at least substantially different
in, P. falciparum compared with other
species; such genes may make good drug 
targets, with less risk of side effects.
Even before the whole genome had been
sequenced, new drug targets were being
identified from searches of the partially
assembled sequence data for unique genes8.
But the total sequence will provide a more
complete picture of the parasite’s inner
workings and the chance to identify vulnera-
ble aspects. So just what have we learnt about
the parasite’s biology from this package of
papers, which comprises its genome
sequence1,4–6; a comparison of its genome
with that of a rodent malaria parasite, P.
yoelii yoelii2; and two proteomics studies of
the proteins expressed at different stages in
the parasite’s life cycle3,7? Where are the
potential weaknesses? And what have we 
discovered about the parasite’s means of
evading the human immune response?
Metabolism
One notable feature of the parasite’s
genome1 is the apparent absence of genes for
proteins that, in other species, are key to
metabolism and the energetics of mitochon-
dria — cellular powerhouses, which produce
the energy-storing molecule ATP. For exam-
ple, the consortium found no predicted
genes for two protein components of ATP
synthase, a mitochondrial ATP-producing
enzyme. (At present, many of the genes are
only ‘predicted’: they have been identified by
gene-searching algorithms, but have not 
yet been confirmed as bona fide genes.)
Similarly, there are apparently no genes 
for components of a conventional NADH
dehydrogenase complex, another key mito-
chondrial enzyme. Perhaps P. falciparum
generates and stores energy by using novel
proteins or mechanisms — potential drug
targets. That the mitochondria are active, at
least in sporozoites and gametocytes, seems
likely, given that the proteomics analyses3,7
detected fragments of enzymes involved in
some typical mitochondrial processes,
including the tricarboxylic-acid cycle and
oxidative phosphorylation.
Also interesting is the number of predict-
ed genes — some 10% — that encode 
proteins associated with the apicoplast1. This
essential cellular compartment is known to
be important for the biosynthesis of fatty
acids and isoprenoids, components of many
membrane proteins, and for iron metab-
olism. But analysis of these genes should
reveal other possible functions, and so new
drug targets. The genome sequence also 
identifies the molecules within the apicoplast
news and views
NATURE | VOL 419 | 3 OCTOBER 2002 | www.natur .com/nature 495
The parasite genome
Biological revelations
Dyann F. Wirth
The genome of the malaria parasite was sequenced with the aim of
learning more about how the parasite works, and with the hope that 
this would reveal potential drug targets. Has that hope been realized?
Liver
Gametocytes
Oocyst
Ookinete
Zygote
Gametes
Sporozoites
Sporozoites
Gut
Merozoites
Red blood
cells
Trophozoite
Salivary
glands
a b
Figure 1 Life cycle of the parasite Plasmodium falciparum. a, When a parasite-infected mosquito feeds
on a human, it injects the parasites in their sporozoite form. These travel to the liver, where they
develop through several stages, finally producing merozoites which invade and multiply, via the
trophozoite stage, in red blood cells. Eventually, up to 10% of all red cells become infected. (Cli ical
features of malaria, including fever and chills, anaemia and cerebral malaria, are all associated with
infected red blood cells, and most current drugs target this stage of the life cycle.) The merozoites in a
subset of infected red blood cells then develop into gametocytes. b, When another mosquito bites the
infected human, it takes up blood containing gametocytes, which develop into male and female
reproductive cells (gametes). These fuse in the insect’s gut to form a zygote. The zygote in turn develops
into the ookinete, which crosses the wall of the gut and forms a sporozoite-filled oocyst. When the
oocyst bursts, the sporozoites move to the mosquito’s salivary glands, and the process begins again.
© 2002 Nature Publishing Group
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Figure 3: Transcriptome of P. falciparum. Transcripts are shown with respect to stage 
[15]. As indicated in rightward panel I, expression of the proteasome is prominent during 
trophozoite stage.  
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Figure 4: Overview of the ubiquitin-proteasome system [27]. A ubiquitin peptide is 
attached to an E1 ubiquitin-activating protein by a process that requires ATP, then 
transferred to an E2 ubiquitin-conjugating enzyme. And E3 ubiquitin ligase then transfers 
the ubiquitin peptide to a substrate protein. This process happens many times, adding 
more ubiquitin molecules to create a polyubiquitin tag, designating the substrate protein 
for degradation by the proteasome. 
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Figure 5: Chemical structures of canonical proteasome inhibitor compounds. 
Pharmacophores are highlighted in red. For PR39 and PR11, amino acid sequences are 
shown. Binding sites within the UPS are unknown [29]. All compounds, except allosteric 
inhibitors PR11 and PR39, have been shown to be active against P. falciparum [29]. 
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Table I: Malaria transmission and treatment information by region [3].  
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Abstract 
The proteasome is a highly conserved multi-subunit protein complex that serves as a 
protein “recycling bin” for eukaryotic cells. It is part of the ubiquitin-proteasome system, 
which consists of 30 to 60 proteins that facilitate the modification and degradation of 
cellular proteins. The proteasome is essential for the growth of rapidly dividing cells, 
which has led to the use of proteasome inhibitors such as bortezomib in the 
chemotherapeutic treatment of cancer. Proteasome inhibitors are currently of interest to 
infectious disease biologists because they also arrest the growth of pathogens, such as the 
malaria parasite Plasmodium falciparum. Although previous studies of the parasite 
proteasome have been pursued, little is currently known about the biology and roles of 
the ubiquitin-proteasome system in P. falciparum.  
 
This study addresses the abilities of proteasome inhibitor compounds to hinder growth 
and development of parasites in culture and to impair the proteolytic activities of the P. 
falciparum proteasome core. MG132, a small-molecule peptide aldehyde proteasome 
inhibitor, was identified as an effective tool compound for studies requiring partial and 
complete proteasome inhibition. Exposure to lower concentrations of MG132 resulted in 
partial proteasome inhibition and developmental delays. Exposure to higher 
concentrations of MG132 led to lethality after 24 hours, but proved reversible when 
incubation time was shortened. This reversibility could allow for study of recovery and 
downstream consequences of temporary proteasome inhibition in live parasites. Overall, 
MG132 is ideal for effective partial or complete inhibition of the P. falciparum 
proteasome.   
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Introduction 
 
Malaria is a vector-borne parasitic infection for which a large portion of the world 
population is at risk. Although the global impact of the disease has been greatly reduced 
in the past several hundred years, it remains a fixture in many parts of Africa, Asia and 
the Americas, and it is responsible for over 200 million symptomatic cases and over 
600,000 deaths, annually [1,2]. Malaria is caused by infection with parasites from the 
genus Plasmodium, which are intracellular eukaryotic organisms that replicate in human 
hosts and in mosquito vectors [3].  
 
Parasite genetic diversity makes conventional vaccination against malaria very difficult 
and largely ineffective for protecting human populations [4,5]. Rapid evolution enables 
the rise of genetic resistance to malaria chemotherapy, making reliable drug treatment a 
challenge [5-7]. Despite the general success of modern treatments, there remains a need 
to develop new drugs directed against diverse targets. Cases of resistance to the current 
standard for chemotherapy, artemisinin-based combination therapy (ACT), have been 
reported [1, 8-11].  
 
The biology of Plasmodium parasites is complex. Although similar to that of other 
eukaryotes in many ways, the genome of Plasmodium falciparum, the species responsible 
for the most severe human malaria cases, contains many genes that have not been well-
studied and lack evident homology to genes with known functions [12,13]. The 
percentages of P. falciparum genes with homologs in other well-studied organisms is 
shown in Table I. Even those parasite genes and gene products with sequence homology 
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to those found in other organisms often do not exhibit similar expression patterns, 
subcellular localization or post-translational modifications, and so they could function by 
mechanisms very different from their homologous counterparts [12,13].  
 
The ubiquitin-proteasome system (UPS) is a eukaryotic subcellular “recycling bin” 
responsible for the breakdown of proteins that are no longer needed by the cell [14-16]. A 
diagram of the 26S proteasome structure, including the 19S proteasome regulatory 
particle and the 20S proteasome core, is shown in Figure 1. The UPS is central to the 
process of clearing misfolded, truncated, or mistranslated proteins from the cell [14-17]. 
It also breaks down stage-specific proteins after they are no longer needed by the cell, 
and so it has a vital role in processes such as cell cycle progression [16,17]. Recent 
studies have shown that the UPS participates in apoptosis, cellular import/export, gene 
expression, actin remodeling, and stress responses [14-20]. The UPS can also affect 
intercellular dynamics such as host-pathogen interactions and inflammation [20-22].   
 
Increased knowledge of the P. falciparum UPS could have many practical applications. 
The pathology and symptomology of parasite infection depends critically on stage 
progression in the liver and in erythrocytes [3]. Frequent, rapid changes in proteome 
composition accompany stage shifting, which suggests that protein degradation by the 
parasite UPS could play a central role in parasite infection [23]. In addition, Plasmodium 
parasites depend on the metabolic resources of a host during every life-cycle stage, 
making host-pathogen interactions critical to the infection processes [3].  
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A variety of small-molecule proteasome inhibitors (SMPIs) have been identified and 
utilized in research and clinical settings [24-28]. SMPIs have been utilized clinically in 
the chemotherapeutic treatment of cancer because of their ability to arrest rapid cell 
division [26-28]. The critical role of the UPS in the cell cycle has also led infectious 
disease biologists to explore SMPIs as tools for the control of pathogens [28-32]. 
Furthermore, UPS function has been shown to have direct impacts on viral and bacterial 
pathogenesis, and could have a significant role in malaria pathogenesis [21-22, 28-32]. 
 
Known SMPIs are numerous, and vary in mechanism of action, specificity, and toxicity 
to various cell types [24, 31-37]. In previous studies of the biology of the proteasome in P. 
falciparum, researchers have made use of several SMPIs such as MG132, bortezomib, 
lacatacystin, epoxomicin and chemical structural variants synthesized by individual labs 
for optimization [31-36]. When choosing an SMPI for a particular research study or 
clinical purpose, the first step is to identify the SMPI that is appropriate for the work at 
hand, knowing that the desired attributes of an ideal SMPI will vary for each type of 
study.  
 
Some SMPIs are reversible inhibitors, meaning proteasome function can be restored with 
removal of the soluble compound [24]. Others are irreversible inhibitors that alter 
proteasome function permanently by covalent molecular interactions [24]. Because the 
activities of many separate components and subunits are required for effective UPS 
function, the specific UPS element(s) with which an SMPI interacts would be another 
important consideration. Some SMPIs target one of the three types of protease activity 
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associated with the 20S proteasome core: trypsin-like (TPL), chymotrypsin-like (CTL), 
and caspase-like (CPL) activities; while others inhibit more than one activity [24,25]. 
Some inhibitors target UPS regulatory subunits [24,25]. Hence, a given compound’s 
range of target(s) within the UPS should be considered, in addition to any off-target 
effects outside of the UPS [24,28,33].  
 
We directly compare the anti-malarial action and inhibition of UPS enzymatic activities 
of several SMPIs in P. falciparum. We find that MG132, a reversible SMPI [24], proves 
to be an effective UPS-directed tool compound in parasite culture over a range of 
concentrations that corresponds with partial or complete proteasome inhibition. Sub-
lethal concentrations of MG132 result in partial proteasome inhibition and a delay in 
stage progression without total arrest of cell proliferation. The inhibitory effects of high 
doses of MG132 are rapid and prove to be reversible following short periods of exposure, 
as affected cultures are able to recover and grow normally after SMPI pressure is 
removed. We demonstrate that MG132 is a rapid and effective SMPI for partial or 
complete inhibition of the P. falciparum proteasome.
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Materials and Methods 
Bioinformatic Analysis 
Plasmodium gene sequences were obtained from the PlasmoDB website: 
http://plasmodb.org/plasmo/ (EuPathDB Project Team, Athens, GA). Homology 
comparisons between P. falciparum genes and those from other species were conducted 
using the PlasmoDB “orthology phylogenetic profile” search algorithm. Sequences from 
other species and “e values” for sequence comparisons were obtained from the 
NCBI/BLAST website: http://blast.ncbi.nlm.nih.gov/Blast.cgi (The National Library of 
Medicine, Bethesda, MD). Multiple sequence alignment was performed using Geneious® 
software (Biomatters Ltd., Auckland, New Zealand).  
 
Strains and Cells 
All strains were obtained from the laboratory of D.F. Wirth (Harvard School of Public 
Health, Boston MA). The strains 3D7 (MRA-102, line P2G12) and Dd2 (MRA-156) 
were used for experiments [38,39]. Hematocrit (packed human red blood cells in CPDA-
1) used for parasite culture was obtained from Research Blood Components (Boston, 
MA). Jurkat cells were obtained from the laboratory of W. Johnson (Boston College, 
Chestnut Hill, MA) and were originally Clone E6-1, TIB-152™ from ATCC (Manassas, 
Virginia).  
 
Proteasome Inhibitors and Control Compounds 
MG132, mefloquine, and azithromycin were obtained from Sigma-Aldrich Co. LLC. (St. 
Louis, MO). Lactacystin was obtained from Cayman Chemical (Ann Arbor, MI). 
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Bortezomib was obtained from LC Laboratories (Woburn, MA). Stock solutions were 
made by dissolving compounds in DMSO at a  concentration of 10 mM.  
 
Parasite Culture Conditions and Stage Synchronization  
All parasite culturing was done under the following standard conditions unless otherwise 
noted: RPMI cell culture medium (Life Technologies Corp., Grand Island, NY) 
supplemented with 5.94 g/L HEPES, 0.05 g/L Hypoxanthine, 2.016 g/L Sodium 
Bicarbonate, and 0.025 mg/mL gentamicin was used for culture of P. falciparum. Either 
0.5% Albumaxx II® (Life Technologies Corp., Grand Island, NY) or 10% Human Serum 
(Interstate Blood Bank, Memphis, TN) were also added to supplement media used for 
parasite culture. All cultures included 1-5% hematocrit. 
 
For parasite growth under standard conditions, cultures were incubated, in a stationary 
manner, at 37oC, in the presence of a gaseous mixture consisting of 5% CO2, 1% O2, 94% 
N2. Cultures were diluted with uninfected red blood cells, and fresh complete medium 
when parasitemia exceeded 1% or at the appropriate time for experimental requirements.  
 
For parasite stage synchronization, culture hematicrit, including infected red blood cells 
(iRBCs), was isolated by centrifugation at approximately 500 x g, and supernatant media 
were discarded. Cells were then incubated in 5% sorbitol at 37oC for 5 minutes. 
Centrifugation was then repeated, and the sorbitol-containing supernatant discarded. 
Cells were then returned to culture with fresh medium.  
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Culture Growth Assay with SYBR Green® 
Cultures for growth assays were incubated in 384-well plates, under standard conditions, 
for 72 hours.  Each sample replicate consisted of 40uL culture with 1% hematocrit at 1% 
parasitemia (unless otherwise noted), 0.5% Albumaxx II, and the appropriate 
concentration of compound or drug being studied. Assays were initialized when 
synchronous parasite cultures were at ring stage, unless otherwise noted. After a defined 
incubation period, sample cultures were lysed and stained by the addition of 10uL lysis 
buffer (0.16% saponin, 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 1.6% Triton X-100) 
with SYBR Green® (Life Technologies Corp., Grand Island, NY) diluted 1:1,000. Plates 
were read with emission/excitation settings at 494 nm/520 nm, respectively. Growth was 
assessed by calculating ratio of the fluorescence readings of small molecule-treated 
sample cultures to those of untreated control cultures incubated in the same plate. Assay 
curves were generated and data analyzed using GraphPad Prism® software (GraphPad 
Software, Inc., La Jolla, CA). The non-linear regression curve algorithm (variable slope) 
with IC50 calculation was used.  
 
Delayed-Death Assay 
To assess any delayed-death effects of compounds, growth assays were performed with 
modifications. In addition to the standard 72-hour incubation, assays were performed 
using 24- and 120-hour incubation times for comparison. For samples incubated for 120 
hours, media was changed and fresh compound added once during incubation (at 72 
hours). At the end of incubation period, samples were lysed and stained in the same 
manner as SYBR Green®-based growth assay. Sample reading and analysis were also 
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conducted according to the protocol for SYBR Green®-based growth assay. Statistical 
significance of observed differences was determined by comparing the IC50 values for 
each incubation time to the values for other incubation times for the same compound with 
Turkey’s multiple comparison test. Statistical tests were conducted using GraphPad 
Prism® software (GraphPad Software, Inc., La Jolla, CA).  
 
20S Proteasome Enzymatic Activity Assays 
Enzymatic activities were assessed using SUC-LLVY-AMC, Z-LLE-AMC, and Boc-
LLR-AMC fluorogenic substrates (Boston Biochem, Cambridge, MA). Stock solutions of 
each of the substrates were made at 100 µM concentration in DMSO. Enzymes were 
prepared from whole-cell lysate obtained from either cultured parasites or Jurkat cells. To 
prepare parasite lysates, synchronous parasites were grown to schizont stage and iRBCs 
were collected by centrifugation at 500 x g. The iRBCs were resuspended in PBS with 
0.15% saponin and incubated at room temperature until RBC lysis (<5 min). Free 
parasites were collected by centrifugation and washed with PBS, then stored at -80oC. On 
the day of the activity assay, parasites were thawed and resuspended in lysis buffer (50 
mM Tris HCl, 25 mM KCl, 10 mM NaCl, 1 mM MgCl, 1 mM ATP, 2% glycerol) and 
0.1mm glass disruption beads. Cells were lysed mechanically by repeated agitation 
(vortex), and lysates were clarified by centrifugation. Supernatant was removed and kept 
on ice to be used as enzyme for assays. Jurkat cells were grown in RPMI supplemented 
with 10% human serum and lysed by agitation with mechanical disruption beads in the 
same manner as isolated parasites. Assay samples were 40 µL total volume and included 
2 µL substrate stock (5 µM final concentration), 4 µL 10x inhibitor compound or plain 
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DMSO, and 5 µL enzyme (lysate), in assay buffer (50 mM Tris HCl, 25 mM KCl, 10 
mM NaCl, 1 mM MgCl, 1 mM ATP). Assays were incubated for 90 minutes at 37oC and 
measured for fluorescence at excitation/emission 380 nm/460 nm, respectively. Activity 
inhibition curves were generated and data analyzed using GraphPad Prism software 
(GraphPad Software, Inc., La Jolla, CA). Non-linear regression curve algorithm (variable 
slope) with IC50 calculation was used.   
 
Stage Delay Assessment 
Parasite stage progression during exposure to sub-lethal levels of MG132 was assessed 
via a 48-hour time course during which 3D7 parasites were counted for parasitemia and 
stage by microscopy at separate time points. A set of 200 µL synchronous sample 
cultures, with 0.5% Albumaxx II, 2% hematocrit, and 1% starting parasitemia, were 
incubated in 96-well plates under standard culture conditions for 48 hours. Cultures were 
diluted 1:5 at ring stage in fresh media, maintaining the same concentrations of 
hematocrit and respective compound. Parasites were examined at each time point by 
fixed-cell light microscopy / visual counting, blind to sample identification, to assess 
developmental stages and parasitemia. For each time point, over 2500 red blood cells 
were counted.  
 
SDS PAGE and Western Blot Analysis 
A set of 25 mL 3D7 cultures at 2% hematocrit and approximately 5% parasitemia were 
exposed to MG132 (or plain DMSO) during early/mid trophozoite stage. One culture was 
harvested for t=0 sample and remaining cultures were supplemented with 50 nM – 1 µM 
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of MG132 or plain DMSO, then incubated under standard conditions for 6 hours, and 
harvested using the same saponin lysis protocol as that described above, for enzymatic 
activity assays. Small aliquots (200 uL) of cultures exposed to 0 (control), 500 nM, and 1 
µM MG132 were saved and diluted 20-fold in MG132-free complete medium and 3% 
hematocrit and incubated under standard culture conditions for 7 days to assess parasite 
recovery. Protein was extracted from harvested parasites by agitation with 2 mm 
disruption beads in modified T-NET lysis buffer (50 nM Tris-HCl pH 7.4, 150 mM NaCl, 
5 mM EDTA, 0.1% Triton X-100, 100 nM MG132, 2 mM Ubiquitin Aldehyde). Samples 
were normalized by keeping lysate volume proportional to original culture volume, with 
the goal of all samples having the same number of cells per unit volume. SDS PAGE gel-
based protein fractionation was conducted using 4–15% Mini-PROTEAN® TGX™ gels 
(BioRad, Hercules, CA 94547) and Tris-glycine buffer (25 mM Tris, pH 8.3, and 192 
mM glycine) with 0.1% SDS. Western blots were generated using Tris-glycine buffer 
containing 15% methanol. An anti-ubiquitin primary antibody (Catalog #P4D1, Santa 
Cruz Biotechnlogy, Dallas, TX), previously shown to detect ubiquitylated proteins in P. 
falciparum, was used to detect the presence of ubiquitin-modified proteins [36]. 
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Results 
Bioinformatic Analysis 
Sequence analysis of individual components of the P. falciparum UPS was conducted in 
order to reveal similarities and differences between parasite UPS subunits and those of 
other organisms. Comparison of “e values” generated by protein sequence alignment of 
subunits from the 26S proteasome complex of P. falciparum and orthologous sequences 
in other organisms indicates a high degree of overall conservation (Table II). The most 
highly conserved subunits, with several comparisons showing an “e value” of 0, 
indicating no significant difference, are the proteasome regulatory subunits (e.g., RPN 
and RPT genes of the 19S proteasome complex). These subunits are responsible for 
substrate recognition, the opening of the proteasome pore, removal of polyubiquitin tags 
bound to substrate, and unfolding the substrate peptide to prepare it for degradation inside 
the 20S proteasome “barrel” [14-17]. 
 
The “alpha” and “beta” subunits of the 20S proteasome core demonstrate sequence 
similarity between species, but to a lesser degree than that we observe for the regulatory 
19S proteasome complex (Table II). A multiple-sequence alignment of one of these units, 
ß5 (an active protease, responsible for the chymotrypsin-like proteolytic activity of the 
proteasome core) is presented in Figure 2. Several residues that demonstrate high 
conservation between the organisms included are also key residues of the active site [14]. 
The protein sequences upstream of the catalytic threonine (Figure 2, first active site 
arrow) exhibit very low conservation between species. Cleavage of this portion of the 
polypeptide, leaving the active threonine at the N-terminus, is necessary for the enzyme 
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to become active after translation [14,16]. Downstream of the catalytic threonine, the N-
terminal region of the mature protein demonstrates a higher degree of conservation than 
the C-terminal region. Overall, the β5 subunit (a common target of inhibitors of 20S 
proteasome proteolytic activity) shows higher sequence conservation between species in 
comparison to the other subunits of the 20S proteasome core, including the well-
conserved catalytic subunits, β1 and β2, but significantly lower conservation than other 
members of the 26S proteasome, such as the regulatory subunits of the 19S proteasome 
regulatory particle (Table II). 
 
P. falciparum Growth Inhibition by Proteasome Inhibitors 
Growth/inhibition curves were generated in order to calculate half-maximal inhibitory 
concentration (IC50) values for each compound. Inhibition of parasite proliferation in 
culture was measured by growing 3D7 and Dd2 parasites for 72 hours (1.5 growth 
cycles) in the presence of varying concentrations of proteasome inhibitors MG132 (0 – 
2.5 µM), bortezomib (0 – 5 µM) and lactacystin (0 – 50 µM) and mefloquine (0 – 625 
nM), a known anti-malarial drug used as a control [42]. Relative DNA content was 
measured by SYBR Green® assay at the end of incubation period (Figure 3). Growth 
IC50 concentrations for each compound were calculated and the averages are indicated in 
Table III. For all compounds tested, IC50 values for the two strains used, 3D7 and Dd2 (a 
chloroquine-resistant strain [39]) were similar, Lactacystin had the highest IC50 value, 
which was in the three-digit nanomolar range (Table III). Bortezomib was the second 
highest, near 100 nM for both strains, and exhibited the highest variability between 
replicates. MG132 had the lowest IC50 values (34 nM and 40 nM for 3D7 and Dd2, 
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respectively) and the lowest standard error among replicate assays.  MG132 was favored 
for further proteasome inhibition work because it exhibited the lowest IC50 values and 
consistent antimalarial activity against cultured parasites. 
 
Delayed Death Assay 
A delayed death assay was conducted to assess whether prolonged exposure to MG132, 
which could be required in studies involving partial proteasome inhibition, could result in 
parasite lethality at significantly lower MG132 concentrations. To check for any delayed 
death effects on parasites resulting from MG132 exposure, SYBR Green® assays were 
used to compare growth rates over varied exposure times (Figure 4). Delayed death is 
defined as a greater than 10-fold reduction in IC50 when compound exposure time is 
extended for an additional growth cycle [43]. This effect could indicate targeting of the 
parasite apicoplast [43]. Mefloquine, which should not affect the apicoplast, and 
azithromycin, which should affect the apicoplast, were included as control compounds. 
Mefloquine is known to be a fast-acting anti-malarial compound, with potent anti-
malarial activity within the first 24 hours of exposure [42]. Azithromycin is known to 
target the apicoplast and to have a pronounced delayed death effect when exposure time 
is extended from 72 to 120 hours (1.5 to 2.5 cycles of growth) [43].  
 
As seen in Figure 4, growth inhibition curves were generated by comparing to control 
cultures, the cultures incubated for 24-, 72- and 120-hours in the presence of the 
compound indicated. IC50 values were calculated and summarized in Table IV. All assays 
began with parasites at ring stage. As predicted, the mefloquine IC50 value did not change 
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notably between 24, 72, and 120 hours of incubation, while the IC50 for Azithromycin 
dropped significantly between 72 and 120 hours. Although there was a slight decrease in 
the MG132 IC50 value when exposure time was extended, the change was less than 2-fold 
(Table IV). Neither the IC50 for MG132 nor the shape of inhibition curve changed 
significantly with respect to incubation time, following a similar pattern to that we 
observe for mefloquine. We conclude that there is no delayed death effect associated with 
prolonged MG132 exposure, so the compound could be used in studies requiring long-
term partial proteasome inhibition without any drastic changes in the concentration 
required to achieve lethality.  
 
Stage Delay Assessment  
In order to assess the ability and speed of parasite progression through growth stages 
while in the presence of sub-lethal MG132 concentrations, cultures were incubated in the 
presence of 25 nM and 50 nM MG132 and monitored for 48 hours. Synchronous 3D7 
parasite cultures at ring stage or mid-trophozoite stage were exposed to MG132, 
mefloquine, or vehicle (DMSO), and parasitemia and stage distribution were quantified at 
12-hour intervals for each culture (Figure 5). Significant delay in stage progression is 
observed at 50 nM MG132, and this delay is similar to that we observe for mefloquine, a 
compound known to cause a delay in parasite stage progression [42]. This delay entails 
an elongation of trophozoite maturation, resulting in inhibitor-treated parasites lagging 
behind control culture stage progression by about 12 hours. This occurred whether 
compound was added during the trophozoite stage or during the ring stage.  Although 
growth is slowed, parasites do exhibit continuing developmental progression throughout 
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the 48-hour incubation period in the presence of up to 50 nM MG132. The continued, but 
slowed, progression of parasites in the presence of 50 nM MG132 indicates that this 
concentration of MG132 can be used for partial proteasome inhibition in live parasites.  
 
Inhibition of Proteasome Enzymatic Activities  
The proteolytic activities associated with functioning proteasomes were measured using 
fluorogenic substrates [25] designed to individually measure chymotrypsin-like (CTL), 
trypsin-like (TPL), or caspase-like (CPL) proteolytic activities. Assay curves were 
generated to measure the abilities of MG132, bortezomib, and lactacystin to inhibit each 
type of activity (Figure 6). Inhibition of activity in the parasite proteasome (3D7 cell 
lysate) was tested and compared to that of the human proteasome (Jurkat cell lysate). 
Activity IC50 values for all compounds were calculated and are summarized in Table V. 
MG132 completely inhibited CTL activity with an IC50 of 129 nM in the parasite 
proteasome, without reducing TPL or CPL activities significantly below 50% at the 
maximum concentration used, 250 µM. This specificity is more apparent for the parasite 
proteasome than the human proteasome, for which all three types of activity are fully 
inhibited by MG132. Bortezomib inhibits CTL activity with an IC50 of 56 nM and CPL 
activity with an IC50 of 1285 nM without reducing TPL activity significantly below 50% 
in the parasite proteasome. Lactacystin reduces CTL activity to minimal levels with an 
IC50 of 3429 nM and lowers CPL activity to moderate levels (not to baseline), but does 
not significantly reduce TPL activity in the parasite lysate. All compounds exhibited 
higher IC50 values for the parasite proteasome than for the human proteasome. 
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Proteasome Inhibition Effects of Various Concentrations of MG132 and Parasite 
Recovery  
 
Accumulation of ubiquitin-tagged proteins, as evidence of proteasome inhibition, was 
examined by western blot in parasites exposed to varying concentrations of MG132 for 6 
hours (Figure 7). This accumulation is visible in all parasite cultures exposed to MG132, 
and it increases notably between 0 and 50 nM, then steadily increases as the 
concentration of MG132 increases, appearing to plateau when 500 nM or greater is added. 
(Figure 7A). Even the lowest MG132 concentration used, 50 nM, is sufficient to cause 
detectable inhibition of the proteasome after 6 hours of exposure.  
 
In order to determine whether cultures exposed to high concentrations of MG132 for 
short periods of time were able to recover following removal of inhibitor, cultures 
exposed to 500 nM or 1,000 nM MG132 for 6 hours were incubated under standard 
culture conditions for seven days following the removal of drug pressure. Growth and 
progression of these cultures was observed and compared to unexposed control cultures 
(Figures 7C and 7D). Although slow growth is apparent for the first cycle following the 6 
hour MG132 exposure (2-3 days), parasites recovered and were growing normally by day 
7.  We conclude that MG132 would be a candidate compound for studies seeking to 
assess the downstream after-effects of temporary proteasome inhibition in live parasites.  
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Discussion 
 
The UPS has numerous roles in the life cycles of eukaryotic cells, and the immediate and 
downstream effects of partial or complete proteasome inhibition vary between species 
[14-17]. Novel roles for the UPS are likely in P. falciparum; an obligate intracellular 
parasite that depends heavily on regular periodic shifts in gene expression that 
accompany stage progression [12-13, 23].  Protein degradation is one of the most 
important functions of the UPS, and the need for constant protein turnover is a hallmark 
of P. falciparum [14-17, 23]. In fact, only 6% of its proteome is common between all 
stages [23]. However, the proteasome and essential components of the UPS are present 
during all parasite developmental stages [16,23]. It is likely that the proteasome, and 
UPS-dependent protein degradation, plays significant roles in stage progression. Study of 
the UPS and the effects of differing levels of proteasome inhibition are desirable for 
better understanding of P. falciparum biology as a whole.  
 
We chose three canonical small-molecule proteasome inhibitors (SMPIs) at the start of 
this work because of their abilities to act as anti-malarials in P. falciparum culture [31-
33]. Enzymatic activity assays were used to examine the ability of each SMPI to hinder 
specific types of catalytic activities in the proteasome core. These comparative studies 
revealed that exposure to MG132, lactacystin or bortezomib each result in complete 
inhibition of culture growth with half-maximal inhibitory concentration (IC50) values 
below 1 µM, comparably to previous studies [31-33]. The compounds demonstrated 
differing levels of inhibition of enzymatic activity. The lower growth IC50 value observed 
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for MG132 in parasite culture and specificity in enzymatic activity assays led us to 
choose the use of MG132 for further examination as a tool compound for partial and 
complete proteasome inhibition studies. 
 
Lactacystin is a commonly used SMPI that has been utilized previously in proteasome 
studies, including experiments with P. falciparum [31-32,44]. It is an irreversible 
inhibitor that is known to covalently modify active sites inside the 20S proteasome core 
[24, 44]. We found lactacystin to have the highest growth IC50 value of the three 
compounds studied, with low variation between independent experiments. In regard to 
enzymatic activity, lactacystin was able to completely inhibit chymotrypsin-like (CTL) 
activity in the P. falciparum proteasome, but did not completely inhibit the trypsin-like 
(TPL) or caspase-like (CPL) activities. However, the compound required a very high 
concentration for inhibition of CTL activity, with an IC50 of over 3,000 nM. Although 
lactacystin is a canonical SMPI and does arrest parasite growth completely, the relatively 
high IC50 values for inhibition of both growth and enzymatic activity raise concerns about 
the efficiency of its use as a tool compound. Furthermore, the nearly 10-fold difference in 
the concentration required for inhibition of enzymatic activity compared to the 
concentration that arrests culture growth could make it difficult to study partial 
proteasome inhibition in live parasites. The large difference in growth IC50 and activity 
IC50 could also be the result of off-target effects overshadowing proteasome inhibition in 
culture, which is also a concern [24, 31-33].  
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Bortezomib is a reversible SMPI that has previously been used in laboratory-based 
proteasome studies, as well as clinical treatments [24,26,31-33,45]. In our hands, this 
compound demonstrated a desirably low growth IC50, but with high variation among 
replicate assays, meaning that its activity in culture is less predictable and consistent. 
This could be due to compound instability problems, as encountered by others when 
using bortezomib in culture medium of neutral or higher pH [45]. In this study, 
bortezomib demonstrated the ability to inhibit CTL and CPL activities in assays, but did 
not reduce TPL activity below 50%. The IC50 for inhibition of CPL activity is higher than 
that of CTL, so experiments aimed at specific inhibition of CTL activity may be feasible 
using lower concentrations. The fact that bortezomib is a commercially available for 
clinical treatment approved for cancer chemotherapy could make it preferable for 
experiments aimed at developing new anti-malarial treatments [24-27]. The similarly low 
IC50 values for inhibition of growth and enzymatic activity might appear to make it an 
attractive candidate for experiments examining proteasome activity in culture. However, 
based on our assessment, it is not ideal for use with P. falciparum in culture because of 
the relatively high variation observed between separate growth assays and persistent 
problems with compound instability [45].  
 
MG132 is a reversible inhibitor that is commonly used in cell culture and in vivo 
proteasome inhibition studies [24, 31-33, 46]. MG132 is also known to act directly on 
20S proteasome catalytic activity, although it does have some off-target effects [24]. In 
this study, MG132 exhibited far less variation in IC50 values between individual growth 
assay replicates, suggesting that there were no problems with compound stability. It also 
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has a relatively low commercial cost. The inhibition of enzymatic activity of the 
proteasome core subunits by MG132, as shown by our in vitro activity assays, seemed to 
be specific to the chymotrypsin-like activity in P. falciparum parasites. Neither the 
trypsin-like nor the caspase-like proteolytic activities of the proteasome are significantly 
affected, in contrast to the impacts of MG132 on human proteasome activities. This is a 
surprising result, and it could make MG132 of interest when precise targeting of CTL 
activity within the UPS is desired, with the caveat that MG132 has been shown to exhibit 
some off-target effects outside of the UPS [24].  
 
Upon further study, we find that MG132 is an effective and fast-acting anti-malarial in 
parasite culture. We do not observe the delayed death effect seen with some anti-malarial 
compounds [43]. Azithromycin, for example, has very little potency unless the parasites 
are incubated for longer than 3 days [43]. In delayed-death assays, MG132 growth curves 
exhibited similar forms to those for mefloquine, a compound known to inhibit growth 
within the first 24 hours of exposure [42]. Thus, MG132 can be relied upon to induce 
similar lethality (or lack thereof) at a given concentration when exposure time is extended. 
This could be of use in longer-term proteasome inhibition experiments.  
 
The ability to induce partial inhibition of proteasome activity with low doses of MG132 
also recommends it as a SMPI tool compound [40-41]. The delay (but not complete 
arrest) seen in developmental stage progression during 48 hours of exposure 
demonstrates the ability of low concentrations of MG132 to create cellular stress without 
causing immediate global lethality. This suggests that any critical processes controlled by 
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the proteasome can be studied using MG132-mediated partial proteasome inhibition in 
live cells by addition of sub-lethal concentrations of MG132; and that experiment 
duration could span at least one complete growth cycle.  
 
MG132 is highly effective for low-level, selective, partial proteasome inhibition in live P. 
falciparum cultures when administered at sub-lethal concentrations. In experiments 
conducted by others, MG132 has been shown to have a dual effect in parasites by 
targeting both the proteasome and falcipain cysteine proteases in P. falciparum [46]. 
However, MG132 has only been shown to inhibit P. falciparum cysteine proteases at 
higher concentrations [46]. Therefore, the cellular stress and inhibition of parasite 
development observed during exposure to low concentrations of MG132 is likely 
primarily due to proteasome inhibition, as demonstrated by the accumulation of 
ubiquitylated cellular proteins in parasites exposed to only 50 nM MG132 [Figure 7]. 
Ubiquitylated proteins accumulate in cells exposed to levels ranging from 50 nM to 1µM, 
in amounts that increase with respect to MG132 concentration [Figure 7]. This suggests 
that the degree of MG132-associated proteasome inhibition in cultured P. falciparum 
cells is dose-dependent. Our demonstration of the ability of low concentrations of 
MG132 to inhibit the proteasome implies that MG132 is an effective compound for the 
study of partial proteasome inhibition. 
 
We show that MG132 is effective for short-term inhibition of UPS function, as evidenced 
by observable proteasome inhibition after only 6 hours of treatment with varying 
concentrations of MG132. We also find that negative effects of proteasome inhibition on 
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parasite growth are reversible after this short exposure time, even at high MG132 
concentrations. Parasites exposed to concentrations as high as 1 µM MG132 for 6 hours 
were able to recover and proliferate normally within 7 days following removal of drug 
pressure. Therefore, transient effects and downstream consequences of short-term 
proteasome inhibition in P. falciparum can be studied using MG132.  
 
From our experiments, and those of others, it appears that the UPS in P. falciparum may 
be particularly crucial to trophozoite development [31-33,46]. The stage delay due to 
proteasome inhibition is most pronounced during the trophozoite stages, in agreement 
with previous studies that have observed progression stalling prior to DNA replication 
[31-33, 46]. Accumulation of ubiquitylated proteins during trophozoite stage is also 
substantial, as we have shown [Figure 7], which may make the roles of the proteasome 
during this stage attractive as a focus in future studies of the biology of the P. falciparum 
UPS.   
 
Overall, MG132 is a cost-effective small molecule proteasome inhibitor that has a 
lengthy history of use in the investigation of UPS function [37, 41,46]. We find that 
MG132 specifically inhibits P. falciparum proteasome CTL activity, within a relatively 
short period of time. Prasad et al. showed that MG132 targets both the 20S proteasome 
and falcipains in P. falciparum [46]. The effects of MG132 on falcipain activity were 
demonstrated at concentrations of 100 nM and higher, but the extent of inhibition of 
falcipains (and other cysteine proteases) by lower MG132 concentrations has not been 
established. We have presented data that show clear evidence of proteasome inhibition at 
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the lower concentration of 50 nM MG132, but more research would be required to assess 
any off-target effects associated with exposure to lower MG132 concentrations. We also 
demonstrate the ability to utilize MG132 reversibly in low-dose and high-dose 
experimental treatments, making it a desirable compound for studying of partial or 
complete inhibition of the proteasome in P. falciparum.  
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Figures and Tables 
 
 
 
a Numbers reported on PlasmoDB website (http://plasmodb.org/plasmo/)  
  
Table I: Orthologous elements common between P. falciparum and other speciesa 
 Species: Common 
Orthologous 
Groups: 
Common  
Distinct Genes 
% P.f. Genes with 
Orthologues 
Toxoplasma gondii 2308 2474 41.9% 
Homo sapiens 1590 1731 29.3% 
Mus musculus 1587 1728 29.2% 
Danio rerio 1567 1705 28.9% 
Anopheles gambiae 1470 1597 27.0% 
Saccharomyces 
cerevisiae 1296 1416 21.9% 
Escherichia coli 360 430 7.2% 
a Numbers reported on PlasmoDB website (http://plasmodb.org/plasmo/)  
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Table II: P. falciparum proteasomal subunits and homologous subunits in other organisms 
PlasmoDB 
Accessiona Gene
a Descriptiona e-values
b:  
H. sapiens S. cerevisiae 
D. 
melanogaster A. gambiae 
PF3D7_1474800 Alpha 1 Alpha Subunit, type 1 9.00E-44 3.00E-53 2.00E-55 2.00E-56 
PF3D7_0608500 Alpha 2 Alpha Subunit, type 2 8.00E-59 9.00E-71 2.00E-69 7.00E-75 
PF3D7_0317000 Alpha 3  Alpha Subunit, type 3 2.00E-33 6.00E-35 5.00E-35 4.00E-46 
PF3D7_1353800 Alpha 4 Alpha Subunit, type 4 4.00E-68 6.00E-67 1.00E-68 2.00E-70 
PF3D7_0727400 Alpha 5 Alpha Subunit, type 5 6.00E-66 3.00E-75 1.00E-72 2.00E-71 
PF3D7_0807500 Alpha 6 Alpha Subunit, type 6 6.00E-40 1.00E-52 3.00E-59 1.00E-60 
PF3D7_1353900 Alpha 7 Alpha Subunit, type 7 4.00E-65 3.00E-58 2.00E-59 1.00E-64 
PF3D7_0518300  Beta 1 Threonine Hydrolase 2.00E-38 4.00E-43 5.00E-48 6.00E-48 
PF3D7_1470900 Beta 2 Threonine Hydrolase 6.00E-29 7.00E-40 3.00E-41 3.00E-36 
PF3D7_0108000 Beta 3 Beta Subunit, type 3 1.00E-51 1.00E-46 1.00E-52 5.00E-47 
PF3D7_0803800 Beta 4 Beta Subunit, type 4 8.00E-26 1.00E-25 5.00E-28 1.00E-39 
PF3D7_1011400 Beta 5 Threonine Hydrolase 6.00E-56 4.00E-64 5.00E-64 4.00E-62 
PF3D7_0931800 Beta 6 Beta Subunit, type 6 4.00E-25 2.00E-27 1.00E-26 8.00E-30 
PF3D7_1328100 Beta 7 Beta Subunit, type 7 2.00E-62 2.00E-68 7.00E-71 1.00E-75 
PF3D7_1311500 RPT 1 ATPase 1.00E-175 0 0 0 
PF3D7_1008400 RPT 2 ATPase (opens pore) 3.00E-165 0 0 0 
PF3D7_0413600 RPT 3 ATPase 1.00E-155 8.00E-168 5.00E-165 7.00E-161 
PF3D7_1306400 RPT 4 ATPase 1.00E-148 2.00E-163 2.00E-165 4.00E-163 
PF3D7_1130400 RPT 5 ATPase (substrate recognition) 6.00E-167 3.00E-176 2.00E-171 4.00E-176 
PF3D7_1248900  RPT 6 ATPase 6.00E-169 3.00E-180 0 1.00E-177 
PF3D7_0205900 RPN 1 26S Regulatory 3.00E-144 6.00E-77 0 3.00E-117 
PF3D7_1466300 RPN 2 Ubiquitin Recognition 4.00E-114 0 4.00E-144 0 
PF3D7_1402300 RPN 6 Non-APTase Regulatory 2.00E-28 5.00E-27 1.00E-27 3.00E-26 
PF3D7_1030500 RPN 9 Non-APTase Regulatory 5.00E-17 3.00E-30 5.00E-31 2.00E-32 
PF3D7_0807800 RPN 10 26S Regulatory 5.00E-28 3.00E-29 4.00E-25 3.00E-31 
a Subunit information was obtained from PlasmoDB website (EuPathDB Project Team, Athens, GA) and  
b e-values were generated through BLAST comparison (NCBI, The National Library of Medicine, Bethesda, MD)!
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a IC50 mean and standard error for three independent experiments 
Strains: 3D7 is sensitive to most anti-malarial drugs, Dd2 is a  
chloroquine-resistant strain [38,39] 
 
 
 
 
a IC50 mean and standard error for three independent experiments 
*Mean IC50 value is significantly different from the other values in the  
same column, p ≤ 0.05, Turkey’s multiple comparison test 
 
  
Table III: IC50 valuesa for inhibition of parasite growth by SMPIs 
3D7 Dd2 
Lactacystin 
(nM) 492 ± 36.7  468 ± 116.1 
Bortezomib 
(nM)  93 ± 22.9 98 ± 41.8 
MG132 
(nM) 40 ± 4.7 34 ± 6.9 
Figure 3: Growth inhibition of cultured P. falciparum by proteasome 
inhibitors. Non-linear regression curves are shown for 3-day incubation of 
3D7 and Dd2 parasite cultures in the presence of three proteasome 
inhibitors: lactacystin, bortezomib, and MG132. Growth ratios were 
generated by comparing final DNA content (assessed via SYBR Green 
assay) to that of control cultures incubated for the same period of time but 
in the absence of inhibitor compounds.  
a IC50 mean and standard error of three independent experiments!
Table IV: IC50 Values f  Delayed Death Assaya  
MG132 
(nM) 
Mefloquine 
(nM) 
Azithromycin 
(nM) 
0.5 Cycles 
(1 Day) 43 ± 8.6 11 ± 3.0 2331 ± 593 
1.5 Cycles 
(3 Days) 35 ± 2.7 11 ± 2.2 2371  ± 491 
2.5 Cycles 
(5 Days) 27 ± 4.1 8 ± 4.1 *150 ± 81 
a IC50 mean a  standard erro  of three ind pendent experiments 
*Mean IC50 value is significantly different from the other values, p ≤ 0.05!
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a IC50 mean and standard error for three independent experiments 
PF = Plasmodium falciparum (parasite lysate) 
HS = Homo sapiens (Jurkat cell lysate) 
N/A = IC50 was not calculated because compound did not substantially reduce activity  
Activity Types = Chymotrypsin-like activity is associated with the β5 subunit, caspase- 
like activity is associated with the β1 subunit, and trypsin-like activity is  
associated with the β2 subunit [14,24,25]. 
 
 
  
Table V: IC50 values for inhibition of proteasome enzymatic activity by SMPIsa 
Inhibition of Enzymatic Activity:  
IC50 Vaule(s) a (nM) 
Inhibitor Substrate: Activity Type PF HS 
MG132  
SUC-LLVY-AMC Chymotrypsin-like 129  (±5.4) 71 (±1.9) 
Z-LLE-AMC Caspase-like N/A 2,237 (±341) 
Boc-LLR-AMC Trypsin-like N/A 798 (±146) 
Bortezomib 
SUC-LLVY-AMC Chymotrypsin-like 56 (±33) 6.5 (±1.4) 
Z-LLE-AMC Caspase-like 1285 (±162) 120 (±17.4) 
Boc-LLR-AMC Trypsin-like N/A 1,430 (±102) 
Lactacystin  
SUC-LLVY-AMC Chymotrypsin-like 3429 (±1202) 760 (±165) 
Z-LLE-AMC Caspase-like N/A 78,437 (±27,871) 
Boc-LLR-AMC Trypsin-like N/A 15,883 (±1642) 
a IC50 values are the mean and standard error of three independent experiments!
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Figure 1: Diagram of the 26S proteasome complex. Shown are regulatory subunits of the 
19S proteasome “lid and base” (brown and orange, respectively) and structural α subunits, 
structural β subunits, and active β subunits of the 20S proteasome core (green, blue, and 
mauve, respectively). Active sites of the β1, β2, and β5 proteases, facing in the interior of 
the proteasome core, are shown in red. During the degradation process, protein/peptide 
substrates that bear a polyubiquitin tag are modified by upstream UPS components, 
including proteasome regulatory subunits that recognize the polyubiquitin tag. The pore 
of the complex is opened by ATPases and the substrate is drawn in, where the 
polyubiquitin tag is removed, releasing free ubiquitin. Substrate is drawn further into the 
complex, where the active proteases of the 20S proteasome core degrade it and release 
small peptides that will be “recycled” by the cell.  
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Figure 2: Multiple sequence alignment of the Beta5 subunit of the 20S proteasome. 
Protein sequence of P. falciparum is compared to species indicated. Key active site 
residues are indicated by red arrows, including the N-terminal threonine (first red arrow) 
[14, NCBI protein database: http://www.ncbi.nlm.nih.gov/protein/]. A histogram along 
the top of the sequence represents the level of identity of each region, and a consensus 
sequence is shown above. The dark green bar traces the universal consensus sequence for 
the 20S proteasome Beta5 subunit as retrieved from the Conserved Domains Database 
(http://www.ncbi.nlm.nih.gov/cdd/).  
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Figure 3: Growth inhibition of cultured P. falciparum by small molecule proteasome 
inhibitors. Non-linear regression curves are shown for 3-day incubation of 3D7 and Dd2 
parasite cultures in the presence of three proteasome inhibitors: lactacystin, bortezomib, 
and MG132. Growth ratios were generated by comparing final DNA content (assessed 
via SYBR Green® assay) to that of control cultures incubated for the same period of time, 
but in the absence of inhibitors.  
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Figure 4: Assessment of delayed death effects of MG132, as compared to mefloquine 
and azithromycin, for growth of 3D7. Non-linear regression curves were generated by 
SYBR Green® assay and growth relative to 3D7 was compared after 1, 3 and 5 days of 
incubation.  
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Figure 5: Delay in developmental stage progression caused by MG132 exposure. MG132, 
mefloquine, or vehicle (DMSO) was added to synchronous parasite cultures during either 
ring stage (A) or mid-trophozoite stage (B) at concentrations indicated. In each chart, 
parasitemia (top, in black) and stage distribution (bottom, in color) at each time point 
over a 48-hour period are shown. Arrows mark instances of 1:5 culture dilution with 
fresh media and uninfected red blood cells. Stage abbreviations: R = ring, ET = early 
trophozoite, MT = mid-trophozoite, LT = late trophozoite, Sh = Schizont 
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Figure 6: Inhibition of P. falciparum proteasome enzymatic activities by small molecule 
proteasome inhibitors. Non-linear regression curves are shown for incubation of 3D7 
parasite (PF) and Jurkat human (HS) cell lysates in the presence of three proteasome 
inhibitors: lactacystin, bortezomib, and MG132. A) Chymotrypsin-like activity assayed 
using substrate SUC-LLVY-AMC. B) Trypsin-like activity assayed using substrate Boc-
LLR-AMC. C) Caspase-like activity assayed using substrate Z-LLE-AMC. 
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Figure 7: Accumulation of ubiquitylated proteins and parasite recovery of cultures 
exposed to MG132 for 6 hours. 3D7 cultures were exposed to varying concentrations of 
MG132 for 6 hours. Accumulation of ubiquitylated proteins in whole-cell parasite lysates 
was detected by western blot using an anti-ubiquitin primary antibody (A) [36]. Total 
protein content of lysates was visualized by Coomassie stain (B). RBC = uninfected red 
blood cell lysate used as a control. After the 6-hour period, cultures exposed to 1,000 nM 
or 500 nM MG132 (and unexposed control cultures) were diluted 20-fold in medium 
without MG132, and allowed to resume growth under standard culture conditions. 
Cultures were monitored over 7 days and growth rates (fold-change in parasitemia) at 2 
days (C) and 7 days post-exposure (D) were compared.   
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Abstract   
The ubiquitin-proteasome system (UPS) is a large protein “recycling” system present in 
eukaryotic cells and inhibition of the UPS by small-molecule proteasome inhibitors is 
toxic to Plasmodium falciparum parasite growth. The proteasome inhibitor MG132 is 
known to target the ß-5 subunit of the 20S proteasome complex, an active threonine 
hydrolase that participates in protein degradation. P. falciparum strains that demonstrate 
resistance to MG132 were developed through intermittent compound exposure.  Growth 
inhibition assays were conducted to assess levels of resistance to MG132, and varying 
levels of tolerance were observed. These lines demonstrated low-level resistance, or 
tolerance, to MG132 with IC50 values of about 2-5 times that of the wild-type parent 
strain. Sequencing revealed non-synonymous point mutations in the β5 subunit of the 20S 
proteasome in all resistant lines.  Tolerance to anti-malarial compounds is a critical 
precursor to clinical resistance and total failure of drug efficacy in clinical settings. A 
deeper understanding of the development of tolerance to proteasome inhibitors like 
MG132 could offer insights into the biology underlying development of resistance and 
the role of the UPS in malaria pathogenesis.  
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Introduction 
 
The evolution of drug resistance in pathogenic organisms is a major concern in the 
control of infectious diseases. Malaria, which is caused by apicomplexan parasites within 
the genus Plasmodia, is no exception [1-9]. Plasmodium falciparum, the species that 
causes the most acute cases of malaria, has developed resistance to many anti-malarial 
drugs [3, 5-9]. Historically, many drugs that had been highly effective for chemotherapy 
when first developed were subsequently rendered obsolete because of the development of 
resistance within parasite populations [1-13].  The appearance and spread of anti-malarial 
resistance within parasite populations soon after widespread deployment of many anti-
malarial drugs is largely due to the rapid evolution that is characteristic of Plasmodium 
species [1-4, 10-13]. Historical survey data highlighting dates that resistance became a 
hindrance to drug efficacy in malaria treatment worldwide [1-4] are shown in Figure 1. 
Although previous clinical and research studies have successfully identified the genetic 
sources of resistance in several cases, insight into the biology of how resistance 
commonly arises in Plasmodium falciparum remains incomplete [1-5, 7-8].  
 
One reason that Plasmodium parasites are highly adaptable is that these species possess 
the ability to generate substantial genetic polymorphisms over time [10-12]. The 
complexity of the parasite life cycle, which includes a single round of sexual 
reproduction within the mosquito vector and multiple rounds of asexual reproduction in 
the human host [13], provides opportunities for the generation of millions of polymorphic 
variants within each species, every year.  Outcrossing, or recombination between 
genomes of parasites with differing genotypes, and inbreeding, or recombination between 
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genomes of parasites with the same genotype, can occur during the sexual recombination 
stage in the mosquito midgut before parasites are transmitted to humans [13]. This is 
especially common in malaria-endemic areas where dense human populations coincide 
with abundant mosquito populations, and single mosquitoes frequently carry multiple 
parasite genomes [6, 8]. Drug pressure from any chemotherapy that infected individuals 
are undergoing will select for parasites bearing resistance alleles, which can arise 
randomly during the many cycles of asexual reproduction in the human bloodstream [10-
12]. Overall, the complex biology of the parasite contributes in many ways to the rapid 
evolution of Plasmodium species, and there is a need for continued research to better 
understand it [14-15]. 
 
Tolerance, or low-level resistance, to anti-malarial compounds is an important component 
of the biological dynamics of resistance [16-19]. Although “complete” resistance to an 
antimalarial drug or drug cocktail can sometimes be associated with single genetic 
variants that arise suddenly, this is not always the case [16-20]. Resistance often develops 
in steps, beginning with an intermediate ability to survive higher concentrations of a 
compound for longer periods of time than a sensitive strain [16-17]. Although tolerant 
parasites may not survive exposure to a drug at the concentration used for 
chemotherapeutic treatment, they may survive lower concentrations that may remain in 
the bloodstream during the days or weeks following treatment [16-19]. If a person is 
infected just after completing a chemotherapy regimen, tolerant parasites introduced into 
their bloodstream have a selective advantage [16-18]. The prominence of tolerance traits 
in a localized parasite population can give rise to higher-level resistance when subsequent 
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mutations occur, which could compromise clinical efficacy of the anti-malarial treatment 
[16-19].  
 
Public health officials have approached the challenge of the spread of drug-resistant 
parasites in a variety of ways [2, 4, 13]. The World Health Organization (WHO) endorses 
combination therapy, as opposed to “monotherapy” (the use of single-drug treatment 
regimes), as the standard treatment for malaria because the use of a cocktail consisting of 
several compounds with diverse targets is less likely to result in resistance selection [2, 
14-15,21-22]. Artemisinin combination therapy (ACT) is currently the most common 
standard malaria treatment worldwide [1-2, 22]. While ACT continues to be highly 
successful in long-term clinical use, recent cases of resistance and reduced sensitivity 
have been reported [23-25].  
 
Parasite physiological systems that facilitate stress tolerance, such as the 
ubiquitin/proteasome system (UPS), could be of importance to the development of 
resistance to anti-malarial compounds [16-20]. The UPS is a complex system used by 
eukaryotic cells for the selective degradation of proteins [26-28]. It consists of a highly 
diverse set of enzymes and structural proteins that identify, tag, and degrade protein 
substrates [26-28]. The UPS is present in the apicomplexan parasite that causes the most 
severe cases of malaria, P. falciparum, and plays a vital role in its life cycle [29-31]. 
Genomic-wide association studies have revealed that the UPS is strongly associated with 
drug response and resistance in P. falciparum field strains [20]. Proteasome inhibition 
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effectively arrests the growth of parasites in culture, leading researchers to identify the 
UPS as a possible target for chemotherapeutic treatment of malaria [29-31].  
 
The proteolytic machinery of the UPS, the “26S proteasome complex,” consists of a 
multi-subunit 19S proteasome regulatory “cap” that controls substrate entry, and a 20S 
proteasome “barrel” that degrades proteins that enter the complex [26-28, 32-33]. The 
20S proteasome particle is composed of stacked seven-subunit rings of peptides called 
alpha (α) and beta (β) subunits. Three of the seven types of β subunits, β1, β2, and β5, are 
active threonine proteases responsible for the catalytic activity of the complex [26-27, 30]. 
These proteolytic enzymes feature three types of activity, chymotrypsin-like (CTL), 
trypsin-like (TPL) and caspase-like (CPL), and function as a group [32-33]. Many 
common proteasome inhibitors target these enzymes, particularly the β5 subunit, which is 
responsible for CTL activity [32-34]. Proteasome inhibition mediated by small-molecule 
proteasome inhibitors (SMPIs) has been utilized clinically for cancer chemotherapy, and 
a number of cases of clinical resistance have been documented [34-41]. In cases in which 
the genetic basis of the resistance has been discovered, nearly all resistance involves 
mutations in the β5 subunit of the proteasome, at or near residues associated with 
enzymatic active sites or inhibitor binding sites [35-41]. Mutations in residues M45, A49, 
A50, C52, and C63 have been linked to SMPI resistance in human cell lines [35-41].  
  
One of the first-identified SMPIs, MG132, targets the N-terminal threonine of the β5 
subunit active site, and has potent anti-malarial activity in vitro [29-33]. We have 
generated parasite lines with increased tolerance to MG132. These parasites, called 
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“MGR” lines, survive high concentrations of MG132 for several days longer than wild-
type (WT) lines and even proliferate under drug pressure. This increased tolerance 
developed after many rounds of intermittent MG132 exposure. After observing parasite 
survival during MG132 treatment, growth inhibition was measured using a SYBR assay 
and IC50 values were calculated. The increased ability to survive in the presence of 
MG132 arose in each culture suddenly, but the observable IC50 values of individual 
MG132-tolerant lines varied. Sequencing of the β5 subunit revealed single non-
synonymous point mutations in each MGR line that were neither present in the parental 
WT population nor previously identified as single-nucleotide polymorphisms in other 
drug resistant parasites strains [42].  We conclude that these mutations arose during the 
course of MG132 selection, and may contribute to MG132 tolerance and/or to the 
MG132-resistance phenotype.  
 
There are several lines of experimentation could be followed if one were to extend the 
work described in this thesis. MGR lines could be subjected to further rounds of selective 
MG132 pressure to develop fully resistant lines, and resistance to other anti-malarial 
compounds could be assessed in those lines. This would extend the work beyond the 
realm of tolerance into the realm of full resistance, and enable exploration of the rate at 
which parasites become completely unresponsive to MG132. Cross-resistance studies 
could be conducted with lines that develop complete MG132 resistance, which could 
elucidate the role(s) that the UPS plays in stress tolerance and general drug resistance in 
P. falciparum. The genome(s) of resistant lines could be sequenced to determine the 
nature and number of mutations necessary to confer complete resistance. Overall, the 
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generation of tolerance to MG132 in P. falciparum, demonstrated by prolonged survival I 
observe in the presence of the compound, is a significant finding that could enable further 
studies of the UPS, drug resistance, and the genetic “bridge” between anti-malarial drug 
sensitivity and resistance. 
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Materials and Methods 
 
Parasite Strains and Cells 
The WT parental strain used for selections was P2G12, a substrain of the P. falciparum 
3D7 strain, obtained from the laboratory of Dr. Dyann Wirth of the Department of 
Immunology and Infectious Disease at the T.H. Chan Harvard School of Public Health 
(Boston, MA USA) [43]. Packed human red blood cells in CPDA-1 used for parasite 
culture were obtained from Research Blood Components (Boston, MA). All mutant lines 
were developed via selection for MG132 resistance in our laboratory. 
 
Compounds and Reagents 
MG132 and mefloquine were obtained from Sigma-Aldrich Co. LLC. (St. Louis, MO). 
Stocks were made by dissolving compounds in dimethyl sulfoxide (DMSO) at a 
concentration of 10 mM. Stock solutions were stored at -80oC.  
 
Parasite Culture Conditions  
All parasite culturing was conducted using the following standard conditions unless 
otherwise noted. Parasites were cultured in RPMI cell culture medium (Life Technologies 
Corp., Grand Island, NY), supplemented with 5.94 g/L HEPES, 0.05 g/L hypoxanthine, 
2.016 g/L sodium bicarbonate, and 0.025 mg/mL gentamicin. Prior to use, 0.5% 
Albumaxx II® (Life Technologies Corp., Grand Island, NY) was added to produce  
“complete” media. All cultures were maintained at 1-5% hematocrit. Cultures were 
incubated at 37°C in the presence of a gaseous mixture consisting of 1% O2, 5% CO2, and 
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94% N2. Cultures were diluted with uninfected red blood cells and fresh complete 
medium when parasitemia exceeded 1%  (as measured by microscopic examination of 
blood smears) or as required for experimental conditions.  
 
Parasite Stage Synchronization 
For parasite stage synchronization, infected red blood cells (iRBCs) were incubated in 
5% sorbitol at 37°C for five minutes. Cells were isolated by centrifugation at ~500xg and 
the supernatant discarded. Cells were then returned to culture with fresh complete 
medium.  
 
Resistance Selection 
Parasite drug resistance was generated by intermittent compound exposure, or repeated 
cycles of drug exposure followed by parasite recovery [25, 44]. Initial selections 
consisted of 100 mL 3D7 culture in complete medium, 3% hematocrit and 1% 
parasitemia, mixed stage. Cultures were exposed to either 50 nM or 250 nM MG132 and 
incubated for at least four days, or two days after signs of slowed or arrested growth. 
Every two to three days, parasites were fed with media containing fresh drug at the same 
concentration or greater. After incubation, drug pressure was removed by replacement of 
culture media with fresh media lacking MG132.  Cultures were permitted to recover 
under standard culture conditions for up to four weeks, during which recovering cultures 
received replacement RBC and media and parasites were monitored by microscopy every 
two to three days. A culture was considered “recovered” when parasitemia returned to 
1% or higher.  The cycle of drug pressure followed by recovery was repeated with the 
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same or increased drug concentrations until parasites showed an ability to proliferate in 
the presence of MG132 at a concentration lethal to the parental strain (over five times the 
IC50, as measured by SYBR Green assays).  
 
SYBR Green Assay for Growth Inhibition 
Growth/inhibition curves were generated by growth of cultures in the presence of MG132 
concentrations ranging from 0-2.5 µM.  Mefloquine was also used as an anti-malarial kill 
control compound [45], at a range of 0-625 nM, and cultures without drug (DMSO 
vehicle only) were used as a growth control. For each assay,180 uL cultures containing 
1% hematocrit at 1% parasitemia were grown at each concentration. Cultures were grown 
in 96-well plates for 72 hours, and four samples of 40 µL of each culture were transferred 
to 384-well clear-bottom, black assay plates for analysis. Each 40 µL sample was 
processed by the addition of 10 µL lysis buffer (0.16% saponin, 20mM Tris-HCl (pH 7.5), 
5mM EDTA, 1.6% Triton X-100) and SYBR Green® (Life Technologies Corp., Grand 
Island, NY) at 1:1,000 dilution.  Samples were incubated at room temperature, protected 
from light, for at least one hour to allow for complete cell and parasite lysis. Fluorescence 
was measured using emission/excitation settings of 494 nm/520 nm, respectively. Culture 
growth was assessed by calculating the ratio of fluorescence readings of compound-
treated cultures as compared to untreated control cultures incubated in the same plate. 
Baseline, which was established by the highest concentration of mefloquine (the kill 
control), was subtracted from readings and ratio of each sample culture growth to no-drug 
control was measured. Growth curves were generated and IC50 values calculated using the 
non-linear regression curve algorithm in GraphPad Prism® 6 software (GraphPad 
Software, Inc., La Jolla, CA). Statistical significance of mean IC50 values were 
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determined by application of the Dunnett's multiple comparisons test, α = 0.05, calculated 
with the GraphPad Prism® 6 software (GraphPad Software, Inc., La Jolla, CA), one-way 
ANOVA algorithm.  
 
 
Dilutional Cloning 
Clonal lines were generated from bulk selection cultures by limiting dilution. All cultures 
were synchronous and at ring stage. Using culture cell density measured using a 
hemacytometer and parasitemia as counted visually by microscopy, calculations were 
made in terms of iRBC/ µL. Culture was diluted in fresh media and 3% uninfected 
hematocrit, with a goal of 10 parasites per 96-well plate, for a Poisson probability of 
generating clonal lines that is greater than 0.99. Diluted sample cultures were then 
divided into the wells of a 96-well plate and grown under standard culture conditions and 
fed every two to four days for four weeks. After 2 weeks, cultures were diluted 1:2 with 
fresh media and hematocrit and plates were checked for parasite growth by lysing and 
analyzing 40 µL of discarded culture as described above. Wells were checked for parasite 
growth in the same manner after three weeks. Any wells without evidence of growth after 
4 weeks were considered clear of parasites. Wells with stable parasite cultures were 
scaled up to 25mL cultures, given an individual line number, and used in subsequent 
experiments. 
 
In order to separate bulk cultures into many reduced-diversity subcultures that can be 
screened for MG132 tolerance, each originating from three or fewer parasites, limiting 
dilution was performed as above with modifications. Reduced diversity subcultures were 
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isolated based on calculations that anticipated thirty-two parasites per culture volume or 
1/3 parasites per well in a 96-well plate. The Poisson probability of obtaining cultures 
that originated from three or fewer parasites using these calculations was predicted to be 
greater than 0.99. 
 
Screening for Increased Drug Tolerance 
 
Partially clonal/reduced diversity lines were screened for MG132 tolerance by growing 
cultures in the presence of 100 nM, 250 nM, and 500 nM MG132, respectively, and 
comparing growth to control cultures incubated without MG132 and cultures grown in 
the presence of 100 nM mefloquine. For comparison, the WT parental 3D7 strain was 
exposed to the same compound concentrations.  
 
Sequencing and Sequence Analysis 
P. falciparum gene reference sequences were obtained from the PlasmoDB website: 
http://plasmodb.org/plasmo/ (EuPathDB Project Team, Athens, GA) and NCBI/GenBank 
website: http://www.ncbi.nlm.nih.gov/genbank/ (The National Library of Medicine, 
Bethesda, MD). A fragment of the β5 subunit was amplified from each sample by 
polymerase chain reaction (PCR) for sequencing, which was conducted by Eton 
Bioscience (Boston Branch, Charlestown, MA 02129). Primers used in sequencing are: 
Beta5 AmpFwd: 5’-CTCAAGTTAATCATTAAAATATATTATAC-3’; Beta5SeqFwd: 
5’-GGAGGAGCTGCTGATTGCTTATATTGG-3’; Beta5Fwd: 5’-
ATGGTAATAGCAAGTGATGAAAGC-3’; and Beta5Rev: 5’-
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TCACATAACATATTGATCCTTTTG-3’. Analysis of sequence data was conducted 
using Finch TV® software (Geospiza, Inc., Seattle, WA 98119), The European 
Bioinformatics Institute website: http://www.ebi.ac.uk/Tools/emboss/ (EMBL-EBI, 
Hinxton, Cambridge, UK), and ClustalW Alignment Software (Conway Institute, UCD 
Dublin, Ireland). 
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Results 
Selection of MG132-resistant parasites  
We subjected sensitive WT 3D7 cultures to repeated rounds of selection via intermittent 
MG132 drug pressure in order to obtain parasite cultures resistant to MG132 [25,44]. 
Cycles of drug pressure, drug removal, and recovery were repeated until an observable 
shift in the ability of the parasites to survive and grow in the presence of MG132 was 
detected.  These rounds of drug exposure and recovery were carried out by two methods: 
gradual increase, where the concentration of MG132 in the initial exposure was sub-
lethal and increased in subsequent cycles; and rapid selection, where a lethal 
concentration was used for every round of selection, beginning with the first round. 
Selection rounds were repeated until parasites were able to proliferate in the presence of 
at least 250 nM MG132 (Table I), compared to the initial MG132 IC50 value of 34 nM in 
WT parasites (Table II).     
 
To assess the differences in changes in IC50 values for MG132 responses that could result 
from the different methods of selection, three separate cultures from the 3D7 parent strain 
were used. These cultures were designated MG132 resistance selection cultures #1, #2, 
and #3. Origin, generations, and numbers of cycles are shown in Figure 2. Selection 
culture #0 was subjected to gradually increasing selection, with the first exposure cycle 
involving the addition of 50 nM MG132, a sub-lethal concentration, to culture medium 
over a six day period. During subsequent cycles, the concentration was increased to 100 
nM, 150 nM, 250 nM, and 500 nM MG132. Before resistance was observed (that is, 
before live parasites were readily visible in smears after two or more days of drug 
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pressure), selection culture #1 (SC1) was split into culture MGR-1 and culture MGR-2, 
and MG132 exposure cycles continued for both cultures separately. Culture MGR-1 was 
eventually separated again into cultures MGR-1A and MGR-1B and subjected to one last 
round of selection. The rapid selection method was employed for selection culture #3 
(SC3), with all selection cycles conducted using 250 nM MG132 or higher, to yield 
culture MGR-3. Cultures MGR-1A, MGR-1B, and MGR-3 needed eight, eight, and seven 
rounds of selection, respectively, to develop increased ability to survive under drug 
pressure. Culture MGR-2 did not develop detectible resistance after nine cycles, so it was 
dropped from the study.  
 
When an observable number of parasites (>0.2% parasitemia) survived in cultures 
incubated for more than two days in the presence of 250 nM or greater concentration of 
MG132, they were considered “tolerant” of the compound and advanced to further study 
(Figure 2). Bulk selection cultures demonstrating increased tolerance to MG132 were 
designated MGR-1A, MGR-1B, and MGR-3. 
 
MG132-sensitive parasite cultures (such as our 3D7 WT parent line) respond to drug 
pressure with a rapid decrease in parasitemia within two days of the addition of at least 
250 nM MG132 (Figure 3). Surviving cultures were considered tolerant when parasites 
grew in number during the first two days of drug pressure, living parasites were still 
detected after four days under drug pressure, and normal growth resumed within one 
week after removal of drug pressure. Selection cultures MGR-1A, MGR-1B, and MGR-3 
all eventually demonstrated the ability to survive longer than 3D7-WT in the presence of 
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high concentrations of MG132, as shown in Figure 3. Parasitemia for all three cultures 
increased during the first two days of exposure to 250nM MG132, indicating the ability 
proliferate under drug concentrations that would be lethal to an MG132-sensitive strain. 
Culture growth slowed and began to decrease after four days, indicating that parasites had 
acquired the ability to survive longer, but not indefinitely, under MG132 drug pressure 
(Figure 3, right panels). 
 
Growth Inhibition Curves and IC50 Values for Bulk Resistant Cultures 
To assess the level of MG132 resistance of each selection culture, growth/inhibition 
curves were generated and half-maximal inhibitory concentrations (IC50 values) 
calculated for MG132 and mefloquine, an anti-malarial compound used as a control [45]. 
Curves were compared to those of the parent WT 3D7 strain. The growth/inhibition 
curves for the effect of MG132 and mefloquine on bulk cultures WT 3D7, MGR-1A, 
MGR-1B, and MGR-3 are shown in Figure 4A and 4C, respectively. Histograms showing 
the shifts in calculated MG132 and mefloquine IC50 values in relation to parental line are 
shown in Figure 4B and 4D, respectively. A notable increase in MG132 IC50 value of 
least two-fold over WT was observed in all selection cultures (Figure 4A and 4B). 
Likewise, notable shifts in mefloquine in IC50 values were also observed in selection 
cultures (Figure 4C and 4D).  
 
Establishment of Reduced-Diversity Subcultures and Clonal Lines From MG132-
Resistant Cultures 
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After completion of selection cycles and confirmation of increased tolerance to MG132 
in parasite cultures, individual tolerant lines were separated from bulk resistance cultures 
by limiting dilution cloning. Two strategies were employed to generate genetically 
distinct parasite lines.  For establishment of lines with reduced genetic diversity, or lines 
that might be clonal but were not assumed to be clonal, limiting dilution was used to 
generate many subcultures that were screened for MG132 resistance. For establishment 
of clonal lines, limiting dilution was employed with a goal of generating clonal parasite 
lines.  MG132 concentrations used for selection, number of cycles, and lines isolated by 
each method are listed in Table I.  
 
For the separation of reduced-diversity subcultures, limiting dilution was used with a 
dilution factor that should have corresponded to 0.33 parasites per well in a 96-well plate 
format. Parasite densities of bulk cultures were estimated by counting parasitemia by 
microscopy and measuring cell density with a hemocytometer. Cultures were then diluted 
and divided into smaller cultures to allow individual (or a few) parasites to grow into 
separate subcultures. MGR-1A and MGR-1B (the first of the bulk selection cultures to 
develop resistance) diluted cultures were separated into a 96-well culture plate for growth. 
A total of 52 wells from MGR-1A and 47 wells from MGR-1B showed parasite growth 
(Table I). Twelve subcultures from each were chosen and screened for MG132 and 
mefloquine tolerance (Figure 5).  Screening consisted of determining parasite growth 
ratios of cultures incubated under drug pressure for three days to the same cultures grown 
without drug pressure over the same time period. All screened cultures showed increased 
parasite survival, to varying degrees. Two lines from bulk culture MGR-1A: MGR-1As-1 
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and MGR-1As-22; and two from MGR-1B: MGR-1Bs-13 and MGR-1Bs-21, were 
chosen for further examination.  
 
Limiting dilution was conducted for all MGR cultures to establish clonal lines. Limiting 
dilution was performed using the same protocol as above except that dilution factor was 
calculated with a goal of 10 parasites from each culture to be divided into a 96-well plate 
to allow individual parasites to form clonal lines. All wells that demonstrated stable 
growth within four weeks of limiting dilution were expanded into clonal lines. Clonal 
lines were isolated from MGR-1A (designated MGR_1Ac-1, MGR_1Ac-2, and 
MGR_1Ac-3), five from MGR-1B, from which three were chosen for study (MGR_1Bc-
1, MGR_1Bc-2, and MGR_1Bc-3), and two from MGR-3 (MGR_3c-1, MGR_3c-2).  
 
IC50 Calculation for Reduced-Diversity Subcultures and Clonal Lines  
IC50 values were calculated from growth/inhibition curves for all clonal lines and reduced 
diversity cultures, and the results are shown in Table II.  As expected, MG132 IC50 values 
for all MGR bulk cultures were greater than for those for 3D7-WT. IC50 values revealed 
increased tolerance to MG132 by a factor between 1.5- and 5-fold for all cultures tested, 
with the exception of MGR-3c-2, a clonal line that did not demonstrate increased MG132 
tolerance. However, with the exception of the MGR-1A-Bulk culture, IC50 values of 
tolerant lines were not high enough to be reflect complete resistance, as determined by 
statistical significance with a P-value < 0.05.  Although separated for only one round of 
selection, IC50 values for reduced diversity subcultures derived from MGR-1A are 
notably higher than those for reduced diversity subcultures derived from MGR-1B. 
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MG132 tolerance in the clonal lines was generally lower than reduced-diversity culture 
and bulk cultures, indicating that parasite population diversity could be a contributing 
factor to overall resistance  [7,9-10]. Slight increases in mefloquine IC50 values were 
observed in most of the tolerant cultures, as well (Figure 6, Table II).  
 
Sequencing of the β5 subunit of MGR and WT lines 
Sequencing was performed to check for mutations in the β5 subunit of the 20S 
proteasome in the MGR and WT cultures as a possible genetic basis for resistance. 
Modifications to the β5 subunit have been linked to proteasome inhibitor resistance in 
humans in previous studies [35-41]. All MGR lines featured single point mutations in the 
β5 subunit, as listed in Table III. Neither the WT nor the MGR bulk cultures appear to 
have a mixed genotype at either of the codons in question, as illustrated by 
chromatograms from the WT and MGR bulk culture PCR-targeted β5 sequencing results 
shown in Figure 7.  Figure 7A shows the DNA sequence flanking the WT codon in 
question and Figures 7B and 7C show the same gene segment in the MGR strains, 
highlighting the base pair change from A to G in MGR-1A and MGR-1B at position 244 
(Table III). This mutation is non-synonymous and results in the amino acid change M22V. 
Figure 7D and 7E show WT and MGR-3 sequencing chromatograms for the area flanking 
the point mutation in culture MGR-3, A695G. Only a single peak exists for base pair 695 
in MGR-3, indicating that it is the predominant genotype. The A/G mutation at position 
695 is non-synonymous and results in the amino acid change G172E (Table III). 
Sequencing revealed that all reduced-diversity and clonal lines contained the same 
mutations found in their respective bulk MGR parental cultures [Table III]. 
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Discussion 
 
Intermittent compound exposure is a canonical method used to generate P. falciparum 
populations resistant to anti-malarial compounds [25,44]. This method has been used to 
generate resistant parasite lines to a variety of compounds, including artemisinin [22-25]. 
Artemisinin resistance was developed over several years and many selection cycles, and 
arose in steps beginning with tolerance, and eventually progressing to high-level 
resistance [25]. Drug tolerance, often a significant precursor to the development of full 
resistance, is currently of interest to researchers for understanding the evolution of 
resistance and for early detection of emerging resistance [16-21].  
 
We have generated parasites with increased tolerance to proteasome inhibitor MG132 in 
fewer than ten rounds of intermittent drug pressure. In previous studies conducted by 
others, increased tolerance to canonical antimalarial compounds has been attained 
through similar methods [25,44]. According to authors, tolerance to mefloquine arose 
rather quickly, within two weeks of exposure to sub-lethal levels of mefloquine [25]. In 
contrast, tolerance to artemisinin arose more slowly, requiring ten rounds of drug 
exposure before measurable changes in drug sensitivity were observed [44]. In this study, 
tolerance to MG132 arose more slowly, in a similar manner to artemisinin, requiring at 
least seven rounds of drug exposure before a decrease in sensitivity to MG132 was 
observed.  
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We used two selection strategies of intermittent compound exposure to encourage the 
emergence of resistance. The first method involved an initial period of prolonged 
exposure to 50 nM MG132, a sub-lethal concentration, similar to a precedential method 
used to obtain mefloquine resistance [25]. Parasites grew under this mild drug pressure 
for six days, creating cellular stress, and then drug was removed before the complete loss 
of detectable growing parasites from the culture.  During subsequent rounds of selection, 
the MG132 concentration was increased incrementally to levels lethal for WT parasites. 
The second method involved using a lethal concentration of MG132 for the first round of 
selection and using the same concentration in subsequent rounds, similar to the method 
employed in the previously mentioned study involving the generation of artemisinin 
resistance [44]. Beginning with a lower concentration of MG132 for selection mimicked 
the low levels of anti-malarial compounds that can be present in the bloodstream of 
patients during and after chemotherapeutic treatment regimens, a condition known to 
facilitate resistance development [2,3,16-18,24]. Reduced bloodstream drug 
concentrations can occur as a result of sub-therapeutic dosing or longer drug half-lives 
that allow residual, sub-therapeutic concentrations to linger in body for an extended time 
after treatment [2,3,16-18,24]. Beginning with a higher concentration of MG132 in 
rounds of selection mimicked therapeutic doses of antimalarial compounds that would 
likely be used in chemotherapy, and selection using this method has been successful for 
the development of drug resistant lines in vitro [2,3,15-18,22,44].  
 
During growth under drug exposure, parasites were observed by microscopy to ascertain 
their ability to survive in the presence of high concentrations of MG132. All MGR lines 
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demonstrated increased survival with exposure to at least 250 nM MG132 for four days, a 
remarkable difference from the parental strain. During cycles of exposure to 
concentrations of 250 nM MG132 or greater, visible parasite growth diminished 
significantly in sensitive strains within two days of exposure. Survival of selection 
cultures was the first evidence of MG132 tolerance [16-19,25], and IC50 values were 
calculated following its appearance.  
 
With the exception of MGR-1A Bulk culture and MGR-1As-22 reduced diversity 
subculture, MG132 IC50 values for selection cultures were not much greater than than 
that for 3D7-WT, so most cultures were not completely resistant to MG132 based on the 
statistical criterion of P < 0.05. Mean IC50 values were usually between two- and six-fold 
higher than for the WT parental line, and parasites survived several days longer while 
exposed to high concentrations of MG132, identifying the lines as MG132-tolerant [21-
24]. In these lines, low-level tolerance to mefloquine, an anti-malarial compound [29,50] 
that was used to check for cross-resistance, was also observed.  Although the changes in 
tolerance level for mefloquine in MGR cultures were slight, the apparent correlation 
between increases in tolerance to MG132 and mefloquine (r = 0.83, P = 0.0001, Figure 6) 
implies that parasites resistant to proteasome inhibitors could be resistant to other anti-
malarial drugs. The observation of increased mefloquine IC50 values in MGR lines could 
be due to an increased ability to withstand cellular stress – conferred by mutations in the 
UPS β5 subunit – even if that stress is induced by exposure to a compound that does not 
target the UPS directly.  
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The MGR cultures contained point mutations in the β5 subunit of the 20S proteasome.  
These mutations do not appear at a comparable level in chromatograms for the WT 
cultures, nor does the WT nucleotide sequence appear in chromatograms for MGR lines. 
In other words, neither the MGR lines nor the WT parental line exhibit a mixed genotype. 
In addition, the nucleotide variants in question are not listed in the PlasmoDB database as 
previously observed single-nucleotide polymorphisms (SNPs) in the 3D7 strain of P. 
falciparum [42], so likely arose during our selections. The emergence of these traits to 
predominance in cultures subjected to selection implies that these mutations result from 
MG132 resistance selection, as P. falciparum does not readily retain mutations without 
selective pressure [18,20, 49-51]. This assertion is further supported by the fact that many 
studies have linked point mutations in the β5 subunit of the 20S proteasome to SMPI 
resistance in other systems [35-41].  
 
A diagram showing the locations of the point mutations in the β-5 subunit protein 
sequence in MGR lines is presented in Figure 8. The mutations are shown in relation to 
several important features of the 20S proteasome β-5 subunit. Amino acids known to be 
part of the active site and the S1 binding pocket [46-48] are indicated. As indicated in 
Figure 8A, the mutation in MGR-1A and MGR-1B, M22V, is adjacent to the amino acid 
Ser21, a residue of the S1 binding pocket, a cavity in the tertiary protein structure known 
to bind small-molecule proteasome inhibitor compounds that affect β-5 subunit catalytic 
function [46-48]. The mutation in MGR-3, G172E, is in close proximity to a cluster of 
residues that are part of the active site, Asp166, Ser169, Gly170 [46-48]. This 
substitution could result in changes in proteasome catalytic function, as the replacement 
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of glycine with glutamic acid could cause a change in either protein conformation or 
enzymatic activity. Increased proteasome activity, either by enhancement of catalytic 
function or overexpression of proteasomes, has previously been linked to proteasome 
inhibitor resistance [36-38, 40-41]. Locations of mutations in the β5 subunit that have 
been linked to proteasome inhibitor resistance (human proteasome β5 subunit residues 
M45, A49, A50, C52, and C63) [35-41] are also indicated in Figure 8. As shown in the 
model of the homologous S. cerevisiae β5 subunit (Figure 8B), both mutations are 
predicted to be in the same general region within the protein tertiary structure, suggesting 
the importance of this region for the action of MG132 [32].  
 
We used two methods to separate genetically distinct lines derived from the original bulk 
selection culture. One method involved the use of dilution cloning to generate “reduced 
diversity” subcultures derived from one or a few individual parasites. These parasite 
populations were then analyzed by two rounds of screening for MG132 tolerance before 
selecting a few sublines to be used for full growth/inhibition curves.  The other method 
involved the use of dilution cloning with a greater dilution factor in order to establish 
several clonal lines for further examination. Although the point mutations observed in the 
parental resistant populations were present in all reduced diversity cultures and clonal 
lines derived from them (Table II), the IC50 values we observed for reduced diversity 
cultures and clonal lines were not equal to those observed for MGR parental bulk cultures. 
Tolerance levels differed, suggesting that secondary genetic variation elsewhere in the 
genome, influencing either MG132 tolerance or overall parasite fitness, was likely 
present. This question could be addressed more rigorously by whole-genome sequencing 
of reduced diversity cultures and clonal lines, to determine whether such mutations could 
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be identified, in the future.  The fitness cost of MG132 tolerance in P. falciparum is 
unknown, so these two methods were employed to ensure that stable cultures could be 
established by at least one method. Generating many subcultures and screening them 
proved to be valuable. The reduced-diversity subcultures of MGR-1A and MGR-1B 
demonstrated differing tolerance levels, and the ability to select from over 40 lines for 
robust growth and higher tolerance resulted in less risk of resistant culture failure in 
subsequent experiments. Overall, the reduced diversity lines had higher MG132 IC50 
values than the clonal lines. One of the MGR-3 lines, MGR-3c-2, did not demonstrate 
tolerance to MG132 as assessed by IC50, which could mean that the overall fitness of that 
parasite line was low, or that secondary mutations that resulted in MG132 sensitivity 
could have occurred in that line.  
 
Our studies have shown that resistance to the SMPI compound MG132 arises quickly and 
predictably in P. falciparum. Several parasite lines were generated with single, stable 
point mutations in the β5 subunit that were retained through several rounds of selection, 
cloning, experimentation, and isolation of DNA for sequencing. Whether proteasome 
inhibitors could be utilized in the chemotherapeutic treatment of malaria is unclear, even 
though they are used as drugs for treatment of other conditions [34-41]. Historically, 
tolerance and resistance mutations selected for by anti-malarial drugs have arisen rapidly 
in the field, which has led to failure of some anti-malarial drugs very soon after their 
introduction [1-3,15,17]. However, these were instances in which anti-malarial 
compounds were administered as monotherapies, rather than as components of 
combination therapies [2-4,18,19]. The distinct mechanisms of SMPI action, as compared 
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to anti-malarial drugs currently used for chemotherapy, could make them effective drug 
cocktail components, although toxicity studies are necessary [2-4,18,19]. In previous 
studies, cases of multi-drug resistance have been observed and traced to mutations in 
genes such as pfMDR (P. falciparum multi-drug resistant locus), and pfCRT (P. 
falciparum chloroquine resistance transporter) [3,5,8,44].  The observed correlation 
between slight increases in MG132 and mefloquine tolerance would need to be verified 
through further study to determine whether the correlation is specific to these tolerance-
selected parasite lines, or indicative of a connection between UPS function and the action 
of quinolone chemotype anti-malarial compounds [20,49]. This idea is worth exploring in 
the future, especially since genome-wide association studies (GWAS) of P. falciparum 
field strains have revealed that several components of the UPS have undergone positive 
selection related to drug resistance [20,49]. This may be due to the role of the UPS in 
cellular stress responses [20,26,27]. The mutations generated in this study add to the 
catalogue of tolerance-associated genotypes, information that may prove useful 
eventually for predicting and tracking resistance to anti-malarial compounds.  
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Figures and Tables 
 
 
 
a MG132 concentrations shown are those that were used for selection cycles, in order 
listed. 
b Numbers of total lines resulting from culture growth after limiting dilution are indicated 
in the first line. Parasite lines (with names) listed below were used in further study. 
Poisson probabilities of lines being clonal are as follows. “Clonal” is defined as a 
culture or line that originated from one parasite, seeded during limiting dilution. 
Poisson probability calculation is based on the number of wells, among all wells 
potentially inoculated, that ultimately yielded viable parasite subcultures. For all 
“clonal” lines: P > 0.99. For “reduced diversity” cultures: P = 0.90 and P = 0.91 for 
MGR-1A and MGR-1B, respectively. For the MGR-1B parental culture, five clonal 
populations arose in 96-well plates, but only three wells were expanded into clonal 
lines. 
 
 
 
 
 
  
a MG132 concentrations shown are those that were used for selection cycles, in order listed. 
b Numbers of total lines resulting from culture growth after limiting dilution are indicated in the first  
 line. Parasite lines listed below are those used in further study.!
Table I: Selection of MG132 Resistance in P. falciparum culturesa 
Selection 
Culture: 
MG132 Concentration 
(x number of cycles): 
Reduced Diversity 
Cultures:b Clonal Lines Isolated:b 
MGR-1A 50 nM (1x) 52 Lines total 3 Lines Total 
75 nM (1x) MGR-1As-1 MGR-1Ac-1 
150 nM (2x) MGR-1As-22 MGR-1Ac-2 
250 nM (4x) MGR-1Ac-3 
MGR-1B 50 nM (1x) 47 lines total  5 Lines Total 
75 nM (1x) MGR-1Bs-13 MGR-1Bc-1 
150 nM (2x) MGR-1Bs-21 MGR-1Bc-2 
250 nM (4x) MGR-1Bc-3 
MGR-3 250 nM (5x) 2 Lines Total 
500 nM (1x) MGR-3c-1 
1,000 nM (1x) MGR-3c-2 
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a IC50 values are the mean and standard error of at least two independent experiments 
* Mean IC50 value is significantly different than wild type, P ≤ 0.05 
** Mean IC50 value is significantly different than wild type, P ≤ 0.01 
a IC50 values are the mean and standard error of at least two independent experiments!
Table II: IC50 Values of Reduced Diversity Cultures and Clonal Lines a 
Type:  
MG132  
IC50  (nM) 
Fold 
Change 
Mefloquine  
IC50  (nM) 
Fold 
Change 
WT 3D7 Parent Line 3D7 WT 34 ± 6.5 7.3 ± 1.3 
Bulk Selection Cultures: MGR-1A-Bulk 158 ± 35** 4.6 17.4 ± 3.9 2.4 
MGR-1B-Bulk 127 ± 59 3.7 15.0 ± 5.4 2.0 
MGR-3-Bulk 76 ± 17 2.3 13.0 ± 2.9 1.8 
Reduced Diversity 
Subcultures: MGR-1As-1 115 ± 65 3.4 21.2 ± 8.8 2.9 
MGR-1As-22 152 ± 52* 4.5 22.7 ± 5.6 3.1 
MGR-1Bs-13 64 ± 18 1.9 12.9 ± 3.0 1.8 
MGR-1Bs-21 92 ± 12 2.7 17.3 ± 2.0 2.4 
Clonal Lines: MGR-1Ac-1 56 ± 12 1.7 10.0 ± 2.2 1.4 
MGR-1Ac-2 70 ± 25 2.1 12.0 ± 4.0 1.6 
MGR-1Ac-3 68 ± 37 2.0 14.0 ± 6.5 1.9 
MGR-1Bc-1 80 ± 20 2.4 15.9 ± 3.6 2.2 
MGR-1Bc-2 56 ± 10 1.6 11.0 ± 2.3 1.5 
MGR-1Bc-3 76 ± 4 2.3 14.8 ± 1.3 2.0 
MGR-3c-1 69 ± 20 2.0 14.1 ± 3.1 1.9 
MGR-3c-2 33 ± 2 1.0 8.5 ± 0.1 1.2 
a IC50 values are t e mean and standard error of at least two independent experim ts 
*!Mean!IC50!value!is!signiﬁcantly!diﬀerent!than!wild!type,!P!≤!0.05!
**!Mean!IC50!value!is!signiﬁcantly!diﬀerent!than!wild!type,!P!≤!0.01!
 93 
 
 a Non-synonymous mutations as detected by sequencing of the  
β5 subunit of the wild type 3D7 parent line and MGR resistance lines.  
 Mutations listed were confirmed in all clonal lines and reduced diversity cultures 
associated with selection cultures listed, by PCR-targeted resequencing. 
 
  
a Non-sy onymous mutati ns as detected by sequencing of the β-5 subunit 
of the wild-type 3D7 parent line and MGR resistant lines. Mutations shown 
were confirmed in all clonal lines and reduced diversity cultures associated 
with selection cultures listed.!
Table III: Point Mutations in the β5 Subunit of the 20S Proteasomea 
Selection Culture: Base Pair Change: Amino Acid Change: 
MGR-1A A244G M22V 
MGR-1B A244G M22V 
MGR-3 G695A G172E 
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Figure 1: Spread of resistance to some common anti-malarial drugs by year [1-4]. 
Overall sensitivity to anti-malarial compounds in historical clinical cases is shown. 
Shading indicates initiation of widespread clinical use of each compound, and fading 
indicates waning of overall potency for treatment of symptomatic malaria cases. SP: 
sulfadoxine-pyrimethamine 
  
  
< 1950 1950 1960 1970 1980 1990 2000 2010 Currently 
Quinine 
Chloroquine 
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Mefloquine 
Atovaquone 
Artemisinin 
Anti-Malarial Drugs: Sensitivity in Clinical Cases 
Figure 1: Worldwide clinical use of anti-malarial drugs and the spread of resistant parasites are represented by the 
timeline. Historical periods where specific anti-malarial drugs were broadly deployed for chemotherapy are shown 
by shading. Fading marks the subsequent years when the spread of resistance compromised overall ffectiveness of 
each drug.“SP” is sulfadoxine / pyrimethamine and “ACT” is artemisinin combination therapy. 
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Figure 2: Development of MG132-resistant cultures through cycles of intermittent 
parasite exposure to MG132. Origin and generations of “MGR” resistant lines are shown, 
as well as number of selection cycles between steps. Selection culture #1 (SC #1) was 
exposed to five cycles of selection before being split into MGR-1 and MGR-2 before 
tolerance was detected; then MGR-1 was split into MGR-1A and MGR-1B. Selection 
culture #3 (SC #3) was an independent line that was never divided into separate 
selections. MGR-2 did not acquire observable tolerance and was eliminated from the 
study.  
MG132 Resistance Selection in P. falciparum 
SC #1 
MGR-2 
SC #3 
Wild-type 3D7 Parent Line 
MGR-1A MGR-1B 
MGR-1A MGR-1B MGR-3 (No Resistance) 
5 Cycles 
MGR-1 
2 Cycles 
4 Cycles 
7 Cycles 
1 Cycle 1 Cycle 
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Figure 3: MG132 tolerance of cultures subjected to resistance selection, assessed by 
observed persistence. During cycles of MG132 selection, cultures were monitored by 
microscopy to check for phenotypic changes in response to drug pressure. Photos shown 
compare the persistence of wild type parasites to MGR lines after 0, 2 and 4 days of drug 
pressure (250 nM MG132). Parasitemia of cultures shown is indicated in the lower right 
corner of each photo. Those marked with an asterisk (*) were diluted 1:5 with fresh 
media and drug on the day the photo was taken, before continuing incubation.  
 
 
Day 0 Day 2 Day 4 
3D7 WT 
(sensitive) 
MGR-1A 
(resistant) 
MGR-1B 
(resistant) 
MGR-3 
(resistant) 
1.6% < 0.2% < 0.2% 
1.6% *3.2% 0.5% 
2.0% *3.4% 
0.7% 2.8% 1.7% 
0.6% 
Persistence of MG132 Resistant Cultures 
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Figure 4: Resistance levels of MGR-1A, MGR-1B, and MGR-3. IC50 curves for bulk 
resistance cultures were compared to WT-3D7. Comparative growth/inhibition curves for 
MG132 and mefloquine are shown in A and C, respectively. Mean IC50 values are shown 
in panels B and D.   
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Figure 4: Resistance levels of MGR-1A, MGR-1B, MGR-3 are measured. IC50 curves for bulk resistance cultures were generated and 
compared to WT-3D7. Comparative IC50 curves for MG132 and mefloquine are shown in A and C, respectively. Mean IC50 values are 
shown in panels B nd D.   
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Figure 5: Reduced-diversity subcultures were screened for tolerance to MG132 by 
growing each culture under drug pressure for three days. Each culture was grown in the 
presence of varying concentrations of MG132 or 100 nM mefloquine (anti-malarial 
control) and ratios of parasite presence (DNA content of culture) after growth period 
compared to unexposed control cultures are shown.  
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Figure 6:  The correlation between fold changes in MG132 and mefloquine IC50 values 
observed in MGR lines is shown. Each point represents one individual MGR line 
(numerical values for individual lines are listed in Table III), X and Y axes represent fold 
changes in mefloquine and MG132 IC50 values, respectively. Plot was generated with 
GraphPad Prism® 6 software linear regression algorithm with Pearson’s correlation 
calculation (GraphPad Software, Inc., La Jolla, CA). 
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Figure 6:  The correlation between fold changes observed in MG132 and mefloquine IC50 
values in MGR lines is shown. Each point represents one individual MGR line (numerical 
valu s for individual lines are lis ed in Table III), X and Y axes represent fold changes in 
mefloquine and MG132 IC50 values, respectively. Plot was generated with GraphPad 
Prism® 6 software linear regression algorithm (GraphPad Software, Inc., La Jolla, CA).  
r = 0.832 
P = 0.0001 
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Figure 7: Sequencing chromatograms of genomic segments within which non-
synonymous mutations were detected in resistant lines, with WT 3D7 chromatograms for 
comparison. WT-3D7, MGR-1A, MGR-1B chromatograms for the genomic segment 
flanking base pair 244 are shown in sections A, B, and C, respectively. WT-3D7 and 
MGR-3 chromatograms for the genomic segment flanking base pair 695 are shown in D  
and E, respectively. Each changed base pair is indicated by a red asterisk.    
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Figure 6: Sequencing chromatograms of areas where non-synonymous mutations were detected 
in resistant lines and WT 3D7 for comparison. WT-3D7, MGR-1A, MGR-1B chromatograms for 
the same sequence are shown in sections A, B, and C, respectively. WT-3D7 and MGR-3 are 
shown in D and E, respectively. Each changed base pair is indicated by a red asterisk.   
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Residues in S1 Binding pocket: 
Thr 1 
Thr 21 
Gly 47 
Ala 49 
Ala 50 
Asp 114 
Residues in the active site: 
 
Thr1,  
Glu17,  
Arg19,  
Lys33,  
Ser129,  
Asp166,  
Ser169,   
Gly170.  
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Figure 7: Diagram of the P. falciparum 20S proteasome mature protein sequence. Tick marks 
begin at the N-terminal threonine (Thr1), since the sequence upstream of it is cleaved to produce 
the mature, active protein. Active site residues (Thr1, Glu17, Arg19, Lys33, Ser129, Asp166, 
Ser169, Gly170) are each marked with a black asterisk and key residues of the S1 binding pocket 
(Thr1, Thr21, Gly47, Ala49, Ala50, Asp114) are each marked with a white asterisk.  Black arrows 
at the top of the diagram point to the amino acid changes in MGR cultures generated in this study. 
Gray arrows below the diagram point to mutations known to be associated with proteasome 
inhibitor resistance; published previously by others [24-29]. Amino acid #63 is cysteine in the 
human proteasome (precedent for proteasome inhibitor resistance in published literature), but is 
isoleucine in P. falciparum, and distinction is noted parentheses.  
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Figure 8: A) Diagram of the P. falciparum 20S proteasome β5 subunit mature protein sequence. 
Tick marks begin at the N-terminal threonine (Thr1), since the sequence upstream of it is cleaved 
to produce the mature, active protein. Active site residues (Thr1, Glu17, Arg19, Lys33, Ser129, 
Asp166, Ser169, Gly170) are each marked with a black asterisk and key residues of the S1 
binding pocket (Thr1, Thr21, Gly47, Ala49, Ala50, Asp114) are each marked with a white 
asterisk.  Black arrows at the top of the diagram point to the amino acid changes in MGR cultures 
generated in this study. Gray arrows below the diagram point to mutations known to be associated 
with proteasome inhibitor resistance; published previously by others [24-29]. Amino acid #63 is 
cysteine in the human proteasome (precedent for proteasome inhibitor resistance in published 
literature), but is isoleucine in P. falciparum, and distinction is noted parentheses. B) Three-
dimensional model of the homologous S. cerevisiae 20S proteasome β5 subunit highlighting 
locations of key residues of the active site and S1 binding pocket. Arrow indicates the general 
area where both mutant residues of MGR lines are expected to be located [27]. Explanation of 
coloring is taken from reference 27: “The hydroxyl oxygen of Thr1 is red and the nitro- gen of its 
free amino group is dark blue; other parts are yellow. Asp17 and Lys33 are colored orange except 
the e-amino group of Lys33, which is also dark blue. The conserved residues Ser129, Asp166 and 
Ser169 (as well as the variable residue 168) are shown in slightly brighter tone of the subunit 
color. Together with Lys33 and Asp17, these conserved residues contribute to the charge relay 
system sur- rounding Thr1. The variable residues at positions 20, 21, 31, 45, 49 and 53 are each 
colored in a still brighter tone and form the surface of the substrate binding pocket.” 
1566 W. Heinemeyer, P. C. Ramos and R. J. Dohmen The ultimate nanoscale mincer
ter of negatively charged residues and was implicated in
the generation of the N-termini of the inactive b6 and b7
subunits. These subunits possess propeptides that un-
dergo intermediate processing, resulting in short propep-
tide remnants in the matured particle, which with their
N-termini meet at a common point at the b-annulus.
However, the hypothesis that processing of the b6 and b7
precursor also occurs at this very point did not prove true,
since with the aid of yeast active site mutants the N-ter-
minal shortening of these precursors of inactive subunits
could clearly be shown to depend on the activity of the
known proteasomal Ntn-hydrolases [32] (see below). The
conformation and orientation of the two propeptide rem-
nants seen in the crystal structure thus must be reached
only after their trimming by neighboring active sites. The
recent report on the bovine 20S proteasome structure re-
vived speculations about an unusual, additional protease
site, which the authors propose to rely on the N-terminal
threonine (Thr-8) of b7 as nucleophile and a different
charge relay system than that characterized for the three
established Ntn-protease subunits [23]. This purely hypo-
thetic site would thus again lie close to the b-annulus and
would have a peptide binding groove that even extends
into the antechamber. Until now, biochemical proof for
such active site is lacking. Remarkably, in the yeast pro-
teasome there exists no corresponding structure, and mu-
tagenesis of the N-terminal Thr-8 of the yeast b7/Pre4
subunit excluded at least its participation in any of the
classical peptidase activities and had no phenotypic con-
sequences [29]. In summary, a verification of this or any
other new proteolytic site is still lacking and would come
as a surprise. 
The distinguishing specificities of the three known active
sites resulting in a preference of cleavage after acidic, ba-
sic or large hydrophobic residues at the P1 position in ar-
tificial peptide substrates must correlate with the charac-
Figure 3. The structures of the three types of active sites in the Saccharomyces cerevisiae 20S proteasome. Upper row, ball-and-stick rep-
resentations; lower row, space-filling representations of the same parts visible above. The views are from similar perspectives to show the
similarities among the active sites. Coloring of the subunits is according to figure 2, except for those residues which are labelled in the up-
per row and contribute to the formation and catalytic function of the active site pocket: The hydroxyl oxygen of Thr1 is red and the nitro-
gen of its free amino group is dark blue; other parts are yellow. Asp17 and Lys33 are colored orange except the e-amino group of Lys33,
which is also dark blue. The conserved residues Ser129, Asp166 and Ser169 (as well as the variable residue 168) are shown in slightly
brighter tone of the subunit color. Together with Lys33 and Asp17, these conserved residues contribute to the charge relay system sur-
rounding Thr1. The variable residues at positions 20, 21, 31, 45, 49 and 53 are each colored in a still brighter tone and form the surface of
the substrate binding pocket.
M22V$
G172E$
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Figure 8: A) Diagram of the P. falciparum 20S proteasome β5 subunit mature protein 
sequence. Tick marks begin at the N-terminal threonine (Thr1), since the sequence 
upstream of it is cleaved to produce the mature, active protein. Active site residues (Thr1, 
Glu17, Arg19, Lys33, Ser129, Asp166, Ser169, Gly170) are each marked with a black 
asterisk, and key residues of the S1 binding pocket (Thr1, Thr21, Gly47, Ala49, Ala50, 
Asp114) are each marked with a white asterisk.  Black arrows at the top of the diagram 
point to the amino acid changes in MGR cultures generated in this study. Gray arrows 
below the diagram point to mutations known to be associated with proteasome inhibitor 
resistance, published previously by others [29-34]. Amino acid #63 is cysteine in the 
human proteasome (precedent for proteasome inhibitor resistance in published literature, 
add REFs), but is isoleucine in P. falciparum, and the distinction is noted parentheses.  B) 
Three-dimensional model of the homologous S. cerevisiae proteasome β5 subunit, 
highlighting locations of key residues within the active site and the S1 binding pocket.  
Positions at which mutant residues of MGR lines (M22V and G172E) are predicted to be 
located are indicated by arrows [32]. Explanation of coloring is taken from Reference 32: 
“The hydroxyl oxygen of Thr1 is red and the nitrogen of its free amino group is dark 
blue; other parts are yellow. Asp17 and Lys33 are colored orange except the epsilon-
amino group of Lys33, which is also dark blue. The conserved residues Ser129, Asp166 
and Ser169 (as well as the variable residue 168) are shown in slightly brighter tone of the 
subunit color. Together with Lys33 and Asp17, these conserved residues contribute to the 
charge relay system surrounding Thr1. The variable residues at positions 20, 21, 31, 45, 
49 and 53 are each colored in a still brighter tone and form the surface of the substrate 
binding pocket.” 
 104 
References 
 
1. Sa, JM, Chong JL, Wellems TE. 2011. Malaria drug resistance: new observations 
and developments. Essays Biochem. 201-1(51):137-160 
 
2.  Sibley CH. 2014. Understanding drug resistance in malaria parasites: basic science 
for public health. Mol Biochem Parasitol. 195(2):107-114 
 
3.  Mita T, Tanabe K, Kita K (2009) Spread and evolution of Plasmodium falciparum 
drug resistance. Parasitol Int. 58(3):201-209 
 
4.  Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy 
PE. 2008. Malaria: progress, perils, and prospects for eradication. J Clin Invest. 
118(4):1266-1276 
 
5.  Le Bras J, Durand R. 2003. The mechanisms of resistance to antimalarial drugs in 
Plasmodium falciparum. Fundam Clin Pharmacol. 17(2):147-153 
 
6.  Talisuna AO, Okello PE, Erhart A, Coosemans M, D'Alessandro U. 2007. 
Intensity of malaria transmission and the spread of Plasmodium falciparum resistant 
malaria: a review of epidemiologic field evidence. Am J Trop Med Hyg. 77(6 
Suppl):170-180 
 
7. Talisuna AO, Bloland P, D'Alessandro U. 2004. History, dynamics, and public 
health importance of malaria parasite resistance. Clin Microbiol Rev. 17(1):235-254 
 
8. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, 
Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, 
Davis TM, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha 
N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé AA, El-
Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, 
Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, 
Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, 
Nzila A, Oguike M, Otienoburu SD, Ogutu B, Ouédraogo JB, Piola P, Rombo L, 
Schramm B, Somé AF, Thwing J, Ursing J, Wong RP, Zeynudin A, Zongo I, 
Plowe CV, Sibley CH; ASAQ Molecular Marker Study Group; WWARN AL 
2014. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter 
and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes 
for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. 
Am J Trop Med Hyg. 91(4):833-843.  
 
9. Barnes KI, White NJ. 2005. Population biology and antimalarial resistance: The 
transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop. 
94(3):230-240 
 
 105 
10. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S, Gujja S, 
Goldberg JM, Young S, Zeng Q, Chapman SB, Dash AP, Anvikar AR, Sutton 
PL, Birren BW, Escalante AA, Barnwell JW, Carlton JM. 2012. The malaria 
parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium 
falciparum. Nat Genet. 44(9):1046-1050 
 
11. Ocholla H, Preston MD, Mipando M, Jensen AT, Campino S, MacInnis B, 
Alcock D, Terlouw A, Zongo I, Oudraogo JB, Djimde AA, Assefa S, Doumbo 
OK, Borrmann S, Nzila A, Marsh K, Fairhurst RM, Nosten F, Anderson TJ, 
Kwiatkowski DP, Craig A, Clark TG, Montgomery J. 2014. Whole-genome scans 
provide evidence of adaptive evolution in Malawian Plasmodium falciparum isolates. 
J Infect Dis. 210(12):1991-2000 
 
12. Kidgell C, Volkman SK, Daily J, Borevitz JO, Plouffe D, Zhou Y, Johnson JR, 
Le Roch K, Sarr O, Ndir O, Mboup S, Batalov S, Wirth DF, Winzeler EA. 2006. 
A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog. 
2(6):e57 
 
13. Heitman J. 2006. Sexual reproduction and the evolution of microbial pathogens. 
Curr Biol. 16(17):R711-725 
 
14. Daily JP. 2006. Antimalarial drug therapy: the role of parasite biology and drug 
resistance. J Clin Pharmacol. 46(12):1487-1497 
 
15. Packard RM. 2014. The origins of antimalarial drug resistance. N Engl J Med. 
371(5):397-399 
 
16. Hastings IM, Watkins WM. 2006. Tolerance is the key to understanding 
antimalarial drug resistance. Trends Parasitol. 22(2):71-77 
 
17. Mideo N, Kennedy DA, Carlton JM, Bailey JA, Juliano JJ, Read AF. 2013. 
Ahead of the curve: next generation estimators of drug resistance in malaria 
infections. Trends Parasitol. 29(7):321-328 
 
18. Hastings IM. 2004. The origins of antimalarial drug resistance. Trends Parasitol. 
20(11):512-518. 
 
19. Mok S, Liong KY, Lim EH, Huang X, Zhu L, Preiser PR, Bozdech Z. 2014. 
Structural polymorphism in the promoter of pfmrp2 confers Plasmodium falciparum 
tolerance to quinoline drugs. Mol Microbiol. 91(5):918-934 
 
20. Park DJ, Lukens AK, Neafsey DE, Schaffner SF, Chang HH, Valim C, Ribacke 
U, Van Tyne D, Galinsky K, Galligan M, Becker JS, Ndiaye D, Mboup S, 
Wiegand RC, Hartl DL, Sabeti PC, Wirth DF, Volkman SK. 2012. Sequence-
based association and selection scans identify drug resistance loci in the Plasmodium 
falciparum malaria parasite. Proc Natl Acad Sci USA. 109(32):13052-13057 
 106 
 
21. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002. 
Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2(4):209-218 
 
22. WHO global malaria programme. 2014. World malaria report 2014. WHO Press, 
World Health Organization 
 
23. Wongsrichanalai C, Sibley CH. 2013. Fighting drug-resistant Plasmodium 
falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 10:908-916 
 
24. Mita T, Tanabe K. 2012. Evolution of Plasmodium falciparum drug resistance: 
implications for the development and containment of artemisinin resistance. Jpn J 
Infect Dis. 65(6):465-475 
 
25. Witkowski B, Lelièvre J, Barragán MJ, Laurent V, Su XZ, Berry A, Benoit-
Vical F. 2010. Increased tolerance to artemisinin in Plasmodium falciparum is 
mediated by a quiescence mechanism. Antimicrob Agents Chemother. 54(5):1872-
1877 
 
26. Kleiger G, Mayor T. 2014. Perilous journey: a tour of the ubiquitin-proteasome 
system. Trends Cell Biol. 24(6):352-359.  
 
27. Nandi D, Tahiliani P, Kumar A, Chandu D. 2006. The ubiquitin-proteasome 
system. J Biosci. 31(1):137-155 
 
28. Amm I, Sommer T, Wolf DH. 2014. Protein quality control and elimination of 
protein waste: the role of the ubiquitin-proteasome system. Biochim Biophys Acta. 
1843(1):182-196 
 
29. Ponts N, Yang J, Chung DW, Prudhomme J, Girke T, Horrocks P, Le Roch KG. 
2008. Deciphering the ubiquitin-mediated pathway in apicomplexan parasites: a 
potential strategy to interfere with parasite virulence. PLoS One. 3(6):e2386 
 
30. Aminake MN, Arndt HD, Pradel G. 2012. The proteasome of malaria parasites: A 
multi-stage drug target for chemotherapeutic intervention? Int J Parasitol Drugs Drug 
Resist. 9(2):1-10 
 
31. Li H, Ponder EL, Verdoes M, Asbjornsdottir KH, Deu E, Edgington LE, Lee JT, 
Kirk CJ, Demo SD, Williamson KC, Bogyo M. 2012. Validation of the proteasome 
as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-
specific toxicity. Chem Biol. 19(12):1535-1545  
 
32. Heinemeyer W, Ramos PC, Dohmen RJ. 2004. The ultimate nanoscale mincer: 
assembly, structure and active sites of the 20S proteasome core. Cell Mol Life Sci. 
61(13):1562-1578 
 
 107 
33. Kisselev AF, Akopian TN, Castillo V, Goldberg AL. 1999. Proteasome active sites 
allosterically regulate each other, suggesting a cyclical bite-chew mechanism for 
protein breakdown. Mol Cell. 4(3):395-402 
 
34. Kisselev AF, van der Linden WA, Overkleeft HS. 2012. Proteasome inhibitors: an 
expanding army attacking a unique target. Chem Biol. 19(1):99-115 
 
35. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. 
2008. Point mutation of the proteasome β5 subunit gene is an important mechanism 
of bortezomib resistance in bortezomib-selected variants of Jurkat T cell 
lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 326:423–431 
 
36. Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, 
Kirk CJ. 2011. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. 
PLoS One. 6(12):e27996 
 
37. Lü S, Wang J. 2013. The resistance mechanisms of proteasome inhibitor bortezomib. 
Biomark Res. 1(1):13  
 
38. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, 
Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra 
B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. 2008. Molecular 
basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation 
and overexpression of PSMB5 protein. Blood. 112(6):2489-2499 
 
39. Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, Wang J. 2009. Different mutants of 
PSMB5 confer varying bortezomib resistance in T lymphoblastic 
lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol. 37(7):831-
837 
 
40. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk 
CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, 
Jansen G, Cloos J. 2012. Impaired bortezomib binding to mutant β5 subunit of the 
proteasome is the underlying basis for bortezomib resistance in leukemia cells. 
Leukemia. 26(4):757-768 
 
41. De Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, 
Chan ET, Kirk CJ, Peters GJ, Kruyt FA. 2012 Proteasome-based mechanisms of 
intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem 
Pharmacol. 83(2):207-217 
 
42. PlasmoDB website (SNP database): http://plasmodb.org/plasmo/ (EuPathDB Project 
Team, Athens, GA) 
 
 108 
43. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, Marti M. 2011. 
A high-throughput screen targeting malaria transmission stages opens new avenues 
for drug development. J. Infect. Dis. 203(10):1445-1453 
 
44. Rojas-Rivero L, Gay F, Bustos MD, Ciceron L, Pichet C, Danis M, Gentilini M. 
1992. Mefloquine-halofantrine cross-resistance in Plasmodium falciparum induced by 
intermittent mefloquine pressure. Am J Trop Med Hyg. 47(3):372-377 
 
45. Foley M, Tilley L. 1997. Quinoline antimalarials: mechanisms of action and 
resistance. Int J Parasitol. 27(2):231-240 
 
46. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. 1997. 
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 386(6624):463-
71 
 
47. Groll M, Berkers CR, Ploegh HL, Ovaa H. 2006. Crystal structure of the boronic 
acid-based proteasome inhibitor bortezomib in complex with the yeast 20S 
proteasome. Structure. 14(3):451-456 
 
48. Groll M, Huber R. 2004 Inhibitors of the eukaryotic 20S proteasome core particle: a 
structural approach. Biochim Biophys Acta. 1695(1-3):33-44 
 
49. Mobegi VA, Duffy CW, Amambua-Ngwa A, Loua KM, Laman E, Nwakanma 
DC, MacInnis B, Aspeling-Jones H, Murray L, Clark TG, Kwiatkowski DP, 
Conway DJ. 2014. Genome-wide analysis of selection on the malaria parasite 
Plasmodium falciparum in West African populations of differing infection 
endemicity. Mol Biol Evol. (6):1490-1499 
 
50. Hastings, I.M. and D’Alessandro, U. 2000. Modelling a predictable disaster: The 
rise and spread of drug-resistant malaria. Parasitol Today 16:340–347 
 
  
Chapter IV: 
 
Summary and Conclusions 
 
  
 110 
Study of the ubiquitin proteasome system (UPS) has proven valuable in virtually all well-
studied eukaryotic organisms [1-5]. Protein turnover and ubiquitin modification of 
cellular proteins are of critical importance to general cell biology, and research conducted 
in these areas has increased the knowledge not only of the UPS itself, but also of many 
other cellular processes [5-11].  The eukaryotic UPS has been shown to directly affect the 
cell cycle, transcription, translation, post-translational modification, protein trafficking, 
actin remodeling, secretion, and cell-cell interactions [1-6]. The components of this study 
of proteasome inhibition in Plasmodium falciparum: the use of low concentrations of 
MG132 for incomplete proteasome inhibition, the use of high concentrations for rapid, 
reversible UPS inhibition, parasite recovery following short-term MG132 exposure, and 
the generation of MG132 tolerance in P. falciparum lines, support the importance of the 
UPS in the malaria parasite life cycle. The data that I have generated in this study, taken 
together with those of others, suggest a significant role for the parasite UPS in P. 
falciparum stage progression and drug resistance [12-14, 17-21].  
 
It has been known for years that the genome of P. falciparum contains homologs of 
canonical components of the UPS, and that complete UPS inhibition halts parasite 
replication and division in vitro [11-14]. Although the essentiality of the UPS for parasite 
proliferation has been well established, knowledge gaps remain regarding its function 
during the complex life cycle of P. falciparum [11-14]. Precedents in other systems have 
shown that the UPS plays a central role in many cellular processes, which is likely true of 
P. falciparum, as well [1-11]. Manipulation of P. falciparum UPS function could further 
elucidate the dynamics of other processes such as the cell cycle regulation, stage 
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progression, transcription, protein homeostasis, host-pathogen interactions, and general 
malaria pathogenesis [1-11].  My work, in conjunction with that of others, has shown that 
the UPS likely plays a significant role in parasite development during all erythrocytic 
stages [10, 12].  
 
Chemical inhibition of the UPS, via the use of compounds that directly interfere with 
UPS function, is highly valuable as a research tool for studying the biology of complex 
cellular systems [5-10]. Targeting of the proteolytic activity of the 20S proteasome core 
particle, the protein-degrading component of the UPS, with small-molecule proteasome 
inhibitor compounds (SMPIs) has been utilized by biologists for study of the UPS and the 
systems affected by the UPS [5-12]. Proteasome inhibition has also been explored 
clinically as a treatment strategy for disease, leading to the use of bortezomib as an anti-
cancer chemotherapeutic drug [15-17].  Infectious disease biologists have also explored 
the prospect of using proteasome inhibition for improved control of pathogens [12, 14, 
17-22].  
 
One of the goals of this study was to better understand the dynamics of the P. falciparum 
UPS through proteasome inhibition by SMPIs. In this work and that done by others, 
SMPIs have been shown to arrest the proliferation of P. falciparum in culture [12, 14, 20-
22]. Commercially available SMPIs vary widely in efficacy, stability, specificity, toxicity, 
and reversibility; so data regarding compound performance in particular systems is 
required to evaluate their usefulness in experimental applications [6-12]. Three 
compounds – MG132, lactacystin, and bortezomib – were chosen for this work because 
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of their previously described ability to inhibit the growth of P. falciparum in culture [10, 
12, 20-22].  MG132 performed arguably better for efficient low-dose proteasome 
inhibition than the other two compounds tested, causing a measurable stage delay without 
causing complete lethality in culture. Although MG132 targets cysteine proteases in P. 
falciparum in addition to the proteasome (e.g., falcipains), this has only been shown to 
occur at higher concentrations than those required for UPS inhibition [22]. However, 
further study would need to be completed to assess the precise compound levels that 
result in off-target (non-UPS) effects [22].  
 
The delay in stage progression observed in P. falciparum due to exposure to sub-lethal 
MG132 concentrations is most pronounced during the trophozoite stage. In addition, 
ubiquitylated proteins accumulate in maturing trophozoites within six hours of exposure, 
suggesting that proteasome-related protein turnover is critical during that stage. From 
these data, it can be inferred that the UPS likely plays a crucial role in trophozoite 
developmental progression. This information could lead to further study of parasite 
proteome maintenance and turnover during trophozoite stage, via the UPS. The UPS also 
has been shown to have critical roles in global transcription, translation integrity, and 
proteome maintenance in other systems, which supports the likelihood of a central role in 
P. falciparum proteome homeostasis and gene expression [5, 6, 8, 10, 23-26].  
 
The dynamics of drug resistance are also important for the study of parasite biology [25-
32]. One canonical function of the UPS is cellular stress tolerance, which is a critical 
component of the early stages of drug resistance development [5, 27-32].  Furthermore, 
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various components of the UPS have been identified in genome-wide association studies 
as being under selection in malaria endemic areas, which implies that the UPS could have 
critical roles in drug resistance and/or the fitness of parasite populations in the field [25-
26]. Therefore, another valuable contribution of this study is the generation of MG132 
tolerance in parasite selection cultures following repeated intermittent exposure to 
MG132.  
 
The generation of MG132 tolerance after fewer than 10 rounds of selection is a 
significant result of this work. Although the measured IC50 values of the MGR lines are 
not much higher than wild type, these lines were able to survive several days longer in 
the presence of concentrations of MG132 that are toxic to the parental wild type line. The 
increased ability of parasites to survive exposure to high levels of anti-malarial 
compounds, even if proliferation is slow, has been identified as a sign of emerging 
resistance and predictor of the possible reductions in clinical efficacy [27-32]. The 
observation that tolerance to an anti-malarial compound does not always result in an 
increased IC50 value has also been made in regard to artemisinin resistance [27-28]. In the 
field, tolerance would likely manifest as parasites that exhibit prolonged clearance times 
in vivo, or that are slower to respond to clinical anti-malarial drug therapy [27-32].  These 
parasites tend to linger in the bloodstream of patients longer during malaria 
chemotherapy; a precursor to the development and eventual spread of fully resistant 
parasites [27-32].  Drug tolerance, as seen in the MGR lines generated by this study, is a 
common bridge between sensitivity and resistance in parasites and is of critical 
importance in the understanding of the emergence of resistance [27-32].  
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In conclusion, study of proteasome inhibition in P. falciparum has the potential to expand 
in many directions. The development of proteasome inhibitors as components of drug 
cocktails in the chemotherapeutic treatment of malaria is a strong possibility [12-14, 22, 
29]. The fact that SMPIs significantly affect parasites at concentrations much lower than 
those that affect the human proteasome in vivo indicates the potential use of proteasome 
inhibition in anti-malarial chemotherapy in humans [12-14, 22, 27, 29]. It is also known 
that even low-level interference in proteasome function can increase the clinical efficacy 
of other drugs and overcome resistance [17, 27, 29]. The MG132-tolerant parasite lines 
generated by this study could be used for further study of drug resistance mechanisms 
resulting from UPS-related stress tolerance, subjected to more compound exposure cycles 
for the generation of higher levels of MG132 resistance, or tested for cross-resistance to 
other proteasome inhibitors or anti-malarial compounds. 
 
Studies like this one are important for filling knowledge gaps related to general parasite 
biology and the genesis of drug resistance. The next steps fort advancing our 
understanding the P. falciparum UPS and its roles in parasite biology could be numerous. 
The MG132-tolerant lines generated by this work, in parallel with other drug-resistant 
lines, could be used to measure cross-resistance to a panel of anti-malarial compounds. 
MG132 could be used to study short- and long-term effects of low-level proteasome 
inhibition, such as impacts on gene expression, stage progression, or protein trafficking. 
Overall, the study of the roles of the UPS, UPS inhibition, and SMPI resistance in P. 
falciparum have far-reaching and significant implications for our understanding of 
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parasite cell biology, malaria infection dynamics, anti-malarial drug development, and 
anti-malarial drug resistance – critical areas in which increased knowledge will advance 
our understanding of parasite biology and enhance our ability to control malaria 
infections in humans.  
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Protocol: Proteasome Activity Assay  
 
Substrates: 
1) Trypsin-like activity:  Boc-LRR-AMC  (FW 773.76)  
(Catalog # S-300, Boston Biochem, Inc., Cambridge, MA)  
a. DMSO stock = 2 mM (20x) = add 3,231 uL DMSO to 5 mg 
2) Chymotrypsin-like activity: Suc-LLVY-AMC  (FW 763.9) 
(Catalog # S-280, Boston Biochem, Inc., Cambridge, MA)  
a. DMSO stock = 2 mM (20x) = add 3,190 uL 
3) Caspase-like activity: Z-LLE-AMC  (FW 664.8) 
(Catalog # S-230, Boston Biochem, Inc., Cambridge, MA)  
a. DMSO stock = 2 mM (20x) = add 2,776 uL 
Buffers: 
Assay/Lysis Buffer, pH 8 
50mM Tris HCl 
25 mM KCl 
10 mM NaCl 
1 mM MgCl 
1 mM ATP 
*2% Glycerol in lysis buffer only 
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Add to 1 L  
Concentration:  Add to 1 L: Add to 100 mL 
(1x) 
Add to 100 mL 
(10x) 
50 mM Tris HCl 50 mL of 1 M Stock 
5 mL of 1 M 
Stock 
50 mL of 1 M 
Stock 
25 mM KCl (FW 74.55) 1.864 g 0.186 g 1.864 g 
10 mM NaCl (FW 58.44) 0.584 g 0.058 g 0.584 g 
1 mM MgCl2 (FW 95.21) 0.095 g 0.010 g 0.095 g 
1.0 mM ATP (FW 
551.14) 0.552 g 0.055 g 0.552 g 
*2% Glycerol (Lysis 
Buffer)  *2ml  
H2O 950 ml 95 ml or 93ml 50 ml  
 
Lysate: 
Add ~5x volume lysate with agitation beads, vortex, alternate with ice 6x 
Assay, each 3x sample: 
15 uL Lysate   
87 uL Assay Buffer 
12 uL 10x Inhibitor or DMSO 
6 uL 20x Substrate  
Divide into 3x 35 uL aliquots for tech reps.  
Incubate at 37oC 90 min in the dark, read at excitation/emission 380/460 nm λem 
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Activity Assay Test: Capacities of Assay Substrates 
 
 
 
 
Figure S1: Enzymatic activity assay linear range assessment in Jurkat cells. X axis = 
lysate concentration.Y axis = fluorescence.   
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Protocol: Parasite Delayed Death Assay (Using SYBR Green) 
 
Cultures: Culture medium RPMI with 0.5% Albumaxx II, 1% hematocrit, synchronized 
ring stage parasites. Incubation is done under standard conditions (provide details). 
 
Compounds (kept in 10 mM DMSO stock), highest concentration used in assay: 
MG132 (Sigma),  2.5 µM  
Azithromycin (Sigma),  20 µM  
Mefloquine (Sigma),  0.625 µM  
 
24 hour incubation: begin with cultures at 1.5-2.0% parasitemia 
72 hour incubation: begin with cultures at 1% parasitemia 
120 hour incubation: begin with cultures at 0.2% parasitemia 
 
Preparation of drug master plates (“source plates”):  
1) Prepare drug plates as “source plates” for addition to culture: 
a. Dilute compound stock solution (10 mM or 25 mM in DMSO) in culture 
medium to a final volume of 800 uL at concentration of 4x appropriate 
highest assay concentration (e.g., 10 uM for 2.5 uM final treatment 
concentration) 
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b. Take 400 uL from first well, add that volume to 400 uL of culture medium 
in the next well and mix, perform successive serial 2x dilutions in culture 
medium to obtain 12 concentrations of each drug, one drug per row of 
source plate 
 
Initial addition of drugs to parasite cultures 
2) Dispense parasite source culture and drug into wells of a 96-well culture plate: 
a. Add 150 uL culture medium and 2 uL of infected RBCs at appropriate 
parasitemia to each well. (Resulting in 1% hematocrit after addition of 50 
uL of drug from the source plate.)   
b. Make at least four replicate wells for each drug concentration assayed (1 
plate per drug, with four rows of drug assay cultures and two rows of 
control cultures with no drug) 
c. Dispense 50 uL of 4x concentrated drug or plain media into each well 
from the source plate, mix wells 
 
Incubation with drugs 
3) Incubate all assay plates under standard conditions (37 °C, 5% CO2 + 1% O2 + 
balance N2), using secondary containers (plastic bins with open water reservoirs) 
to assure humidity and minimize well drying 
 
Harvest incubation cultures  
4) Harvest after incubation period* 
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a. Develop and read cultures:  
i. Mix cultures to distribute cells uniformly in medium, then transfer 
40 uL of each culture into a black, clear-bottom, 384-well plate 
(Greiner Bio-One, Inc., Monroe, North Carolina, USA) 
ii. Add 10 uL of SYBR Green buffer (0.16% saponin, 20 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 1.6% (w/v) Triton X-100) with 1/1000 
SYBR Green to each well of 96 well plate  
iii. Seal plate with foil and keep at room temperature for 1-24 hours 
iv. Read plates using SYBR standard protocol (see Chapter 2, 
Methods) 
 
* Feed 120-hour cultures after 72 hours of incubation: 
v. Remove 160 uL of culture medium from each well of 120-hour 
culture plate, being careful not to disturb cells in the bottom 
vi. Add 120 uL of fresh culture medium 
vii. Add 40 uL of 4x concentrated drug, diluted the same way as before, 
from fresh source plate, mix  
viii. Incubate plates under the same growth conditions for an additional 
48 hours 
ix. After incubation, develop and read cultures using SYBR buffer as 
described above  
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Parasite Minimal Medium (Export Media for Recover of Secreted Proteins)  
 *These components are for incomplete media. Final concentrations of 0.5% Albumaxx II 
or 5-10% human serum should be added for complete media preparation. 
 
Inorganic salts (mg/L) 
Ca(NO3)2 · 4H2O 100.0 
KCl  400.0 
MgSO4 (anhydrous)      48.8 
NaCl  5,300 
NaHCO3  2,000 
Na2HPO4 (anhydrous)     800 
 
Amino acids (essential amino acids in bold) (mg/L)  
Adenine A    18 
Alanine A    57 
Arginine   57 
Asparagine   57 
Aspartic acid   57 
Cysteine   57 
Glutamic acid   57 
Glutamine   300 
Glycine   57 
Histidine   57 
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myo-Inositol I    57 
Isoleucine   57 
Leucine L    285 
Lysine   57 
Methionine   57 
p-Aminobenzoic   6 
Phenylalanine   57 
Proline   57 
Serine   57 
Threonine   57 
Tryptophan   57 
Tyrosine   57 
Valine   57 
  
Other components (mg/L) 
d-Ca pantothenate  0.25  
d-Glucose  2,000.0 
HEPES  5,958.0  
Hypoxanthine  50 
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References for Minimal Medium Recipe: 
Divo, A. A., T. G. Geary, N. L. Davis, and J. B. Jensen. (1984) Nutritional 
requirements of Plasmodium falciparum in culture. I. Exogenously supplied 
dialyzable components necessary for continuous growth. J. Protozool. 32:59-64. 
Schuster FL (2002) Cultivation of plasmodium spp. Clin Microbiol Rev. 15(3):355-
364. 
 
 
 
 
 
 
Figure S2: Growth of parasites in minimal media compared to standard RPMI. X axis = 
Log10 (concentration of Albumaxx II stock); Y axis = growth of parasites as measured by 
SYBR Green analysis, compared to growth in complete RPMI medium. 
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Appendix II:  
Additional Figures 
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Proteasome inhibition and HRP II in P. falciparum parasites  
 
The ubiquitin-proteasome system (UPS) has wide-ranging effects on the biology of 
Plasmodium falciparum [1-3]. Interference in UPS function by chemical proteasome 
inhibition has been explored as both a method for understanding P. falciparum biology 
and as a potential strategy for anti-malarial chemotherapeutic treatment [1-3]. During the 
course of my experiments in proteasome inhibition in P. falciparum, I observed that 
exposure to MG132, a small-molecule proteasome inhibitor, resulted in the accumulation 
of histidine-rich protein II (HRP II) in cultured parasites. In order to assess the scope of 
this effect, experiments were performed to visualize HRP II levels in parasites or culture 
medium following incubation of cultures in the presence of MG132.  
 
HRPII is a P. falciparum parasite protein that is secreted from infected red blood cells of 
malaria-infected individuals [4-7]. It accumulates in large quantities and is readily 
detectible in the blood of infected persons; and its presence is often used as an indicator 
of malaria infection in rapid diagnostic tests [4-7]. While the details of HRP II function in 
the P. falciparum life cycle have not been fully investigated, the protein likely plays a 
role in malaria pathology [4-7].  
 
In order to detect HRP II secretion from P. falciparum-infected red blood cells, early 
ring-stage 3D7 cultures were incubated in the presence of 0 nM – 50 nM MG132 for 12 
and 24 hours, and HRP II present in culture medium was assessed. A western blot of 
relative amounts of HRP II captured from culture media over time is shown in Figure S3. 
 132 
A visible reduction in HRP II secretion is apparent in cultures exposed to 50 nM MG132 
for 12 and 24 hours. No visible reduction in HRP II secretion is apparent in cultures 
grown without drug or in cultures exposed to 100 nM mefloquine, used as an anti-
malarial control compound [8].  
 
In order to assess HRP II accumulation in P. falciparum parasites due to exposure to 
MG132, parasites from the experiment above were isolated and cellular protein assayed 
by western blot. Figure S4 shows a western blot of HRP II in cell lysates of cultures 
exposed to 0 – 50 nM MG132 or 0 – 60 nM mefloquine. Heightened levels of HRP II are 
detected in parasites incubated in the presence of 12.5 nM – 100 nM MG132. Very little 
accumulation of HRP II is detected in parasites incubated without drug or with 
mefloquine, an anti-malarial compound known to arrest P. falciparum growth within 24 
hours [8].   
 
The experiments above suggest that proteasome inhibition by MG132 interferes with 
secretion of HRP II from malaria-infected red blood cells. More research would be 
required in order to fully understand the mechanism of this possible interference. The 
inability of mefloquine to cause the same level of HRP II accumulation in the growth 
medium suggests that this effect is specific to the action of MG132, and not simply a 
consequence of arrested parasite growth. Although MG132 has been shown to target both 
the 20S proteasome and falcipains (cysteine proteases) in P. falciparum, these data 
suggest proteasome inhibition is most likely the cause of HRP II accumulation [9]. The 
ability of low concentrations of MG132 to cause accumulation of HRP II points to 
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proteasome inhibition as the primary cause of this accumulation, since MG132 has only 
been shown to inhibit falcipains at concentrations above 100 nM [9].  
 
In order to fully assess the relationship between HRP II and proteasome inhibition, more 
research would be required. Because HRP II has a possible role in malarial pathology, 
thiese data obviously support the notion of using low-level proteasome inhibition in 
chemotherapeutic drug cocktails [4-7]. Exploration of the UPS and HRP II could also 
lead to increased knowledge of the biology of protein export/secretion in P. falciparum, 
which is not fully understood [6-7]. Overall, the fact that proteasome inhibition by 
MG132 impacts HRP II secretion is an important finding, but more research would be 
required to fully understand the implications.  
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Figure S3: HRPII secretion. Western of HRPII in parasite growth media after 12 or 24 hr 
drug pressure. Western blot and probing of concentrated media with HRPII primary 
antibody (left); Coomassie stain of identical gel with same samples (right). 
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Figure S4: HRPII accumulation in parasites due to MG132 exposure. Western blot and 
probing of HRPII in ring/early trophozoite stage parasites after 12 hr drug pressure from 
MG132 or mefloquine. 
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Multiple Sequence Alignment: Proteasome α-1 Subunit 
 
 
 
 
 
ProteasomeAlpha1_08-21-2009.apr
 Section 1
1 3210 20(1) 
MF RNQY DSDV TVWS PQGRLHQVEYA MEAV KLGAG-Alpha1-Proteasome-XP_319444 (1) 
MF RNQY DNDT TTWS PQGRLFQVEYA MEAV KQGDM-Alpha1-Proteasome-NP_609623  (1) 
MF RNQY DNDV TVWS PQGRIHQIEYA MEAV KQGHS-Alpha1-Proteasome-NP_002777 (1) 
MY RNLY DTDN IIYS PEGRLYQVEYA SEAI KQGPF-Alpha1-Proteasome-PF14_0716 (1) 
MF RNNY DGDT VTFS PTGRLFQVEYA LEAI KQGSC-Alpha1Proteasome-NP_014045 (1) 
MF RNQY D D TVWS PQGRLHQVEYAMEAVKQGConsensus (1) 
 Section 2
33 6440 50(33) 
SA TVGLKNKDFAVLIALKRAS SELS SYQKKIIAG-Alpha1-Proteasome-XP_319444 (33) 
AA TVGL KGTDYAVLAAL CRTS KDTN TLQR KIMDM-Alpha1-Proteasome-NP_609623  (33) 
SA TVGLKSK THA VLVA LKRAQSEL AAH QKKI LHS-Alpha1-Proteasome-NP_002777 (33) 
TC AVAI KSKD YVVVSGL KKCI SKLS FPQE KIFPF-Alpha1-Proteasome-PF14_0716 (33) 
SV TVGL RSNT HAVL VALKRNADELS SYQK KIISC-Alpha1Proteasome-NP_014045 (33) 
SA TVGL KSKD HAVL VALKR SSELSSYQKKIIConsensus (33) 
 Section 3
65 9670 80(65) 
SI DDHL GLSF AGIT ADARILSRYLRQE CL NYKAG-Alpha1-Proteasome-XP_319444 (65) 
PV DDHV GMSI AGLT ADA RVVC QYMR TECM AYRDM-Alpha1-Proteasome-NP_609623  (65) 
HV DNHI GISI AGLT ADA RLLC NFMR QE CL DSRHS-Alpha1-Proteasome-NP_002777 (65) 
KI DDYI GISM SGIT SDAKVLTKFMQNECLSHKPF-Alpha1-Proteasome-PF14_0716 (65) 
KC DEHM GLSL AGLA PDARVLS NYLR QQCN YS SSC-Alpha1Proteasome-NP_014045 (65) 
 I DDHI GISI AGLT ADARVLSNYMRQECL YKConsensus (65) 
 Section 4
97 128110(97) 
YA YDAF YPVGRLISNLG NKMQ VCTQ RYDR RPYAG-Alpha1-Proteasome-XP_319444 (97) 
HS YNAE FPVR RLVS NLG NKLQ TTTQ RYDR RPYDM-Alpha1-Proteasome-NP_609623  (97) 
FV FDRPLPVSRLVS LIGSKTQ IPTQ RYGR RPYHS-Alpha1-Proteasome-NP_002777 (97) 
FL YNEN INIE SLVR SVADKYQKNTQKSSKRAFPF-Alpha1-Proteasome-PF14_0716 (97) 
LV FNRK LAVE RAGH LLC DKAQ KNTQ SYGG RPYSC-Alpha1Proteasome-NP_014045 (97) 
FV YN  LPV RLVS  LG K Q  TQRY RRPYConsensus (97) 
 Section 5
129 160140 150(129) 
GV GL LVIGYDDQGPHI YQTCP SAN FFDCKAMSAG-Alpha1-Proteasome-XP_319444 (129) 
GV GL LVAGYDEQGPHI YQVMP TANV LNCK AMADM-Alpha1-Proteasome-NP_609623  (129) 
GV GL LIAG YDDMGPHI FQTCPSAN YFD CRAM SHS-Alpha1-Proteasome-NP_002777 (129) 
GV GL MIAAYHN-EPCIF ETRP NGSY FEYD ALSPF-Alpha1-Proteasome-PF14_0716 (129) 
GV GL LIIGYDKSGAHLL EFQP SGNV TELY GTASC-Alpha1Proteasome-NP_014045 (129) 
GV GLLI AGYD D GP HIFQT PSANYFDCKAMSConsensus (129) 
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 Section 6
161 192170 180(161) 
IG SRSQ SAR TYLE KHLATFPD CT-- KDELIRHAG-Alpha1-Proteasome-XP_319444 (161) 
IG SRSQ SAR TYLE RNMESFED CD-- MDELICHDM-Alpha1-Proteasome-NP_609623  (161) 
IG ARSQ SAR TYLE RHMSEFME CN-- LNELVKHHS-Alpha1-Proteasome-NP_002777 (161) 
FG ARSH ASK TYLE KNLHLFEE CS-- LEELILHPF-Alpha1-Proteasome-PF14_0716 (160) 
IG ARSQ GAKT YLE RTLD TFIK IDGN P DELIKASC-Alpha1Proteasome-NP_014045 (161) 
IG ARSQ SART YLER  L TF DC   LDELIKHConsensus (161) 
 Section 7
193 224200 210(193) 
GV QALQ DTLP NEVE LNNKNISIAIV GK GE NFHAG-Alpha1-Proteasome-XP_319444 (191) 
AI QAIR GSLG -SDD VENL TIN VAIV GK DV PFKDM-Alpha1-Proteasome-NP_609623  (191) 
GL RALR ETLP AEQD LTTKNVSIGIVGK DL EFTHS-Alpha1-Proteasome-NP_002777 (191) 
CL KALK CSLS SESE LTISNTALAVVGK NH PWQPF-Alpha1-Proteasome-PF14_0716 (190) 
GV EAIS QSLR -DES LTVDNLSIAIV GK DT PFTSC-Alpha1Proteasome-NP_014045 (193) 
GL  ALR  SL  E D LT  NISIAIVGKD PF Consensus (193) 
 Section 8
225 256230 240(225) 
VL EEQE NDKY LSNIVRR GGAA PEAA GGSQ PPRAG-Alpha1-Proteasome-XP_319444 (223) 
MF TEAE NQKY VKLV KAMDPPLEADHDPLS EEGDM-Alpha1-Proteasome-NP_609623  (222) 
IY DD DDVSPFLEGLEER PQRK AQPA QPAD EPAHS-Alpha1-Proteasome-NP_002777 (223) 
EI SS LQLEEYLSKVKMD AEQE QVEE NVQN EANPF-Alpha1-Proteasome-PF14_0716 (222) 
IY DGEAVAKYI------ ---- ---- ---- ---SC-Alpha1Proteasome-NP_014045 (224) 
IY DE E V KY L  V                E  Consensus (225) 
 Section 9
257 288270(257) 
DD GDDQ PPNV PDPI PVVAMET-----------AG-Alpha1-Proteasome-XP_319444 (255) 
MS DDDMTDHGPSSSGVP PNDT SDME TTAS TGGDM-Alpha1-Proteasome-NP_609623  (254) 
EK ADEP MEH- ---- ------------------HS-Alpha1-Proteasome-NP_002777 (255) 
E- ---- ---- ---- ------------------PF-Alpha1-Proteasome-PF14_0716 (254) 
-- ---- ---- ---- ------------------SC-Alpha1Proteasome-NP_014045 (235) 
E  DD                           Consensus (257) 
 Section 10
289292(289) 
-- --AG-Alpha1-Proteasome-XP_319444 (276) 
SD AHDM-Alpha1-Proteasome-NP_609623  (286) 
-- --HS-Alpha1-Proteasome-NP_002777 (264) 
-- --PF-Alpha1-Proteasome-PF14_0716 (255) 
-- --SC-Alpha1Proteasome-NP_014045 (235) 
    Consensus (289) 
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 Section 1
1 3310 20(1) 
MASE RYSF SLTT FSP SGKLV QIEYALA AVAA GAAG-Alpha2-Proteasome-XP_550819 (1) 
MATE RYSF SLTT FSP SGKLV QLEYALA AVSG GADM-Alpha2-Proteasome-NP_524328 (1) 
MAER GYSF SLTT FSP SGKLV QIEYALA AVAG GAHS-Alpha2-Proteasome-NP_002778 (1) 
MADG EYSFSLTTFSP T GKL VQIE YALN RVSS SSPF-Alpha2-Proteasome-PFF0420c (1) 
-MTD RYSF SLTT FSP SGKLG QIDYALT AVKQ GVSC-Alpha2-Proteasome-NP_013618 (1) 
MATE RYSF SLTT FSPSGKLVQIEYALAAVAGG AConsensus (1) 
 Section 2
34 6640 50(34) 
PSV GIKAVNGV VIA TE NKQKSILYDEHSVHKVEAG-Alpha2-Proteasome-XP_550819 (34) 
PSV GIIASNGV VIA TE NKHKSPLYEQHSVH RVEDM-Alpha2-Proteasome-NP_524328 (34) 
PSV GIKAANGV VLA TE KKQKSILYDERSVHKVEHS-Alpha2-Proteasome-NP_002778 (34) 
PALG IRAK NGV IIAT EKKSPNELIEENSIFKIQPF-Alpha2-Proteasome-PFF0420c (34) 
TSLG IKAT NGV VIAT EKKSSSPLAMSETLSKVSSC-Alpha2-Proteasome-NP_013618 (33) 
PSVG IKA NGVV IATEKK KS LYDE SVHKV EConsensus (34) 
 Section 3
67 9980(67) 
MVTN HIGM IYSG MGPDYRLLVKQARKLAQN-Y YAG-Alpha2-Proteasome-XP_550819 (67) 
MIYN HIGM VYSG MGPDYRLLVKQARKIAQT-Y YDM-Alpha2-Proteasome-NP_524328 (67) 
PITK HIGL VYSG MGPDYRVLVHRARKLAQQ-Y YHS-Alpha2-Proteasome-NP_002778 (67) 
QISE HIGI VYAG MPGDFRVLLKRARKEAIR- YSPF-Alpha2-Proteasome-PFF0420c (67) 
LLTP DIGA VYSG MGPDYRVLVDKSRKVAHTSY KSC-Alpha2-Proteasome-NP_013618 (66) 
MIT HIGM VYSG MGPDYRVLVKRARKLAQ  Y YConsensus (67) 
 Section 4
100 132110 120(100) 
LTYR EPIP T S QLVQ KVATVMQEYTQSGGVRPFGAG-Alpha2-Proteasome-XP_550819 (99) 
LTYK EPIP VSQLVQR VATL MQEY TQSG GVRPFGDM-Alpha2-Proteasome-NP_524328 (99) 
LVYQ EPIP T A QLVQ RVASVMQEYTQSGGVRPFGHS-Alpha2-Proteasome-NP_002778 (99) 
LQYG SEIL VKE LVKI IASI VQEFTQTGGVRPFGPF-Alpha2-Proteasome-PFF0420c (99) 
RIYG EYPP TKLL VSEVAKIMQEATQSGGVRPF GSC-Alpha2-Proteasome-NP_013618 (99) 
L Y EPIP TSQL VQRVASIMQEYTQSGGVRPF GConsensus (100) 
 Section 5
133 165140 150(133) 
VSLL ICGWDDGR-PY LFQC DPSG AYFAWKATAMAG-Alpha2-Proteasome-XP_550819 (132) 
VSLL ICGWDNDR-PY LYQS DPSG AYFAWKATAMDM-Alpha2-Proteasome-NP_524328 (132) 
VSLL ICGWNEGR-PY LFQS DPSG AYFAWKATAMHS-Alpha2-Proteasome-NP_002778 (132) 
LSLL ICGVDVYG-Y HLYQIDPSG CY FNWM ATCVPF-Alpha2-Proteasome-PFF0420c (132) 
VSLL IAGHDEFNGFS LYQVDPSG SYFPWKATAISC-Alpha2-Proteasome-NP_013618 (132) 
VSLL ICGW DE R  PYLYQ DPSGAYFAWKATA MConsensus (133) 
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 Section 6
166 198180(166) 
GKNA NNGK TFLEKR YSEDL EL DDAV HTAI LTLKAG-Alpha2-Proteasome-XP_550819 (164) 
GKNA VNGK T F LEKR YSEDLE LDDAVHTAILTLKDM-Alpha2-Proteasome-NP_524328 (164) 
GKNY VNGK T F LEKR YNEDL ELED AIHT AILT LKHS-Alpha2-Proteasome-NP_002778 (164) 
GKDY QNNM SFLE KR YNKDIEIEDAIHTAILTLKPF-Alpha2-Proteasome-PFF0420c (164) 
GKGS VAAK TFLE KR WNDELELEDAIHIALLTLKSC-Alpha2-Proteasome-NP_013618 (165) 
GKNA VNGK TFLE KRYNEDLELEDAIHTAILTL KConsensus (166) 
 Section 7
199 231210 220(199) 
EGFE GQMN ADNI EVGIC DA NG-- ---- ------AG-Alpha2-Proteasome-XP_550819 (197) 
EGFE GKMT ADNI EIGIC DQ NG-- ---- ------DM-Alpha2-Proteasome-NP_524328 (197) 
ESFE GQMT EDNI EVGIC NE AG-- ---- ------HS-Alpha2-Proteasome-NP_002778 (197) 
ESYE GVLN EKNI EIGVAYDNKP---------- -PF-Alpha2-Proteasome-PFF0420c (197) 
ESVE GEFN GDTI ELAIIGDENPDLLGYTGIPT DSC-Alpha2-Proteasome-NP_013618 (198) 
ESFE G MN ADNI EIGIC DNG            Consensus (199) 
 Section 8
232 252240(232) 
---- FRRLDPSDVQD YLAN IPAG-Alpha2-Proteasome-XP_550819 (218) 
---- FQRLDPASIKD YLAS IPDM-Alpha2-Proteasome-NP_524328 (218) 
---- FRRLTPTEVKD YLAA IAHS-Alpha2-Proteasome-NP_002778 (218) 
---- FKILTQNEIK DYLIEIEPF-Alpha2-Proteasome-PFF0420c (219) 
KGPR FRKLTSQEIND RLEA L-SC-Alpha2-Proteasome-NP_013618 (231) 
    FRRL TP E IKDYLAAI Consensus (232) 
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 Section 1
1 3210 20(1) 
MS SIGT GYDLS ASTFSPDGR VF QVEYAMKAVEHS-Alpha3-Proteasome-AAH29402 (1) 
MS SIGT GYDLS ASQFSPDGR VF QIEYAAKAVEAG-Alpha3-Proteasome-XP_321089 (1) 
MS TIGT GYDLS A SQFS PDGR VF QIDYASKAVEDM-Alpha3-Proteasome-NP_724834 (1) 
MT SIGT GYDLS N SVFS PDGR NF QVEYAVKAVESC-Alpha3-Proteasome-NP_015007.2 (1) 
MA GLSA GYDL S VSTFSPDGR LYQ VEYI YKSI NPF-Alpha3-Proteasome-PFC0745c (1) 
MS SIGT GYDL SAS FSPDGRVFQVEYA KAVEConsensus (1) 
 Section 2
33 6440 50(33) 
NS STAI GIRC K DGVVF GVEKL VL SKLY EEGS NHS-Alpha3-Proteasome-AAH29402 (33) 
NS GTVI GLRG KDGV VLA VEKL ITS KLY EP DCGAG-Alpha3-Proteasome-XP_321089 (33) 
KS GTVI GIR GKDAVVLA VEKI ITS KLYEP DA GDM-Alpha3-Proteasome-NP_724834 (33) 
NG TTSI GI KCNDGVVFAVEKL ITS KLLVPQKNSC-Alpha3-Proteasome-NP_015007.2 (33) 
NN NTAL CLEC KDGI ICCCINSNM DK NKMI KK NPF-Alpha3-Proteasome-PFC0745c (33) 
NS  TAI GIRC KDGV V AVEKLITSKLYEP  NConsensus (33) 
 Section 3
65 9670 80(65) 
-- KRLFNVDRHVGMAVAGLLA DARS LADM AREHS-Alpha3-Proteasome-AAH29402 (65) 
-- TRIF TIDTSIGMAI SGMITDGRAVVDIARQAG-Alpha3-Proteasome-XP_321089 (65) 
-- GRIF TIEK NI GMA VAGLVADG NFVA DIAR QDM-Alpha3-Proteasome-NP_724834 (65) 
-- VKIQVVDRHIGCVYS GLIP DGRH LVNR GRESC-Alpha3-Proteasome-NP_015007.2 (65) 
SY NRIYHVNNNIIITYS GFDG DARN IIDR ARSPF-Alpha3-Proteasome-PFC0745c (65) 
   RIF  VDR  IGM AVSGLIADGR LVDIAR Consensus (65) 
 Section 4
97 128110(97) 
EA SNFR SNFG YN IPLKH LADR VAMY VHAY TLYHS-Alpha3-Proteasome-AAH29402 (95) 
EA ASYR QQNN RP IPLKQ LNDR LSSY FHAY TLYAG-Alpha3-Proteasome-XP_321089 (95) 
EA ANYR QQFE QA IPLKH LCHR VAGY VHAY TLYDM-Alpha3-Proteasome-NP_724834 (95) 
EA ASFK KLYKTP IPIPAFADR LGQY VQAH TLYSC-Alpha3-Proteasome-NP_015007.2 (95) 
EA NTYY YNFH TN IPLHI LVNR ISLY IHAY TLYPF-Alpha3-Proteasome-PFC0745c (97) 
EA ASYR  NF   IP LK L DRLA YVHAYTLYConsensus (97) 
 Section 5
129 160140 150(129) 
SA VRPF GCSFMLG SYS VN DGAQL YMID PSG VSHS-Alpha3-Proteasome-AAH29402 (127) 
SA VRPF ATIVMYY-------- ---- ---- -YFAG-Alpha3-Proteasome-XP_321089 (127) 
SA VRPF GLSIILASWDEV EGPQLYKIEPSG SSDM-Alpha3-Proteasome-NP_724834 (127) 
NS VRPF GVSTIFGGVDK N- GAHLYMLEPSGS YSC-Alpha3-Proteasome-NP_015007.2 (127) 
WH MRPF AASIIISSFNE KDKG DIYC IEP NGACPF-Alpha3-Proteasome-PFC0745c (129) 
SA VRPF G SI ILGS F   DGA LY IEPSGS Consensus (129) 
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 Section 6
161 192170 180(161) 
YG YWGC AIGKARQAAKT EIEK LQMK ---E MTCHS-Alpha3-Proteasome-AAH29402 (159) 
QG YFGC AVGKAKQ TAKTEIEK LKLS --- DMSVAG-Alpha3-Proteasome-XP_321089 (142) 
FG YFAC ASGK AKQ LAKT EMEK LKM- ---D MRTDM-Alpha3-Proteasome-NP_724834 (159) 
WG YKGA ATGK GRQS AKAELEKLVDHHPE G LSASC-Alpha3-Proteasome-NP_015007.2 (158) 
YK YSGI VIGK NKEM FKTEIEKKDYK--- D INVPF-Alpha3-Proteasome-PFC0745c (161) 
YG YFGC AIGK AKQ AKTEIEKL M    DMS Consensus (161) 
 Section 7
193 224200 210(193) 
RD IVKE VAKI IYIV HDE VKDK --A FELELSWVHS-Alpha3-Proteasome-AAH29402 (188) 
KD LVLT AGKI IYQV HDE LKDK --DF KLEL SWVAG-Alpha3-Proteasome-XP_321089 (171) 
DE LVES AGEI IYKV HDE LKDK --DF RFEM GLVDM-Alpha3-Proteasome-NP_724834 (187) 
RE AVKQ AAKI IYLA HEDNKEK--DFELEISWCSC-Alpha3-Proteasome-NP_015007.2 (190) 
RD AIED IY KFILTS DDHMNKN NLQNLVNFSWIPF-Alpha3-Proteasome-PFC0745c (190) 
RD LV  AAKI IY V HDELKDK  DF LELSWVConsensus (193) 
 Section 8
225 256230 240(225) 
GE -L TNGRHEIVPKDIREE AEKYAKESLKEEDHS-Alpha3-Proteasome-AAH29402 (218) 
CQ -DSNGIHKTVPAEVY AA AN RAGQ EAVD EDDAG-Alpha3-Proteasome-XP_321089 (201) 
GR -V TGGLHLIN PSELTEK ARKAGDAANKDEDDM-Alpha3-Proteasome-NP_724834 (217) 
SL SETNGLHKFVKGDLLQE AIDFAQKEINGDDSC-Alpha3-Proteasome-NP_015007.2 (220) 
CK -ESSYEFQNIHEEIL TP AL NKAV EYIE KLNPF-Alpha3-Proteasome-PFC0745c (222) 
   ETN GLH  VP EI   A K A EAI EDDConsensus (225) 
 Section 9
257 288270(257) 
ES DDDN M--- ---- ------------------HS-Alpha3-Proteasome-AAH29402 (249) 
SD NEI- ---- ---- ------------------AG-Alpha3-Proteasome-XP_321089 (232) 
SD NETH ---- ---- ------------------DM-Alpha3-Proteasome-NP_724834 (248) 
DE DEDD SDNV MSSD DENAPVATNANATTDQEGSC-Alpha3-Proteasome-NP_015007.2 (252) 
-- ---- ---- ---- ------------------PF-Alpha3-Proteasome-PFC0745c (253) 
 D  E                            Consensus (257) 
 Section 10
289 293(289) 
-- ---HS-Alpha3-Proteasome-AAH29402 (256) 
-- ---AG-Alpha3-Proteasome-XP_321089 (237) 
-- ---DM-Alpha3-Proteasome-NP_724834 (254) 
DI HLESC-Alpha3-Proteasome-NP_015007.2 (284) 
-- ---PF-Alpha3-Proteasome-PFC0745c (253) 
     Consensus (289) 
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 Section 1
1 3310 20(1) 
-MSRRYDSRTT IFSPEGRL YQVE YA ME AIGH AGHS-Alpha4-Proteasome- NP_002780 (1) 
-MARRYDSRTT IFSPEGRL YQVE YA ME AISH AGAG-Alpha4-Proteasome-XP_315057 (1) 
-MARRYDSRTT IFSPEGRL YQVE YA ME AISH AGDM-Alpha4-Proteasome-NP_476691 (1) 
MGSRRYDSRTT IFSPEGRL YQVE YA LE SISH AGSC-Alpha4-Proteasome-NP_011651 (1) 
-MARRYDSRTT TFSPEGRL YQVE YA LE AINN ASPF-Alpha4-Proteasome-PF13_0282 (1) 
 MARRYDSRTTIFSPEG RLYQ VEYA MEAI SHAGConsensus (1) 
 Section 2
34 6640 50(34) 
TCLGILANDGVLLAAER RNIH KL LDEV FF SEKIHS-Alpha4-Proteasome- NP_002780 (33) 
TSLGILAKDGILLAAER RNTNKLLDNVIF SE KIAG-Alpha4-Proteasome-XP_315057 (33) 
TCLGILAEDGILLAAEC RSTN KLLD SAIP SEKIDM-Alpha4-Proteasome-NP_476691 (33) 
TAIGIMASDGIVLAAER KVTS TLLE QDTS TEK LSC-Alpha4-Proteasome-NP_011651 (34) 
ITIGLITKDGVILGADK VFIS KLID KANN Y E KIPF-Alpha4-Proteasome-PF13_0282 (33) 
T LGILA DGILLAAER R T KLLD     SEKIConsensus (34) 
 Section 3
67 9980(67) 
YKLN EDMACSVAG ITS DAN VLTN ELRL IAQR YLHS-Alpha4-Proteasome- NP_002780 (66) 
YKLND DMVCSVAG ITS DAN VLTN LLRV IAQR YQAG-Alpha4-Proteasome-XP_315057 (66) 
YRLND NMVCSVAG ITS DAN VLTS ELRL IAQR YQDM-Alpha4-Proteasome-NP_476691 (66) 
YKLND KIAVAVAG LTA DAEILINTARIHAQNYLSC-Alpha4-Proteasome-NP_011651 (67) 
YKIDKHIFCGVAG LNAD ANIL INQS RLYA QRY LPF-Alpha4-Proteasome-PF13_0282 (66) 
YKLND M CSVAGITSD ANVL TN L RLIA QRYLConsensus (67) 
 Section 4
100 132110 120(100) 
LQYQEPIPCEQLVTALC DIKQ AYTQ FGGKRPFGHS-Alpha4-Proteasome- NP_002780 (99) 
LNYGEAMPCEQLVSHLC DVKQ AYTQ YGGKRPFGAG-Alpha4-Proteasome-XP_315057 (99) 
FSYGEVIPCEQLVSHLC DIKQ AYTQ YGGKRPFGDM-Alpha4-Proteasome-NP_476691 (99) 
KTYNEDIPVEILVRRLS DIKQ GYTQ HGGL RPF GSC-Alpha4-Proteasome-NP_011651 (100) 
YNYNEVQPVSQLVVQIC DIKQ SYTQ YGGL RPY GPF-Alpha4-Proteasome-PF13_0282 (99) 
 NYNE IPCEQLVS LC DIKQ AYTQ YGGK RPFGConsensus (100) 
 Section 5
133 165140 150(133) 
VSLLYIGWDKHYGFQLY QSD PSGNY GGWKATCIHS-Alpha4-Proteasome- NP_002780 (132) 
VSILYMGWDKHYGYQLY QSD PSGNY GGWKATCIAG-Alpha4-Proteasome-XP_315057 (132) 
VSLLYMGWDNKYGYQLY QSD PSGNY GGWKATCIDM-Alpha4-Proteasome-NP_476691 (132) 
VSFIYAGYDDRYGYQLY TSNP SGNY TG WKAI SVSC-Alpha4-Proteasome-NP_011651 (133) 
VSFLIGGYDTKDGYQLY HTDP SGNY SG WFAT AIPF-Alpha4-Proteasome-PF13_0282 (132) 
VSLLYMGWD KYGYQLY QSDP SGNY GGWK ATCIConsensus (133) 
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 Section 6
166 198180(166) 
GNNSAAAVSMLKQDYKE GE-- -MTL KSAL ALA IHS-Alpha4-Proteasome- NP_002780 (165) 
GNNSAAAVSALKQE LSD SD-- -ISLVQAQDLAVAG-Alpha4-Proteasome-XP_315057 (165) 
GNNFGAAISMLKQE LAD KENV KLTLADAKDLAIDM-Alpha4-Proteasome-NP_476691 (165) 
GANTSAAQTLLQMDYKD DMK- --- VDDAIELALSC-Alpha4-Proteasome-NP_011651 (166) 
GTNNLTASSVLKQE WKN DM-- -- TLEE GL LLALPF-Alpha4-Proteasome-PF13_0282 (165) 
GNNSAAAVSMLKQEYKD  E   ITL  DAL DLAIConsensus (166) 
 Section 7
199 231210 220(199) 
KVLNKTMDVSKLSAEKV EIAT LTR- -E NGKTV IHS-Alpha4-Proteasome- NP_002780 (195) 
KVLSKT LDMTKLT SEK IEMAVLTR --E NNKTVIAG-Alpha4-Proteasome-XP_315057 (195) 
KVLSMTLDTTKLT PEKV EMAT LQR- -V DNKTV YDM-Alpha4-Proteasome-NP_476691 (198) 
KTLSKT TDSSALTYDRL EFATIRKGAN DGEV YQSC-Alpha4-Proteasome-NP_011651 (195) 
KTLAKSTDTEIPKSEKI ELAY LTN- -K DG EVY QPF-Alpha4-Proteasome-PF13_0282 (194) 
KVLSKTLDTSKLTSEKI EMAT LTR   DG KTV Consensus (199) 
 Section 8
232 264240 250(232) 
RVLKQK EVE QLI KKHE EEE AKAE REKK EK EQKEHS-Alpha4-Proteasome- NP_002780 (226) 
KILSSA EVDGLIAKYEK AE AEAEAAKKEK LG QKAG-Alpha4-Proteasome-XP_315057 (226) 
SVLEKP DVEKLIEKYTK VQ AEAEAAKKEK QA KQDM-Alpha4-Proteasome-NP_476691 (229) 
KIFKPQ EIKDILVKTGI TKK DED EEA DEDMK--SC-Alpha4-Proteasome-NP_011651 (228) 
KYLTEK EIEELIKLYTQ KYI KE- ---- ---- --PF-Alpha4-Proteasome-PF13_0282 (225) 
KIL   EVE LI KY    AE AE  KKEK     Consensus (232) 
 Section 9
265267(265) 
KDKHS-Alpha4-Proteasome- NP_002780 (259) 
S--AG-Alpha4-Proteasome-XP_315057 (259) 
PTKDM-Alpha4-Proteasome-NP_476691 (262) 
---SC-Alpha4-Proteasome-NP_011651 (259) 
---PF-Alpha4-Proteasome-PF13_0282 (247) 
   Consensus (265) 
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ProteasomeAlpha5_08-25-2009.apr
 Section 1
1 3310 20(1) 
MFLTRSEYDRGV NTFSPEG RLFQ VEY A IE AI KLHS-Alpha5-Proteasome-NP_002781 (1) 
MFLTRSEYDRGV NTFSPEG RLFQ VEY A IE AI KFAG-Alpha5-Proteasome-XP_314945 (1) 
MFLTRSEYDRGV NTFSPEG RLFQ VEY A IE AI KLDM-Alpha5-Proteasome-NP_725669 (1) 
MFLTRSEYDRGV STFSPEG RLFQ VEY S LEAI KLSC-Alpha5-Proteasome-NP_011769 (1) 
MFSTRSEYDRGV NTFSPEG RLFQ VEY A LGAI KLPF-Alpha5-Proteasome-PF07_0112 (1) 
MFLTRSEYDRGVNTFSP EGRL FQVE YAIE AIKLConsensus (1) 
 Section 2
34 6640 50(34) 
GSTA IGIQTSEGVCLAV EKRITSPLMEPSSI EKHS-Alpha5-Proteasome-NP_002781 (34) 
GSTA IGISTPDGVVMAV EKRI TSSL IEPS KMEKAG-Alpha5-Proteasome-XP_314945 (34) 
GSTA IGICTPEGVVLAV EKRITSPLMVPSTVEKDM-Alpha5-Proteasome-NP_725669 (34) 
GSTA IGIATKEGVVLGV EKRA TSPL LESD SIE KSC-Alpha5-Proteasome-NP_011769 (34) 
GSTA VGICVNDGVILAS ERRI SSTL IEKD SVE KPF-Alpha5-Proteasome-PF07_0112 (34) 
GSTAIGI T EGVVLAV EKRI TSPL IEPS SIEKConsensus (34) 
 Section 3
67 9980(67) 
IVEI DAHIGCA MSGL IAD AKTLIDKARVETQNHHS-Alpha5-Proteasome-NP_002781 (67) 
IVEVDRHIGCA TSGL MAD SRTL LDRARIECQNHAG-Alpha5-Proteasome-XP_314945 (67) 
IVEVDKHIGCA TSGL MAD ARTLI ER ARVE CQNHDM-Alpha5-Proteasome-NP_725669 (67) 
IVEI DRHIGCA MSGL TAD ARSMIEHARTAAVTHSC-Alpha5-Proteasome-NP_011769 (67) 
LLSIDDHIGCA M SGL MADA RTLI D YARVEC NHYPF-Alpha5-Proteasome-PF07_0112 (67) 
IVEIDRHIGCAMSGLMA DART LIDR ARVE CQNHConsensus (67) 
 Section 4
100 132110 120(100) 
WFTYNETMTVESVTQAV SNLA LQFG EEDA DP--HS-Alpha5-Proteasome-NP_002781 (100) 
WFVYNERMSVESCAQAV SNVA IQFG DGDD TD- -AG-Alpha5-Proteasome-XP_314945 (100) 
WFVYNERMSIESCAQAV STLA IQFG DSGD SDG ADM-Alpha5-Proteasome-NP_725669 (100) 
NLYYDEDINVESLTQSV CDLA LRFG EGAS GE-ESC-Alpha5-Proteasome-NP_011769 (100) 
KFIYNENINIKSCVELI SELA LDFS NLSD SKRKPF-Alpha5-Proteasome-PF07_0112 (100) 
WFVYNE MSVESC QAV S LA LQFG D  D SD  Consensus (100) 
 Section 5
133 165140 150(133) 
GAMSRPFGVA LLFGGVDEK G- PQLFHMDPSGTFHS-Alpha5-Proteasome-NP_002781 (131) 
SAMSRPFGVA ILFAGIENG E- PQLWHMDPSGTYAG-Alpha5-Proteasome-XP_314945 (131) 
AAMSRPFGVA ILFAGIEAG Q- PQLWHMDPSGTFDM-Alpha5-Proteasome-NP_725669 (133) 
RLMSRPFGVA LLIAGHDAD DGY QLFHAEPSGTFSC-Alpha5-Proteasome-NP_011769 (132) 
KIMSRPFGVA LLIGGVDKN G- PCLWYTEPSGTNPF-Alpha5-Proteasome-PF07_0112 (133) 
 AMSRPFGVALLFAGID     PQLW HMDP SGTFConsensus (133) 
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 Section 6
166 198180(166) 
VQCDARAIGS ASEGAQ SSLQEVYHKSMTLKE AIHS-Alpha5-Proteasome-NP_002781 (163) 
IRFDAKAIGS GSEGAQ QNLQEYYLPTMTIKEAIAG-Alpha5-Proteasome-XP_314945 (163) 
VRHGAKAIGS GSEGAQ QNLQDLFRPDLTLDEAIDM-Alpha5-Proteasome-NP_725669 (165) 
YRYNAKAIGS GSEGAQ AELLNEWHSSLTLKE AESC-Alpha5-Proteasome-NP_011769 (165) 
TRFSAASIGS AQEGAE LLLQENYKKDMTFEQ AEPF-Alpha5-Proteasome-PF07_0112 (165) 
VRF AKAIGSGSEGAQ  LQE  Y  SMTL KEAIConsensus (166) 
 Section 7
199 231210 220(199) 
KSSLIILKQVME EKLNA TNIE LATV QP-G QN FHHS-Alpha5-Proteasome-NP_002781 (196) 
NLALSTLKQVME EKLNS TNVE VMTM TP-K EL FRAG-Alpha5-Proteasome-XP_314945 (196) 
DISLNTLKQVME EKLNS TNVE VMTM TK-E RE FYDM-Alpha5-Proteasome-NP_725669 (198) 
LLVLKILKQVME EKLDE NNAQLSCITK-QDG FKSC-Alpha5-Proteasome-NP_011769 (198) 
ILALTVLRQVME DKLST SNVE ICAI KKSD QT FYPF-Alpha5-Proteasome-PF07_0112 (198) 
 LAL ILKQVMEEKLNS TNVE L TI TK    FYConsensus (199) 
 Section 8
232 262240 250(232) 
MFTKEE LEEVIKDI--- ---- ---- ---- --HS-Alpha5-Proteasome-NP_002781 (228) 
MFSKEE VEEYINN---- ---- ---- ---- --AG-Alpha5-Proteasome-XP_314945 (228) 
MFTKEE VEQHIKNIA-- ---- ---- ---- --DM-Alpha5-Proteasome-NP_725669 (230) 
IYDNEKTAELIKELKEK EAAE SPEE ADVE MSSC-Alpha5-Proteasome-NP_011769 (230) 
KYNTDDISRIIDVLPSP VYPT IDMT A--- --PF-Alpha5-Proteasome-PF07_0112 (231) 
MFTKEEVEEIIK I                 Consensus (232) 
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 Section 1
1 3210 20(1) 
-- -MSRGSSAGF DRH ITIFSP E GRLYQ VE YA FHS-Alpha6-Proteasome-NP_002782 (1) 
-- -MSRGSSAGF DRH ITIFSP E GRLYQ VE YA FAG-Alpha6-Proteasome-XP_318387 (1) 
-- -MSRGSSAGF DRH ITIFSP E GRLYQ VE YA FDM-Alpha6-Proteasome-NP_724614 (1) 
MS GA AAASAAGYDRHITIFSP EG RLYQ VEYA FSC-Alpha6-Proteasome-NP_011504 (1) 
-- -MVRPSQSMYDRHLTIFSP DG NLYQ IEYA IPF-Alpha6-Proteasome-MAL8P1.128 (1) 
   MSR GSSA GFDR HITIFSPEGRLYQVEYAFConsensus (1) 
 Section 2
33 6440 50(33) 
KA INQ GGLTSVAV RGK DCAVIVT QK-- ---- KHS-Alpha6-Proteasome-NP_002782 (30) 
KA INQ EGLTSIALKGKD CAVV ATQK ---- -- KAG-Alpha6-Proteasome-XP_318387 (30) 
KA IAQE NIT TVALKSGD CAVV ATQK ---- -- KDM-Alpha6-Proteasome-NP_724614 (30) 
KA TNQT NINS LAVR GKD CTVV ISQK ---- -- KSC-Alpha6-Proteasome-NP_011504 (33) 
KA VKNT NITS V GVKGE NCAVIIS QKKM ATQY IPF-Alpha6-Proteasome-MAL8P1.128 (30) 
KA INQ NITS VAVK GKDCAVVITQK      KConsensus (33) 
 Section 3
65 9670 80(65) 
VP DKLLDSSTVTHLF KITENIGC VMT GMTADSHS-Alpha6-Proteasome-NP_002782 (56) 
IP DKLI DPAT VTHL YRITREI GCVM TGRIADSAG-Alpha6-Proteasome-XP_318387 (56) 
VT EKNI VPET VTHL F RITKDI GCAM TGRI ADSDM-Alpha6-Proteasome-NP_724614 (56) 
VP DKLLDP TTVSYI FC ISRTIGMVVNGPIPDASC-Alpha6-Proteasome-NP_011504 (59) 
SQ DKLL DYNNITNIYNI TDEI GCSM VGMP GDCPF-Alpha6-Proteasome-MAL8P1.128 (62) 
VP DKLL DP T VTHL FRITREIGCVMTG IADSConsensus (65) 
 Section 4
97 128110(97) 
RS QVQR ARYEAANWKYKYGYE IPVD MLCKRIAHS-Alpha6-Proteasome-NP_002782 (88) 
RS QVQR ARYEAANWRYKYGYE IPVD VLCRRM AAG-Alpha6-Proteasome-XP_318387 (88) 
RS QVQ KARYEAANFRY KYGYEMPVDVL CRRI ADM-Alpha6-Proteasome-NP_724614 (88) 
RN AALR AKAE AAEF RYKYGYDMPCDVLAKRMASC-Alpha6-Proteasome-NP_011504 (91) 
LS MVYK ARSE ASEF LYSNGYNVNAETLCRNICPF-Alpha6-Proteasome-MAL8P1.128 (94) 
RS QVQR ARYE AANF RYKYGYEIPVDVLCRRIAConsensus (97) 
 Section 5
129 160140 150(129) 
DI SQVYTQ NAEMRPLGC CMIL IG IDEE QGPQ VHS-Alpha6-Proteasome-NP_002782 (120) 
DI SQVYTQ NAEMRPLGCS IVMI AFDAENGPAVAG-Alpha6-Proteasome-XP_318387 (120) 
DI NQVY TQ NAEMRPLGC S MVL IA YDNE IGPS VDM-Alpha6-Proteasome-NP_724614 (120) 
NL SQIY TQ RAYMRPLG VILTF VSVD EELG PSISC-Alpha6-Proteasome-NP_011504 (123) 
DK IQVY TQ HAYMRLHAC SGMI IGID ENNK PELPF-Alpha6-Proteasome-MAL8P1.128 (126) 
DI SQVY TQNA EMRP LGCSMVLIAIDEENGPSVConsensus (129) 
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 Section 6
161 192170 180(161) 
YK CDPA GYYC GFKA TAAGVKQTESTSFLEKKVHS-Alpha6-Proteasome-NP_002782 (152) 
YK TDPA GYYC GYHA ISVGVKQTEANSYLEKKLAG-Alpha6-Proteasome-XP_318387 (152) 
YK TDPA GYFS GFKA CSVGAKTLEANSYLEKKYDM-Alpha6-Proteasome-NP_724614 (152) 
YK TDPA GYYV GYKA TATGPKQQEITTNLENHFSC-Alpha6-Proteasome-NP_011504 (155) 
FK FDPS GFCA GYRA CVIGNKEQESISVLERLLPF-Alpha6-Proteasome-MAL8P1.128 (158) 
YK TDPA GYY GYKA  AVG KQ EA SYLEKKLConsensus (161) 
 Section 7
193 224200 210(193) 
KK K--- ---- -F DWTF EQTVETAITCLSTV LSHS-Alpha6-Proteasome-NP_002782 (184) 
KR K--- ---- -A ELSE EETIQLAITCLSTV LAAG-Alpha6-Proteasome-XP_318387 (184) 
K- ---- ---- -P NLSEEKAIQLA ISCL SSVLADM-Alpha6-Proteasome-NP_724614 (184) 
KK SKI- --DH IN EESW EKVVEFAITHMIDALGSC-Alpha6-Proteasome-NP_011504 (187) 
EK RKKK IQQE TI DEDI RNTTILAIEALQTILAPF-Alpha6-Proteasome-MAL8P1.128 (190) 
KK K         D S E TI LAITCLSTVLAConsensus (193) 
 Section 8
225 256230 240(225) 
ID FKP SEIEVGVV TVENPKFR ILTE AEID AHLHS-Alpha6-Proteasome-NP_002782 (208) 
VD FKP TEIEIGIVSKEKPEFR TLTE DEIE VHLAG-Alpha6-Proteasome-XP_318387 (208) 
ID FKP NGIEIGVVSK S DPTFRILDEREIEEHLDM-Alpha6-Proteasome-NP_724614 (206) 
TE FSKN DLEV GV ATKD- -K FF TLSA ENIE ERLSC-Alpha6-Proteasome-NP_011504 (216) 
FD LKAS EIEV AIVS TKNRN FT QISE KEID NYLPF-Alpha6-Proteasome-MAL8P1.128 (222) 
ID FKPS EIEV GVVS KE P FR LSE EIE HLConsensus (225) 
 Section 9
257 263(257) 
VA LAER DHS-Alpha6-Proteasome-NP_002782 (240) 
TA IAEKDAG-Alpha6-Proteasome-XP_318387 (240) 
TK IAEK DDM-Alpha6-Proteasome-NP_724614 (238) 
VA IAEQ DSC-Alpha6-Proteasome-NP_011504 (246) 
TY IAER DPF-Alpha6-Proteasome-MAL8P1.128 (254) 
TA IAEK DConsensus (257) 
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 Section 1
1 3210 20(1) 
MS SRYD RA ITVFSPDGH LLQVE YAQEAVRKGSAG-Alpha7-XP_315431 (1) 
MS SRYD RA VTIFSPDGH LLQVEY AQEA VRKGSDM-Alpha7-Proteasome-NP_525092 (1) 
-- MS YDRA ITVF SPDG H L FQVE YAQEAVK KGSHS-Alpha7-Proteasome-NP_002783 (1) 
-M SGYD RA LSIFSPDGH IFQVE YALEAVKRGTSC-Alpha7-Proteasome-NP_014604 (1) 
-- MS YDRA ITVF SPDG H L LQVE HALEAVK KGGPF-Alpha7-Proteasome-MAL13P1.270 (1) 
  S YD RAIT VFSP DGHLLQVEYAQEAVKKGSConsensus (1) 
 Section 2
33 6440 50(33) 
TA IGVR GKDVVVLGVEK KSVA K LQEER-TVR KAG-Alpha7-XP_315431 (33) 
TA VGVR G ANCVVLGVEKKSVA QL QEDR -KVR KDM-Alpha7-Proteasome-NP_525092 (33) 
TA VGVR G RDIVVLGVEKKSVA K L QDER -TVR KHS-Alpha7-Proteasome-NP_002783 (31) 
CA VGV KGKNCVVLGCER RSTL KLQD TRIT PSKSC-Alpha7-Proteasome-NP_014604 (32) 
CA VAIK SSNFAVLAVEK KNIP KLQN PK-T TEKPF-Alpha7-Proteasome-MAL13P1.270 (31) 
TA VGVR GKN VVLG VEKKSVAKLQDER TVRKConsensus (33) 
 Section 3
65 9670 80(65) 
IC LLDH HVVM A FAGLTADARV LINR A Q VQCQ SAG-Alpha7-XP_315431 (64) 
IC MLDN HVVM A FAGLTADARI MINR AQVECQ SDM-Alpha7-Proteasome-NP_525092 (64) 
IC ALDD NVCM AFAG LTADARIVINRARVEC QSHS-Alpha7-Proteasome-NP_002783 (62) 
VS KIDS HVV LSFSGLNA DSRI LI EK ARVE AQSSC-Alpha7-Proteasome-NP_014604 (64) 
LI KLDE HNCL AFAG LNADARVLVNKTRLECQRPF-Alpha7-Proteasome-MAL13P1.270 (62) 
IC  LD HVVM AFAG LTADARILINRARVECQSConsensus (65) 
 Section 4
97 128110(97) 
HK LSEE DPVT LEYI TRYI AEL KQKH TQSN GRRAG-Alpha7-XP_315431 (96) 
HR LNVE DPVT LEYI TRF IAQL KQKY TQSN GRRDM-Alpha7-Proteasome-NP_525092 (96) 
HR LTVE DPVT VE YITRY I ASLKQRYTQSN GR RHS-Alpha7-Proteasome-NP_002783 (94) 
HR LTLE DPVT VE YLTRY VAGV QQRY TQSG GVRSC-Alpha7-Proteasome-NP_014604 (96) 
YY LNMD EPAPVDYIAKY VAKV QQKF THRG GVRPF-Alpha7-Proteasome-MAL13P1.270 (94) 
HR LTVE DPVT VEYI TRYIA LKQKYTQSNGRRConsensus (97) 
 Section 5
129 160140 150(129) 
PF GISCLIGGFD-YDGV PHLY KTEP SG VY CEWAG-Alpha7-XP_315431 (128) 
PF GISCLIGGFD-ADGS AH LF QTEP SG IFYEYDM-Alpha7-Proteasome-NP_525092 (128) 
PF GISALIVGFD-FDGT PRLY QTDP SG TYHAWHS-Alpha7-Proteasome-NP_002783 (126) 
PF GVSTLIAGFDPRDDE PKLY QTEP SG IYSSWSC-Alpha7-Proteasome-NP_014604 (128) 
PF GIATLIAGFK-NNKE IC IY QTEP SG IYAAWPF-Alpha7-Proteasome-MAL13P1.270 (126) 
PF GIS LIAG FD  DG P LYQTEPSGIY AWConsensus (129) 
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 Section 6
161 192170 180(161) 
KA NATG RSAK TVRE FLEEHYS-PAA VSTE EGTAG-Alpha7-XP_315431 (159) 
KA NATG RSAK VVRE FFEKSYR-E EE VANE HGADM-Alpha7-Proteasome-NP_525092 (159) 
KA NAI GRGAKSVREFLE KNYT -D EA IETD DLTHS-Alpha7-Proteasome-NP_002783 (157) 
SA QTIG RNSK TVRE FLEKNYDRK EP PATV EECSC-Alpha7-Proteasome-NP_014604 (160) 
KA QAIG KNAK IVQE FLEKNYQ---ENME QKDCPF-Alpha7-Proteasome-MAL13P1.270 (157) 
KA NAIG R AK TVRE FLEKNY   E VATEE  Consensus (161) 
 Section 7
193 224200 210(193) 
IT LAIR ALL EVVQSGQ KSLEVAVM RRD EPMK MAG-Alpha7-XP_315431 (190) 
VK LAIR ALL EVAQSGQ NNLEVAIMENGKPLKMDM-Alpha7-Proteasome-NP_525092 (190) 
IK LVIK ALL EVVQSGGKNIEL AVM RRDQSLKIHS-Alpha7-Proteasome-NP_002783 (188) 
VK LTVR SLLE VVQT GAKNIEITVVKPDSDIVASC-Alpha7-Proteasome-NP_014604 (192) 
IF LALK AIFE VVEL SSKNVEVALLT-EKDLTFPF-Alpha7-Proteasome-MAL13P1.270 (186) 
IK LAIR ALLE VVQS G KNIEVAVMR D  LKMConsensus (193) 
 Section 8
225 255230 240(225) 
LD AQTI EEYV KKIE LAKEE EA EKKK AKK- --AG-Alpha7-XP_315431 (222) 
LD TDVI TDYV KIIE KEKEE EL EKKK QKK- --DM-Alpha7-Proteasome-NP_525092 (222) 
LN PEEI EKYV AEIE KEKEE -N EKKK QKKA S-HS-Alpha7-Proteasome-NP_002783 (220) 
LS SEEI NQYV TQIE QEKQEQQEQDKKKKSNHSC-Alpha7-Proteasome-NP_014604 (224) 
IE EQEI NSM VELIDQER TKNN EQNE ---- --PF-Alpha7-Proteasome-MAL13P1.270 (217) 
LD  EEI   YV   IE  EKEE NEKKK KK   Consensus (225) 
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 Section 1
1 3310 20(1) 
MLSSTAMYSAPGRDLGM EP HRAA GPLQLR FSPYHS-Beta1-Proteasome-NP_002784 (1) 
---M LGIENFP------ -E YEVP GARKVQ FYPYAG-Beta1-Proteasome-XP_315096 (1) 
-MSRLGFEQFP------ -D YQVP GMKHPD FSPYDM-Beta1-Proteasome-NP_524115 (1) 
-MATIASEYSS------ -- EASN TPIE HQ FNPYSC-Beta1-Proteasome-NP_009512 (1) 
MDLI LYNDNLTEKKTEK ENVI EH GRGFKR WYPYPF-Beta1-Proteasome-MAL13P1.270 (1) 
 MS LA EN P        Y   G     F PYConsensus (1) 
 Section 2
34 6640 50(34) 
VFNGG TILAIAG EDFA IVASDTR LSEG FSIH TRHS-Beta1-Proteasome-NP_002784 (34) 
ESNGG SVV AIA GEDFAVI GADTR LSSGYS IHTRAG-Beta1-Proteasome-XP_315096 (24) 
ESNGG SIVAIAG DDFA VIA ADTR LSSGYNIHSRDM-Beta1-Proteasome-NP_524115 (26) 
GDNGG TILGIAGEDFAV LAGDTR NITD YSIN SRSC-Beta1-Proteasome-NP_009512 (25) 
IDNGG TVIGL TG KDYV ILAADTR LSLS YSIY TRPF-Beta1-Proteasome-MAL13P1.270 (34) 
  NGGTILAIAGEDFAV IAAD TRLS SGYS IHTRConsensus (34) 
 Section 3
67 9980(67) 
DSPKCYKLTDKTV IGCS GFHG DCLT LTKI IEA RHS-Beta1-Proteasome-NP_002784 (67) 
TQNKLFRLSDKTV LAS TGCWCDTLALTSLVKVRAG-Beta1-Proteasome-XP_315096 (57) 
TQSKLFKL SPQTVLGSA GCWA DTLS LTGS IKV RDM-Beta1-Proteasome-NP_524115 (59) 
YEPKVFDCGDNIVMSAN GFAA DGDA LVKR FKNSSC-Beta1-Proteasome-NP_009512 (58) 
FCPKISKLTDKCIIGSS GMQS DIKT LHSL LQKKPF-Beta1-Proteasome-MAL13P1.270 (67) 
  PKLFKLSDKTVIGSS G  A D LT LT L IK RConsensus (67) 
 Section 4
100 132110 120(100) 
LKMYKHSN-NKAMTTGA IAAM LS TILYSRRFFPHS-Beta1-Proteasome-NP_002784 (100) 
MQMYKDQH-QKNMSTPA VAQM LS ILMY NRRF FPAG-Beta1-Proteasome-XP_315096 (90) 
MQSYEHTH-LRTMTTEA VAQM LS IAMYNRRFFPDM-Beta1-Proteasome-NP_524115 (92) 
VKWYHFDHNDKKLSINS AARN IQHL LYGK RFF PSC-Beta1-Proteasome-NP_009512 (91) 
IQLFVLEH-SHYPDIHV IARL LCVI LYSR RFF PPF-Beta1-Proteasome-MAL13P1.270 (100) 
MQMY   H  K MST A IA M LSII LY R RFFPConsensus (100) 
 Section 5
133 165140 150(133) 
YYVYNIIGGLDEEGKGA VYSF DPVG SYQR DSFKHS-Beta1-Proteasome-NP_002784 (132) 
YYVSNVLAGLDQDGKGV VYSY DPIG HCEM TTYRAG-Beta1-Proteasome-XP_315096 (122) 
YYVSNILA GIDNEGKGV VYSY DPIG HCEK ATY RDM-Beta1-Proteasome-NP_524115 (124) 
YYVHTIIAGLDEDGKGA VYSF DPVG SYER EQC RSC-Beta1-Proteasome-NP_009512 (124) 
YYAFNILA GVDENNKGV LYNY DSVG SYCE ATH SPF-Beta1-Proteasome-MAL13P1.270 (132) 
YYV NILAGLDEDGKGV VYSY DPVG SYER  TYRConsensus (133) 
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 Section 6
166 198180(166) 
AGGSASAMLQPLLDN QV GFK-------- NMQNVHS-Beta1-Proteasome-NP_002784 (165) 
AGGSAGPLLQ PVLDNQ IGQK-------- NMLNAAG-Beta1-Proteasome-XP_315096 (155) 
AGGTAGTLLQ PVLDNQ IGHKNM------ NLEDADM-Beta1-Proteasome-NP_524115 (157) 
AGGAAASLIMPFLDN QV NFKN QYEP GTN GKV KKSC-Beta1-Proteasome-NP_009512 (157) 
CVGSGSQLILPILDN RV EQKN ---- ---- -QL IPF-Beta1-Proteasome-MAL13P1.270 (165) 
AGGSAS LLQPVLDNQV G KN        N M   Consensus (166) 
 Section 7
199 231210 220(199) 
EHVP LSLDR AMR LVKD VFISAAERDVYTGDALRHS-Beta1-Proteasome-NP_002784 (190) 
DPEP VKMEKAISIIKDT FISA TERD IYT GDSVIAG-Beta1-Proteasome-XP_315096 (180) 
DKIK LTKERAVSVASDT FISA AERD IYT GDSVLDM-Beta1-Proteasome-NP_524115 (184) 
PLKY LSVEEVIKLVRDS FTSA TERH IQVG DGL ESC-Beta1-Proteasome-NP_009512 (190) 
KNTN FNLGDDINFVKDA ITSA TERD IYT GDKTLPF-Beta1-Proteasome-MAL13P1.270 (189) 
D   LSLERAI LVKDT FISA TERD IYTG DSLLConsensus (199) 
 Section 8
232 250240(232) 
ICIVTKEGIREETVSLR KDHS-Beta1-Proteasome-NP_002784 (223) 
INIIT KDGIKEETL HL RKDAG-Beta1-Proteasome-XP_315096 (213) 
INIIT KDGIEVRTLTLR QDDM-Beta1-Proteasome-NP_524115 (217) 
ILIVTKDGVRKEFYE LK RDSC-Beta1-Proteasome-NP_009512 (223) 
IYVIDKMGINVNTLDLK QDPF-Beta1-Proteasome-MAL13P1.270 (222) 
I IITKDGIR ETL LR KDConsensus (232) 
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 Section 1
1 3310 20(1) 
--ME YLIG IQGP DYV LVAS DRVA ASNIVQMKDDHS-Beta2-Proteasome-NP_002785 (1) 
LTME TL MGIRGPDF VMLAADCTH AH SIMV LKDDAG-Beta2-Proteasome-XP_319581 (1) 
--ME TL LGIKGPDF VMLAADTTH ARSIIVMKEDDM-Beta2-Proteasome-NP_609804 (1) 
--MD IILG IRVQ DSVILASSKAV TRGI SVLKDSSC-Beta2-Proteasome-NP_010928 (1) 
--MD TLIG LRGN NFVVLAADTYSIN SIIKLKNDPF-Beta2-Proteasome-PF14_0676 (1) 
  ME TLIG IRGP DFVMLAAD   A SIIVLKD DConsensus (1) 
 Section 2
34 6640 50(34) 
HD-K MFKM SEKI LLLCVGEAGDTVQFAEYIQK NHS-Beta2-Proteasome-NP_002785 (32) 
ED-K ILKV SDNL MLATMGEAGDRVQFTEYISK NAG-Beta2-Proteasome-XP_319581 (34) 
QN-K IHKV SDSL LISTVGESGDTEQFTEFISK NDM-Beta2-Proteasome-NP_609804 (32) 
DD-K TRQL SPHT LMS FAGE AGDT VQFA EYIQANSC-Beta2-Proteasome-NP_010928 (32) 
DNTK FYDI HGNK CLL LG GSIGDRLQFGEFIRKNPF-Beta2-Proteasome-PF14_0676 (32) 
DD K I KV SD L LLS VGEAGDTVQFAEYI K NConsensus (34) 
 Section 3
67 9980(67) 
VQLY KMRN GYEL SP TAAANFTRRNLADCLRSRTHS-Beta2-Proteasome-NP_002785 (64) 
ILLY RMRN GYEL GP KAAAHFTRRNLADYLRSRTAG-Beta2-Proteasome-XP_319581 (66) 
IALY KMRN GY DLSP RESAHFTRKNLAEYLRSRTDM-Beta2-Proteasome-NP_609804 (64) 
IQLY SIRE DYEL SP QAVSSFVRQELAKSIRSRRSC-Beta2-Proteasome-NP_010928 (64) 
VHLY QYQN NTDM FVKSFAFFTRKNLAYYLR-R NPF-Beta2-Proteasome-PF14_0676 (65) 
I LY KMRN GYEL SPKAAA FTRKNLADYLRSR TConsensus (67) 
 Section 4
100 132110 120(100) 
PYHV NLLL AGYD EHE G-PA LYYM DYL AALAKAPHS-Beta2-Proteasome-NP_002785 (97) 
PYHV NLLV GGYD EVD G-PQ LHYI DYL ANSLPVKAG-Beta2-Proteasome-XP_319581 (99) 
PYQV FMFV AGYD PNA G-PELTFIDYL ANALPVNDM-Beta2-Proteasome-NP_609804 (97) 
PYQV NVLI GGYD KKK NKPE LYQI DYL GTKVELPSC-Beta2-Proteasome-NP_010928 (97) 
PFEV NCLI AGYD KKD G-YQ LYWCDYL SNMDS VNPF-Beta2-Proteasome-PF14_0676 (97) 
PY V NLLI AGYD   DG P LYYIDYLAN L V  Consensus (100) 
 Section 5
133 165140 150(133) 
FAAH GY GAFLTLSIL DRYY TPTISRERAVEL LRHS-Beta2-Proteasome-NP_002785 (129) 
HGAH GY GGMFVNSIF DRYH HDKI TQKE AYEIFRAG-Beta2-Proteasome-XP_319581 (131) 
YAG HGY GAIF ASSI YDRYWHPNITQAEAYDVFKDM-Beta2-Proteasome-NP_609804 (129) 
YGAH GY SGFY TFSL LDHHYRPDMTTEEGLDLLKSC-Beta2-Proteasome-NP_010928 (130) 
KGAH GY GAYLVSAIL DKYY HENLTVDEALDIFKPF-Beta2-Proteasome-PF14_0676 (129) 
YGAH GYGA FF  SILDRYYHP IT EEALDIF KConsensus (133) 
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 Section 6
166 198180(166) 
KCLE ELQK RFIL NLP TFSV RIID KNGI HDLDNIHS-Beta2-Proteasome-NP_002785 (162) 
KGVT EIHK RLIL NLP NFKV AVID KDGV KYLDDIAG-Beta2-Proteasome-XP_319581 (164) 
KCIA EIQK RLVV NLK NFTV AVVD KDGV RDLEPIDM-Beta2-Proteasome-NP_609804 (162) 
LCVQ ELEK RMPM DFKGVIVKIVDKDGI RQVDDFSC-Beta2-Proteasome-NP_010928 (163) 
LCFE ELKK RFLL TQINYELRIMYDNKVETQYV TPF-Beta2-Proteasome-PF14_0676 (162) 
KCV EL K RLIL NL NF VRIIDKDGVR LD IConsensus (166) 
 Section 7
199 209(199) 
SFPK QGS- ---HS-Beta2-Proteasome-NP_002785 (195) 
TPDS LKQA SAAAG-Beta2-Proteasome-XP_319581 (197) 
SAAS LAA- ---DM-Beta2-Proteasome-NP_609804 (195) 
QAQ- ---- ---SC-Beta2-Proteasome-NP_010928 (196) 
V--- ---- ---PF-Beta2-Proteasome-PF14_0676 (195) 
S          Consensus (199) 
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ProteasomeBeta3_08-25-2009.apr
 Section 1
1 3410 20(1) 
-MSI MS YNGG AVMAMKGKNCVAIA ADRRFGI-QAHS-Beta3-Proteasome-NP_002786 (1) 
-MSI LA YNGG CVVA MKG KNCV AIA TDH RFGV -QAAG-Beta3-Proteasome-XP_321394 (1) 
-MSI LA YNGG CVVA MRG KDCV AIA TDH RFGI -QADM-Beta3-Proteasome-NP_649858 (1) 
MSDPSSINGG IVVA MTGKDCVAIA CDLRLGS-QSSC-Beta3-Proteasome-NP_011020 (1) 
----------- --- MSGSN CVAI A CDLRLGANTFPF-Beta3-Proteasome-PFA0400c (1) 
 MSILAYNGG VVAM KGKN CVAI A D RFGI QAConsensus (1) 
 Section 2
35 6840 50(35) 
QMVTTDFQKIF PMGD RLYI GLAG LATDVQTVAQRHS-Beta3-Proteasome-NP_002786 (33) 
QTIATDFEKVF EINP HMYL GLVG LQTDILTVYQRAG-Beta3-Proteasome-XP_321394 (33) 
QTISTD FKKV FHIGPRMFLGLTGLQTDILT VRDRDM-Beta3-Proteasome-NP_649858 (33) 
LGVSNKFEKIF HYG- HVFL GITG LATDVTTLNEMSC-Beta3-Proteasome-NP_011020 (34) 
TTVSTK FSKI FKMNNNVYVGLSGLATDIQT LYEIPF-Beta3-Proteasome-PFA0400c (21) 
QTVSTDF KIF  IG  MYL GLTG LATDI TV ERConsensus (35) 
 Section 3
69 10280 90(69) 
LKFRLNLY EL KEGRQIKPYTLMSMVANLLY EKRFHS-Beta3-Proteasome-NP_002786 (67) 
LLFRKNLY EV RENRQMTPERFAAMLSNFLY EKRFAG-Beta3-Proteasome-XP_321394 (67) 
LMFRKNLY ET RENREMCPKPFSAMMSSFLY EHRFDM-Beta3-Proteasome-NP_649858 (67) 
FRYK TN LY KL KEERAIEPETFTQLVSSSL YERRFSC-Beta3-Proteasome-NP_011020 (67) 
LRYRVNLY EV RQDAE MDVECFANMLSSIL YSNRFPF-Beta3-Proteasome-PFA0400c (55) 
LRFR NLYELR E R M PE  FAA MLSS LYEKRFConsensus (69) 
 Section 4
103 136110 120(103) 
GPYYTEPVIAG LDP K----------- T FKPF IC SHS-Beta3-Proteasome-NP_002786 (101) 
GPYFIEPVIAG LDP K----------- T YEPF IC NAG-Beta3-Proteasome-XP_321394 (101) 
GPYFIEPVVA GLDP K----------- T MEPF IC NDM-Beta3-Proteasome-NP_649858 (101) 
GPYFVGPVVA GINSK----------- S GKPF IAGSC-Beta3-Proteasome-NP_011020 (101) 
SPYFVNPIVVG FKLK HYVD EEGE KKV NYEPYLTAPF-Beta3-Proteasome-PFA0400c (89) 
GPYFIEPVVAG LDPK            TYEPFIC Consensus (103) 
 Section 5
137 170150 160(137) 
LDLIGC PMVT DDFVVSGTCAE QMYG MCE SLWEPNHS-Beta3-Proteasome-NP_002786 (124) 
MDLIGC PNLP NDFVVAGTCAE QLYG MCE TLWKPDAG-Beta3-Proteasome-XP_321394 (124) 
MDLIGC PNAP DDFVVAGTCAE QLYG MCE TLWKPDDM-Beta3-Proteasome-NP_649858 (124) 
FDLIGC IDEA K DFIVSG TASD QLFG MCE SLYEPNSC-Beta3-Proteasome-NP_011020 (124) 
YDLIGA KCET R DFVVNG VTSE QLFG MCE SLYVKDPF-Beta3-Proteasome-PFA0400c (123) 
MDLIGCP    DFVV AGTC AEQL YGMCESLW PDConsensus (137) 
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 Section 6
171 204180 190(171) 
MDPDHLFE TI SQAMLNAVDRD AVSGMGVI VHIIEHS-Beta3-Proteasome-NP_002786 (158) 
LESDSLFE VI SQALVNAFDRD AISGWGAT VYIIEAG-Beta3-Proteasome-XP_321394 (158) 
LEPD QL FE VI AQSIV NA FDRD AMSGWGATVYIIEDM-Beta3-Proteasome-NP_649858 (158) 
LEP EDL FE TI SQALLNA ADRD ALSGWGAVVYII KSC-Beta3-Proteasome-NP_011020 (158) 
QDENGLFE TI SQCLLSALDRD CISGWGAE VLVLTPF-Beta3-Proteasome-PFA0400c (157) 
LEPD LFETIS QALL NA D RDAI SGWGA VYIIEConsensus (171) 
 Section 7
205 218(205) 
KDKIT T RTLK ARMDHS-Beta3-Proteasome-NP_002786 (192) 
KEKITV KKLK TRMDAG-Beta3-Proteasome-XP_321394 (192) 
KDKIT E RTLK TRMDDM-Beta3-Proteasome-NP_649858 (192) 
KDEVVKRYLKM RQDSC-Beta3-Proteasome-NP_011020 (192) 
PEKIIKKKLKA RMDPF-Beta3-Proteasome-PFA0400c (191) 
KDKIT R LK RMDConsensus (205) 
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CLUSTAL 2.1 multiple sequence alignment
DM-Beta4-Proteasome-NP_649529       MLNN-YNSLAQPMWQNGPAPGEFYNFTGGQTPVQQLPRELTTMGPYGTKH 49
HS-Beta4-Proteasome-XP_317860       MYPMGGNSMAGPFWSNGPAPGAFYNFPGSTVAGGAMQARSDTPGEFGTQR 50
HS-Beta4-Proteasome-NP_002787       -MEAFLGSRSG-LWAGGPAPGQFYRIP-STPDSFMDPASALYRGP--ITR 45
SC-Beta4-Proteasome-NP_116708       -------MNHDPFSWGRPADSTYGAYN----------TQIANAGASPMVN 33
PF-Beta4-Proteasome-MAL8P1.142      -------------------------------------------------M 1
                                                                                      
DM-Beta4-Proteasome-NP_649529       STASSTTGTSVLGIRYDSGVMLAADTLVSYGSMARYQNIERVFKVNKNIL 99
HS-Beta4-Proteasome-XP_317860       SYYPVTTGTSVVGLMFKDGVIIAADKLISYGSLARFHDVDRVYRINDKTV 100
HS-Beta4-Proteasome-NP_002787       TQNPMVTGTSVLGVKFEGGVVIAADMLGSYGSLARFRNISRIMRVNNSTM 95
SC-Beta4-Proteasome-NP_116708       TQQPIVTGTSVISMKYDNGVIIAADNLGSYGSLLRFNGVERLIPVGDNTV 83
PF-Beta4-Proteasome-MAL8P1.142      TLGPVVTGTSVIAIKYKHGIMIAADRKASYGSYAKFQNVERIFKINNKTV 51
                                    :  . .*****:.: :. *:::***   ****  ::..:.*:  :... :
DM-Beta4-Proteasome-NP_649529       LGGSGDFADIQSIKRNIDQKMIE----DQCCDDNIEMKPKSLASWMTRVL 145
HS-Beta4-Proteasome-XP_317860       LGIGGDFADFQYIKRHIDQKVID----DQCLDDKNEMKPRSFYNWLTRVM 146
HS-Beta4-Proteasome-NP_002787       LGASGDYADFQYLKQVLGQMVID----EELLGDGHSYSPRAIHSWLTRAM 141
SC-Beta4-Proteasome-NP_116708       VGISGDISDMQHIERLLKDLVTENAYDNPLADAEEALEPSYIFEYLATVM 133
PF-Beta4-Proteasome-MAL8P1.142      MGFSGELADAQYLHELLTRKNINN--LSEKKRKEDMYTPQHYHSYVSRVF 99
                                    :* .*: :* * :.. :     :    .          *    .::: .:
DM-Beta4-Proteasome-NP_649529       YNRRSRMNPLYIDVVVGGVDN----------------------------- 166
HS-Beta4-Proteasome-XP_317860       YNRRSEFQPLYLDLVIGGMQ------------------------------ 166
HS-Beta4-Proteasome-NP_002787       YSRRSKMNPLWNTMVIGGYA------------------------------ 161
SC-Beta4-Proteasome-NP_116708       YQRRSKMNPLWNAIIVAGVQS----------------------------- 154
PF-Beta4-Proteasome-MAL8P1.142      YVRKNRIDPLFNNIIIAGINSQKYDNNDDNVLLYTNKNNDDEQNEYKNNE 149
                                    * *:..::**:  :::.*                                
DM-Beta4-Proteasome-NP_649529       ------EGTPYLANVDLRGRSYEDYVVATGFARHLAVPLVREKKPKDRDF 210
HS-Beta4-Proteasome-XP_317860       ------DGEPFLGHVNLRGRSYTSNVVATGYGTHLALPLLREWSENPTAY 210
HS-Beta4-Proteasome-NP_002787       ------DGESFLGYVDMLGVAYEAPSLATGYGAYLAQPLLREVLEKQPVL 205
SC-Beta4-Proteasome-NP_116708       ------NGDQFLRYVNLLGVTYSSPTLATGFGAHMANPLLRKVVDRESDI 198
PF-Beta4-Proteasome-MAL8P1.142      EYKEIHKDDLYIGFVDMHGTNFCDDYITTGYARYFALTLLRDHYKDN--- 196
                                          ..  ::  *:: *  :    ::**:. ::* .*:*.        
DM-Beta4-Proteasome-NP_649529       TAV---EASELIRTCMEVLYYRDTRNISQYTVGVCSVN-GCGVEG----P 252
HS-Beta4-Proteasome-XP_317860       QTLGQPEANDLMKRVMEVLWYRDCRSDPKYSQAVCTAD-GVKVDA----D 255
HS-Beta4-Proteasome-NP_002787       SQT---EARDLVERCMRVLYYRDARSYNRFQIATVTEK-GVEIEG----P 247
SC-Beta4-Proteasome-NP_116708       PKTTVQVAEEAIVNAMRVLYYRDARSSRNFSLAIIDKNTGLTFKK----N 244
PF-Beta4-Proteasome-MAL8P1.142      --MTEEEARILINECLRILYFRDATSSNFIQIVKVTSK-GVEYEEPYILP 243
                                           *   :   :.:*::**  .           . *   .      
DM-Beta4-Proteasome-NP_649529       FQVN-ENWTFAETIKGY----- 268
HS-Beta4-Proteasome-XP_317860       CFVA-QNWELAHTIKGY----- 271
HS-Beta4-Proteasome-NP_002787       LSTE-TNWDIAHMISGFE---- 264
SC-Beta4-Proteasome-NP_116708       LQVENMKWDFAKDIKGYGTQKI 266
PF-Beta4-Proteasome-MAL8P1.142      CVLNSADYVYPSTLLPPAGCMW 265
                                          .:  .  :        
        
PLEASE NOTE: Showing colors on large alignments is slow.
Alignments < ClustalW2 < EMBL-EBI http://www.ebi.ac.uk/Tools/services/web/toolresult.ebi?jobId=cl...
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 Section 1
1 3410 20(1) 
-------M ALAS -VLE RPLP VNQ R--- ---- -- GHS-Beta5-Proteasome-NP_002788 (1) 
-MALAELCGLS QGGLFHDASMGNDMFHRD --IALAG-Beta5-Proteasome-XP_559226 (1) 
-MALAEICKIS NAPY MRPNAWS SAD VEEE --QK GDM-Beta5-Proteasome-NP_652014 (1) 
MQAIADSFSVP N-RL VKEL QYD NEQNLES DFVT GSC-Beta5-Proteasome-AAA34906 (1) 
-MVIASDESFM NEID NLIN D V EDER ---- -----PF-Beta5-Proteasome-PF10_0111 (1) 
 MAIAE  SLS N  L  R   V N E         GConsensus (1) 
 Section 2
35 6840 50(35) 
FFGLGGRADL LD LGPG SLS DGLS LAAP GW GVPE EHS-Beta5-Proteasome-NP_002788 (18) 
NTQNLQNNM SLAVPPFQ DPALNL AKLQ AAGE SSGAG-Beta5-Proteasome-XP_559226 (32) 
LMCNLANPY TLAAPPFE NPLHNL NQIQ ANGD KTGDM-Beta5-Proteasome-NP_652014 (32) 
ASQFQRLAP SLTVPPIA SPQQFL RAHT DDSR NPDSC-Beta5-Proteasome-AAA34906 (34) 
---IDNDEL EFCVAPVN VPRNFI KYAQ TQNK K--PF-Beta5-Proteasome-PF10_0111 (25) 
         SL  VPP    P    L    QA G    Consensus (35) 
 Section 3
69 10280 90(69) 
PGIEMLHGTTT L AFKFRHGVIV AAD SRA TAGAYIHS-Beta5-Proteasome-NP_002788 (52) 
IKMDFDHGTTT L GFRFQGGVILAVDSRAT GGQFIAG-Beta5-Proteasome-XP_559226 (66) 
VKINFDHGTTT L GFKFKGGVLLAVDSRAT GGSYIDM-Beta5-Proteasome-NP_652014 (66) 
CKIKIAHGTTT L AFRFQGGIIVAVDSRAT AGNWVSC-Beta5-Proteasome-AAA34906 (68) 
-LFDFHKGTTT L AFKFKDGIIVAVDSRAS MGSFIPF-Beta5-Proteasome-PF10_0111 (54) 
 KIDF HGTTT LAFK FKGG VIVA VDSRATAGSFIConsensus (69) 
 Section 4
103 136110 120(103) 
ASQTVK KVIE IN PYLLGT MAG GAAD C S FWER LLAHS-Beta5-Proteasome-NP_002788 (86) 
GSQTMKKIVEI NDYLLGT LAGGAADC VYWDRVLAAG-Beta5-Proteasome-XP_559226 (100) 
GSQSMKKIVEI NQFMLGT LAGGAADC VYWDRVLSDM-Beta5-Proteasome-NP_652014 (100) 
ASQTVK KVIE IN PFLLGT MAG GAAD C Q FWET WLGSC-Beta5-Proteasome-AAA34906 (102) 
SSQNVEKIIEI NKNILGT MAGGAADC LYWEKYLGPF-Beta5-Proteasome-PF10_0111 (87) 
ASQTVKKIIEI N FL LGTM AGGA ADCVYWERVLAConsensus (103) 
 Section 5
137 170150 160(137) 
RQCRIY ELRN KERISVA AAS KLLANMVYQ YK GMGHS-Beta5-Proteasome-NP_002788 (120) 
KECRIY ELRN KERISVA AAS KIMSNIVY YYK GMGAG-Beta5-Proteasome-XP_559226 (134) 
KECRLHELRN KERISVAAASK IMAN IAHE YKG MGDM-Beta5-Proteasome-NP_652014 (134) 
SQCRLHELRE KERISVAAASK ILS NLVYQ YK GAGSC-Beta5-Proteasome-AAA34906 (136) 
KIIKIYELRN NEKISVRAAST ILS NILYQYKG YGPF-Beta5-Proteasome-PF10_0111 (121) 
K CRIYELRNK ERIS VAAA SKIL SNIVYQYKGMGConsensus (137) 
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 Section 6
171 204180 190(171) 
LSMGTMICGWD KR -GPGLYYVDSEGNRISG ATFSHS-Beta5-Proteasome-NP_002788 (154) 
LSMGMMLAGYD KR -GPQLYYIDSEGTRTPG KVFSAG-Beta5-Proteasome-XP_559226 (168) 
LSMGMMLAGYD KR -GPGLYYVDSEGSRTPG NLFSDM-Beta5-Proteasome-NP_652014 (168) 
LSMGTMICGYT RKEG PTIY YVDS DGTRLKGDIFCSC-Beta5-Proteasome-AAA34906 (170) 
LCCGIILSGYD HT-G FNMF YVDD SGKKVEGNLFSPF-Beta5-Proteasome-PF10_0111 (155) 
LSMGMMLAGYD KR G P LY YVDS EGTRI G LFSConsensus (171) 
 Section 7
205 238210 220(205) 
VGSG SV YAYG VMDRGYSYDLEVEQAYDLAR RA IYHS-Beta5-Proteasome-NP_002788 (187) 
VGSG SI YAYG VL DSGYHWDLTDEEAQDLG RRA IYAG-Beta5-Proteasome-XP_559226 (201) 
VGSG SL YAYG VL DSGYHWDLEDKEAQELG RRA IYDM-Beta5-Proteasome-NP_652014 (201) 
VGSG QT FAYG VL DSNYKWDLSVEDALYLG KRSILSC-Beta5-Proteasome-AAA34906 (204) 
CGSG ST YAYS ILDSAYDYNLNLDQAVELAR NAIYPF-Beta5-Proteasome-PF10_0111 (188) 
VGSGSIYAYGV LDSG Y WD L VE EA DLGRRAIYConsensus (205) 
 Section 8
239 272250 260(239) 
QATYRDAYSGG AVNLYHVREDGWIRVSS-D NVADHS-Beta5-Proteasome-NP_002788 (221) 
HATHRDAYSGG IVRVYHIKPSGWVNISN- QDCMDAG-Beta5-Proteasome-XP_559226 (235) 
HATFRDAYSGG IIRVYHIKEDGWVNISN- TDCMEDM-Beta5-Proteasome-NP_652014 (235) 
AAAHRDAYSGG SVNLYHVTEDGWIYHGN-H DVGESC-Beta5-Proteasome-AAA34906 (238) 
HATFRDGGSGG KVRV FHIHKN GYDK IIEG EDVFDPF-Beta5-Proteasome-PF10_0111 (222) 
HATHRDAYSGG  VRV YHIK EDGW I ISN  DV DConsensus (239) 
 Section 9
273 290280(273) 
LHEKYSGSTP- ---- ---HS-Beta5-Proteasome-NP_002788 (254) 
LHFQFKEEKNK KFGE TA-AG-Beta5-Proteasome-XP_559226 (268) 
LHYMYQEQLKQ QAAK ---DM-Beta5-Proteasome-NP_652014 (268) 
LFWKVK EEEG SSTTLLAKSC-Beta5-Proteasome-AAA34906 (271) 
LHYHYTNPEQK DQYV M--PF-Beta5-Proteasome-PF10_0111 (256) 
LHY Y E           Consensus (273) 
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 Section 1
1 3410 20(1) 
MAATLLAARGA GPAP AWGP EAFT P DWESREVSTGHS-Beta6-Proteasome-NP_002789 (1) 
----------- ---- --MD SDCS N DWRNAHH STGAG-Beta6-Proteasome-XP_320065 (1) 
----------- ---- ---- MQPD F DFTDTPVSTGDM-Beta6-Proteasome-AAL49013 (1) 
----------- ---- MNGI QVDI N RLKKGEVSLGSC-Beta6-Proteasome-NP_012533 (1) 
----MDVVNES QIKC HEEK SWDD EYDIKTP ISDGPF-Beta6-Proteasome-PFI1545c (1) 
                        DW    VSTGConsensus (1) 
 Section 2
35 6840 50(35) 
TTIMAV QFDG GVVLGAD SRT TTGSYIA NRVT DKLHS-Beta6-Proteasome-NP_002789 (35) 
TTIMAV EFDG GVVIGADSRTS TGTY VANR VTD KLAG-Beta6-Proteasome-XP_320065 (18) 
TTIMAV EFDG GVVIGADSRTS SGAY VANR VTD KLDM-Beta6-Proteasome-AAL49013 (16) 
TSIMAV TFKD GVILGADSRTT TGAY IA NRVTD KLSC-Beta6-Proteasome-NP_012533 (20) 
TTIIGI IYDN GVMLACDSRTSSGTFISNK CSRKIPF-Beta6-Proteasome-PFI1545c (31) 
TTIMAV FDGG VVLG ADSR TSTG TYIANRVTDKLConsensus (35) 
 Section 3
69 10280 90(69) 
TPIHDRIFCCR SG SAADTQAVADAVTYQLG FHSIHS-Beta6-Proteasome-NP_002789 (69) 
TKLTDKIYC C RSG SAAD TQAI ADIV AY SLNY HENAG-Beta6-Proteasome-XP_320065 (52) 
TRI TDK VYCC RSG SAADTQAIADIV AYSLNYHENDM-Beta6-Proteasome-AAL49013 (50) 
TRVHDKI WCC RSG SAADTQAIADIV QYHLELYTSSC-Beta6-Proteasome-NP_012533 (54) 
NRINENLYVCR SG ASAHSQKIIEIIKHYCV SMK NPF-Beta6-Proteasome-PFI1545c (65) 
TRI DKIYCCR SGSA ADTQ AIAD IV Y L YH NConsensus (69) 
 Section 4
103 136110 120(103) 
ELNE------- ---- ---- ---- -----------HS-Beta6-Proteasome-NP_002789 (103) 
QTGE------- ---- ---- ---- -----------AG-Beta6-Proteasome-XP_320065 (86) 
QTNK------- ---- ---- ---- -----------DM-Beta6-Proteasome-AAL49013 (84) 
QYG-------- ---- ---- ---- -----------SC-Beta6-Proteasome-NP_012533 (88) 
ENRKKGRFHEG ETIY DETT YDEE IDIDSINYLDYPF-Beta6-Proteasome-PFI1545c (99) 
Q                                 Consensus (103) 
 Section 5
137 170150 160(137) 
----------- ---- ---- ---- P PLV HTAASLFHS-Beta6-Proteasome-NP_002789 (107) 
----------- ---- ---- ---- P PLVE DAANEFAG-Beta6-Proteasome-XP_320065 (90) 
----------- ---- ---- ---- DA LVFEAASEFDM-Beta6-Proteasome-AAL49013 (88) 
----------- ---- ---- ---- T PSTETAASVFSC-Beta6-Proteasome-NP_012533 (91) 
NNNNDNNLVTK NKYF YEDK FNDY N PLVE NVAHITPF-Beta6-Proteasome-PFI1545c (133) 
                        PLVE AASIFConsensus (137) 
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 Section 6
171 204180 190(171) 
KEMCYRYREDL MAGI IIAGWDPQEGGQVY SVP MGHS-Beta6-Proteasome-NP_002789 (118) 
RQYCYNYRDTL VAGI IVAGWDAKHGGQVY SVP VGAG-Beta6-Proteasome-XP_320065 (101) 
RNYCYSYRESL LAGI IVAGWDEQRGGQVY SIPLGDM-Beta6-Proteasome-AAL49013 (99) 
KELCYENKDNL TAGI IVAGYDDKNK GEVY TIPLGSC-Beta6-Proteasome-NP_012533 (102) 
KKIIYTNNNFL SCAL IFGG YDKI KKQ QLY AVNLNPF-Beta6-Proteasome-PFI1545c (167) 
K ICY YRD L LAGI IVAG WD   GGQVYSVPLGConsensus (171) 
 Section 7
205 238210 220(205) 
G-MMVRQSFAI GGSGSSYIYGYV DA TYRE GM TKEHS-Beta6-Proteasome-NP_002789 (152) 
G-MQIRQSVTI GGSG SSYIYGFVKENYRE GMPRDAG-Beta6-Proteasome-XP_320065 (135) 
G-MLTRESCTI GGSG SSFIYGFVREHYRPN MALEDM-Beta6-Proteasome-AAL49013 (133) 
G-SVHKLPYAI AGSG STFIYGY CDKNFRE NMSKESC-Beta6-Proteasome-NP_012533 (136) 
GSIIEKHDFAV SGSG SIYIQSYLQDKYKKF MTKKPF-Beta6-Proteasome-PFI1545c (201) 
G MI R SFAI GGSG SSYI YGYV  E YRE MTKEConsensus (205) 
 Section 8
239 272250 260(239) 
ECLQFTANALA LAME RDGS SGG VIRLAAIA ESGVHS-Beta6-Proteasome-NP_002789 (185) 
ECV EFV KKSI FHAMYHDGSSGG VCRIGVI TKDGVAG-Beta6-Proteasome-XP_320065 (168) 
DCVTFVKKAVQ HAIY HDGS SGG VVRIGIIT KDGIDM-Beta6-Proteasome-AAL49013 (166) 
ETVDFIKHSLS QAIK WDGS SGG VIRMVVLT AAGVSC-Beta6-Proteasome-NP_012533 (169) 
ECFNLILNCVK YAMH NDNS SGG LIRIVNIT KSFVPF-Beta6-Proteasome-PFI1545c (235) 
ECV FIK AL HAMY  DGS SGGV IRIGVITKSGVConsensus (239) 
 Section 9
273 300280 290(273) 
ERQVLLGDQIP KFAV AT LPPA ---- ---HS-Beta6-Proteasome-NP_002789 (219) 
EREVFFAPRDY ENVG AR RAGA PSVS VQAAG-Beta6-Proteasome-XP_320065 (202) 
ERRIFYNTESG ASAV SS TPSF FSSE ---DM-Beta6-Proteasome-AAL49013 (200) 
ERLIFYPDEYE QL-- ---- ---- -----SC-Beta6-Proteasome-NP_012533 (203) 
EEFTVVNTQMN FQY- ---- ---- -----PF-Beta6-Proteasome-PFI1545c (269) 
ER IFY         A            Consensus (273) 
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 Section 1
1 3310 20(1) 
--MA AVSV YAPP V GGFSFDNC RRNA VLE ADFAKHS-Beta7-Proteasome-NP_002790 (1) 
--MT TDIA REFE AP GFSFENC RRN- --- AQLVKAG-Beta7-Proteasome-XP_317882 (1) 
--MD LDNA RELP R AGFNFDNC KRN- --- ATLLNDM-Beta7-Proteasome-AAB82570 (1) 
---- ---- ---- M AGL SFDN YQRN----NF L AESC-Beta7-Proteasome-NP_014800 (1) 
MKLE YINI LKEE N GGYNFDNL KRN- ---E I L KEPF-Beta7-Proteasome-PF13_0156 (1) 
  M          AGFSFDNCKRN    A L  Consensus (1) 
 Section 2
34 6640 50(34) 
RGYK LPKV RKTG TTI AGVVYKDG IVLGADTR ATHS-Beta7-Proteasome-NP_002790 (32) 
NGFV PPKM IKTG TTI CGIIYKDGVILG ADTR ATAG-Beta7-Proteasome-XP_317882 (28) 
RGFK PPIT TKTGTTI VGIIYKDGVILG ADTR ATDM-Beta7-Proteasome-AAB82570 (28) 
NSHT QPKATSTGTTI VGVKFNNGVVIA AD TR STSC-Beta7-Proteasome-NP_014800 (18) 
KGVK FPQF RKTG TTI CGLVCQNAVILG ADTR ATPF-Beta7-Proteasome-PF13_0156 (30) 
RGFK  PK  KTG TTI GIIYKDGVILGADTRA TConsensus (34) 
 Section 3
67 9980(67) 
EGMV VADK NC SKIHF ISPN IY CCGAG TAADTDMHS-Beta7-Proteasome-NP_002790 (65) 
EGPI VADK NC EKIHY LAKN MYCC GAG TAADTEMAG-Beta7-Proteasome-XP_317882 (61) 
EGPI VSDK NC AKIHY LAKN IY CCGAG TAADTEMDM-Beta7-Proteasome-AAB82570 (61) 
QGPI VADK NC AKLHR ISPK IWCA GAG TAADTEASC-Beta7-Proteasome-NP_014800 (51) 
EGPI VADK NC SKLHY ISKN I WCAGAG VAG DLEHPF-Beta7-Proteasome-PF13_0156 (63) 
EGPI VADK NCAK IHYISKNIYCCGAGTAADTE MConsensus (67) 
 Section 4
100 132110 120(100) 
TTQL ISSNLE LH SL STGRLPRVVTANRMLKQMLHS-Beta7-Proteasome-NP_002790 (98) 
TTQM IASN LELH RL NTGRTVP VVVANTMLKQFLAG-Beta7-Proteasome-XP_317882 (94) 
TTDL ISSQ LELH RLQ TDRE VRVV AANT MLKQMLDM-Beta7-Proteasome-AAB82570 (94) 
VTQL IGSNIELH SL YTSREPRVVSALQMLKQHLSC-Beta7-Proteasome-NP_014800 (84) 
TTLW LQHN VELH RLN TNTQ PRVSMCVSRLTQELPF-Beta7-Proteasome-PF13_0156 (96) 
TTQL ISSN LELH RLNT R PRVV ANTMLKQ LConsensus (100) 
 Section 5
133 165140 150(133) 
FRYQ GYIGAALVLG GVD VTGP HLYS IY PHGS TDHS-Beta7-Proteasome-NP_002790 (131) 
FRYQ GYVSAALVLG GVD TTGS YIYC IYPH GS TDAG-Beta7-Proteasome-XP_317882 (127) 
FRYQ GHISAALVLG GVD KTGP HIYS IHPH GS SDDM-Beta7-Proteasome-AAB82570 (127) 
FKYQ GHIGAYLIVA GVD PTGSHLFSIHAHGS TDSC-Beta7-Proteasome-NP_014800 (117) 
FKYQ GYKVCAIVLG GVD VNGPQLYGIHPHGS SCPF-Beta7-Proteasome-PF13_0156 (129) 
FRYQ GYI AALV LGGVD TGPHLYSIHPHGST DConsensus (133) 
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 Section 6
166 198180(166) 
KLPY VTMGSGSL AA MAVFEDKFR PD MEEEEAKNHS-Beta7-Proteasome-NP_002790 (164) 
KLPY ATMGSGSL AA MSVFESRWKPDM SEEEGKKAG-Beta7-Proteasome-XP_317882 (160) 
KLPY ATMGSGSL AA MTVFESRWKPD LSEE EGKKDM-Beta7-Proteasome-AAB82570 (160) 
VGY YLSLGSGSL AA MAVLESHWKQDLTKEEAIKSC-Beta7-Proteasome-NP_014800 (150) 
LLPF TALG SGSL NA MAVLEAKYR DNMTIEEGKNPF-Beta7-Proteasome-PF13_0156 (162) 
KLPY  TMG SGSL AAMAVFESKWKPDMSEEEGK KConsensus (166) 
 Section 7
199 231210 220(199) 
LVSE AIAA GIFN DLGSG SNIDLCVISKNK-LDFHS-Beta7-Proteasome-NP_002790 (197) 
LVRD AIAA GVFN DLGSG SNIDLCVIRKDA-TEYAG-Beta7-Proteasome-XP_317882 (193) 
LVRD ADPT GVFN DLGSG SNIDLCVIRKGS-VEYDM-Beta7-Proteasome-AAB82570 (193) 
LASD AIQA GIWN DLGSG SNVDVCVMEIGKDAEYSC-Beta7-Proteasome-NP_014800 (183) 
LVCE AICA GIFN DLGSG GNVDICVITKDS-YQHPF-Beta7-Proteasome-PF13_0156 (195) 
LV D AI A GIFN DLGSGSNIDLCVI K S  E YConsensus (199) 
 Section 8
232 264240 250(232) 
LRPY TVPN KKG TRLG R- YRCEKGTTAV LTEKITHS-Beta7-Proteasome-NP_002790 (229) 
LRTY EEA NKKG TRS LA- YDFKQGTTAV LQ SKCYAG-Beta7-Proteasome-XP_317882 (225) 
LRNY ELA NKKG KRQ LD- YRFKTGTSTVLHTNIKDM-Beta7-Proteasome-AAB82570 (225) 
LRNY LTPN VREE KQKS- YK FPRG TTAV LKESIVSC-Beta7-Proteasome-NP_014800 (216) 
IRPY KEPN MRLY HLPHPTI YPKGTTPILSEKIEPF-Beta7-Proteasome-PF13_0156 (227) 
LR Y   PN KKG R    YRF KGTTAVL EKI  Consensus (232) 
 Section 9
265 287270(265) 
PLEI EVLE ETVQ TMDTS------HS-Beta7-Proteasome-NP_002790 (261) 
KVDV TDT VVRHLVPE GVES MDTAAG-Beta7-Proteasome-XP_317882 (257) 
DLLV TER VQAVPMEI S--- ----DM-Beta7-Proteasome-AAB82570 (257) 
NICD IQEE QVDI TA---------SC-Beta7-Proteasome-NP_014800 (248) 
YIKK FIS VED A--- ---------PF-Beta7-Proteasome-PF13_0156 (260) 
 I V    V                Consensus (265) 
Wednesday, August 26, 2009 16:00:50 Page 2
 165 
Appendix IV: 
Materials and Methods for Appendices 
 
  
 166 
Materials and Methods for Appendices 
 
 
Figure S1: Activity Assay Linear Range  
 
Jurkat cells used for this experiment were obtained from the laboratory of W. Johnson 
(Biology Department, Boston College, Chestnut Hill, MA) and were originally Clone E6-
1, TIB-152® from ATCC (Manassas, Virginia). Jurkat cells were grown in RPMI 
supplemented with 10% human serum, and lysed by agitation with 0.1 mm glass 
disruption beads in assay lysis buffer (see protocol). Lysate was clarified by 
centrifugation at 5,000 rpm in a microcentrifuge, and supernatant was saved for “enzyme” 
sample. Lysate was diluted 1:2 in assay buffer by serial dilution to obtain 12 “enzyme” 
samples of different concentrations. Each enzyme sample was added to 2 µL assay 
substrate and incubated for 90 minutes at 37oC and measured for fluorescence at 
excitation/emission 380 nm/460 nm, respectively. Data were analyzed using GraphPad 
Prism® software (GraphPad Software, Inc., La Jolla, CA).  
 
Figure S2: Parasite growth in minimal media 
Cultures volumes of 180 µL with 1% hematocrit and 1% parasitemia were grown in 
minimal medium (see protocol above) supplemented with different amounts of Albumaxx 
II (Life Technologies, Inc., Grand Island, NY), alongside cells from the same culture 
grown in standard RPMI complete medium (see Methods, Chapter II) supplemented with 
differing amounts of Albumaxx II. Cultures were grown under standard conditions and 
processed in the same manner as SYBR Green® growth assays (see methods, Chapter II 
and Chapter III). Data were analyzed using GraphPad Prism® software (GraphPad 
Software, Inc., La Jolla, CA), using a linear regression algorithm. 
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Figure S3: HRPII secretion 
3D7 cultures were incubated in parasite minimal medium (export medium, see protocol 
above) in a 10 mL volume each, inoculated with 2% hematocrit and 1% parasitemia at 
ring stage, supplemented with 0.5% Albumaxx II, then were exposed to MG132, 
mefloquine, or DMSO at concentrations indicated. One culture was harvested for t = 0 
samples, and remaining cultures were supplemented with 12.5 nM or 50 nM MG132, 100 
nM mefloquine, or DMSO vehicle, and incubated for 12 hr or 24 hr under standard 
conditions (See Chapter 2, methods). After incubation, cultures were separated by 
centrifugation at 500xg. A volume of 5 mL supernatant medium was concentrated down 
to 200 µL using 3,000 NMWL Amicon filters (EMD Millipore, Inc., Billerica 
Massachusetts ).  Western and Coomassie stain were obtained in the same manner as 
described in Chapter II, Methods. Samples were normalized by volume, and 12 µL 
concentrated medium was added per well.   Primary antibody was anti-HRPII 
(Plasmodium falciparum, Santa Cruz Biotechnology, Dallas, TX).  
 
Figure S4: HRPII Accumulation 
Cultures were set up in the same manner described above, except in a 25 mL volume, and 
incubated with 12.5-100 nM MG132, 7.5-60 nM mefloquine, or DMSO vehicle. Parasites 
were harvested by saponin lysis, as described in Chapter II, Methods. Protein was 
extracted from parasites by agitation with 2 mm disruption beads in T-NET lysis buffer 
(50 nM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100). Samples 
were normalized by keeping lysate volume proportional to original culture volume, with 
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the goal of all samples having the same number of cells per unit volume. Westerns and 
Coomassie-stained gels were set up as described above and in Chapter II, Methods. 
Primary antibody was anti-HRPII, same as above.   
 
Multiple Sequence Alignments 
 
All P. falciparum gene sequences were obtained from the PlasmoDB website, Release 
6.0: http://plasmodb.org/plasmo/ (EuPathDB Project Team, Athens, GA). Sequences 
from other organisms were obtained from NCBI/BLAST website: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi (The National Library of Medicine, Bethesda, MD). 
Multiple sequence alignments were performed using ClustalW software [European 
Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Hinxton, 
Cambridge, UK].  For β4 alignment, the following chart is a guide for colors: 
AVFPMILW RED Small (small+ hydrophobic (incl.aromatic -Y)) 
DE BLUE Acidic 
RK MAGENTA Basic - H 
STYHCNGQ GREEN Hydroxyl + sulfhydryl + amine + G 
Others Grey Unusual amino/imino acids, etc. 
 
For all other alignments, colors are for visualization only, with yellow columns showing 
conserved residues, blue showing partial conservation, and green showing amino acid 
property conservation (e.g., conservation in terms of polarity, charge, etc.).  
 
 
 
 
